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Brain aging, the phenomenon by which the passage of chronological time is associated with 
reduced brain volume, is important because it is regarded as a key component of increased 
dementia risk. The main purpose of this thesis is to present a model and supporting data that 
enhances knowledge of the underlying processes that drive brain aging and dementia risk. This 
has been done using structural and functional MRI scans from the Cardiovascular Health Study-
Cognition Study (CHS-CS), a longitudinal community cohort study of elderly individuals that 
possesses extensive clinical and neuropsychological data. The model defended in this 
dissertation states that the relationship between older age and lower gray matter volume is not 
strictly a function of the passage of chronological time. Rather, older age is correlated with 
vascular diseases that themselves are a driving force behind brain aging. Most importantly, the 
three entities of aging, vascular disease, and neurodegeneration overlap in key strategic areas of 
the brain. Thus, a large factor behind dementia risk is that there are common brain areas that 
serve as sites of synergy by which age, vascular disease, and neurodegeneration can summate 
and thus amplify the risk for cognitive impairment and dementia.  
Using a whole brain method for analyzing structural MRI scans, we have found that the 
age and vascular disease, as reflected by white matter hyperintense lesions (WMHL) jointly 
affect areas of the brain known to be targeted by age and neurodegeneration and that they 
interact in these key strategic brain regions.  Finally, results from perfusion MRI imaging will be 
 iv 
reported showing that hypertension as the main predictor of lower regional cerebral blood flow. 
Taken together, these data will be interpreted to support the following model: structural and 
functional changes in an aging brain are modulated by hypertensive vascular disease. 
Additionally, the damage exerted by neurodegenerative processes on the brain is also modified 
by vascular disease. Finally, there are common strategic anatomical sites in which this synergy 
occurs and they include areas with important cognitive functions such as the hippocampus, 
cingulate gyrus, and precuneus.   
This model has several broad implications. First, it suggests that age related brain atrophy 
and perhaps even neurodegenerative atrophy itself can be reduced in magnitude if underlying 
vascular diseases are either prevented or better managed. Second, such a reduction in brain aging 
may lower risk for dementia by providing additional brain reserve. Third, key strategic brain 
regions provide a basis for further study and therapeutic targets.  
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1.0  INTRODUCTION 
Neurodegenerative dementias are devastating syndromes in which cognitive function deteriorates 
to the point where an individual can no longer care for themselves, interact optimally with 
others, or retain personal memories. It is a common disorder among older adults, affecting 10% 
of those older than age 65 (1). Alzheimer’s disease (AD) is the most common cause of dementia 
in the elderly and is projected to afflict 34 million persons worldwide by 2025 
(http://www.searo.who.-int/EN/Section1174/Section1199/Section1567/Section1823_8066.htm). 
In the United States, it is the 7th leading cause of death, costs over $1 trillion a year, and induces 
immeasurable emotional suffering and burden in patient families (http://www.alz.org/national/-
documents/report_alzfactsfigures2009.pdf).  The only two firmly established risk factors are 
genetic predispositions and old age (≥65) (2-6). Vascular diseases such as hypertension (HTN) 
by contrast, are putative risk factors for AD but are the focus of multiple investigations due their 
high prevalence in the elderly. HTN also contributes to vascular dementia (VaD), the second 
most common form of dementia in which cerebral infarcts produce a different cognitive 
syndrome (7). Often, AD and VaD pathologies co-exist and overlap. Although 
neurodegenerative dementias encompass no less than a dozen different variants, for the purposes 
of this dissertation, the term dementia will refer only to AD (65% of our cases), vascular 
dementia (13% of cases), and cases where both pathologies may coexist (17% of cases).  
Understanding the relationship between brain aging and vascular disease is of particular 
 1 
importance because such work can lend insight into how age confers its considerable risk for 
dementia on the brain.  Insight into the common areas of overlap and synergy between age, 
vascular disease, and neurodegeneration is also desirable because it provides an idea of what 
brain regions need to be most carefully considered in terms of vulnerability and therapeutics.  
 
The reduction of brain volume with age is a commonly reported phenomenon in both 
neuropathological and neuroimaging literature (8, 9). These frequently show a reduction in gray 
matter (GM) volume as age increases, with a concomitant increase in cerebrospinal fluid (CSF). 
The focus on gray matter is due to specific structures affected by AD and these include the 
hippocampal formation, posterior cingulate, and precuneus.   While such structures have been 
shown to lose gray matter with age, the underlying nature of this relationship is not clear but is 
important to understand because of the role aging plays as a powerful risk factor for AD. The 
work presented in this doctoral dissertation had three major objectives: i) To identify markers of 
hypertensive vascular disease that are associated with both age and reduced gray matter in a 
cohort of elderly non-demented individuals ii) To test assess the interrelationships among age, 
WMHL, AD and its precursor stage, mild cognitive impairment (MCI) in terms of common 
strategic anatomical regions. iii) To assess the functional consequences of HTN using perfusion 
MRI.  These objectives were accomplished using clinical, structural, and perfusion imaging data 
a large prospective community cohort, the Cardiovascular Study Cognition Study (CHS-CS). 
This first chapter will review pertinent literature and outline the rationale behind undertaking the 
stated objectives. 
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1.1 EVIDENCE FOR A RELATIONSHIP BETWEEN VASCULAR DISEASE AND 
BRAIN AGING 
With the passage of chronological time from birth there are multiple deleterious alterations in the 
brain.  These include loss of neuronal cell bodies in neocortical, hippocampal, and cerebellar 
areas (10, 11), shrinkage of neurons (12), and suboptimal DNA repair (13). These underlying 
processes generally manifest as a reduction in brain volume, measured by actual tissue loss in the 
parenchyma or increased CSF in the cerebral sulci and ventricles. Brain parenchyma usually 
shrinks 0.12% per annum in persons aged 24-46 and this number increases to 0.35% per annum 
in individuals between age 59-79 (8). In particular, gray matter volume decline is 4 times that of 
total parenchyma (gray plus white matter) shrinkage – 0.90% versus 0.20% (14).  Age related 
brain volume loss provides a powerful explanation for why aging is such a substantial risk factor 
for dementia: with advanced age is less brain volume and thus less reserve against a future 
neurodegenerative process.  Aging, however, is not a unitary condition and many processes can 
mediate and/or moderate the relationship between age and reduced brain volume. Such factors 
would have to be associated with age and have a mechanism for reducing brain volume. Those 
that will be discussed here are hypertension and its common end organ outcome in the brain: 
small vessel ischemic disease, as indexed by white matter hyperintense lesions (WMHL). 
In discussing HTN, I will focus on the most common form: essential hypertension and 
HTN will refer only to this form for the remainder of this document. HTN is a chronic disease of 
vasculature characterized by a sustained increase in systolic blood pressure (SBP) over diastolic 
blood pressure (DBP) of 140/90 mm hg (15).  Hypertensive disease can over time exert end 
organ damage including left-ventricular hypertrophy in the heart, microalbuminuria in the 
kidney, and small vessel ischemic disease in the brain (16).  This damage can subsequently cause 
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catastrophic events such as myocardial infarction, renal failure, and stroke. Age is a powerful 
predictor for HTN such that the percent of persons with the condition increases from 5% among 
those individuals aged 18-29 to 45% for those aged 50-59 to 65% in those 80+ year olds (17). 
HTN is therefore one of the most common medical afflictions among the elderly population.  
Radiological studies have shown that HTN can affect brain integrity beyond watershed 
and subcortical regions. Such work shows that HTN is correlated with gray matter volume loss 
and abnormal cognition in non-demented individuals. A voxel level analysis of 76 men and 58 
women (mean age of 60) showed that elevated blood pressure (SBP) predicts lower brain 
volumes in the supplementary motor area and adjacent superior frontal gyrus, the anterior 
cingulate cortex, and middle temporal gyrus in the male group. In that same group of subjects 
there were also deficits in executive function and working memory with higher SBP (18).  An 
earlier structural MRI study of 18 cognitively normal elderly hypertensive males with an (mean 
age of 69) and 17 age-equivalent male normotensives showed smaller left hemisphere brain 
volumes and larger CSF volumes in the lateral ventricles (19).    
A study of 529 participants grouped by age (18-46 and 47-83) showed that both young 
and older hypertensive subjects had reduced cognitive function as assessed by multiple 
examinations with the Wechsler Adult Intelligence Scale. The older group had a higher 
magnitude of blood pressure related cognitive decline (β = -.09 vs. β = -.05 for younger) 
controlling for age, education, occupation, gender, alcohol consumption, cigarettes/day, 
psychotropic medication, body mass index, and major depressive disorder (20).  HTN can 
modify age related gray matter volume loss and this was illustrated in a structural MRI study of 
27 “young old” (age 56-69) and “old-old” (age 70-84) HTN subjects and 20 age-equivalent 
normotensive controls (21). The study demonstrated an interaction between age and HTN in 
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temporal and occipital CSF and the old-old HTN group had smaller volumes of thalamic nuclei 
and larger volumes of CSF in the cerebellum and temporal lobes compared to the young-old 
group. Taken together, these studies suggest that HTN can modify age-related gray matter 
volume loss and cognitive decline in non-demented persons. Specifically HTN moderates, or 
strengthens, the relationship between aging and declines in gray matter. Consequently, one 
would expect that for a given age an individual brain with HTN would look “older” than another 
brain without HTN. 
There are several mechanisms by which HTN can induce neuronal cell loss or size 
reduction. One prominent mechanism is hypoperfusion secondary to vascular remodeling, which 
involves a series of degenerative microvascular changes including atherosclerosis, 
arteriosclerosis, smooth muscle hypertrophy, thickening of the tunica intima, and narrowing of 
the vessel lumen (22). Vascular remodeling often results from the increased wall stress induced 
by chronically elevated mean arterial pressure and leads to cerebral hypoperfusion, focal 
ischemia, perivascular edema, compromise of the blood-brain barrier, cortical deafferentation, 
and temporary loss of brainstem/spinal reflexes (cerebral diaschesis) (23).   Because vascular 
remodeling can lead to decreased regional cerebral blood flow (rCBF), compromised neuronal 
metabolism, and subsequently reductions in the size and number of neurons, this appears as gray 
matter volume loss.  
HTN can also lead to reduced GM volume by causing cerebral microbleeds. Cerebral 
microbleeds are small hemosiderin deposits visible on T2 weighted magnetic resonance imaging 
and are seen more often in patients with lacunar infarcts, intracerebral hemorrhage, and WMHL 
than in those with cardio/atheroembolic infarcts (24).  They are thought to be connected to small 
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vessel vascular damage, actual small hemorrhages, and microaneurysms – all of which result 
from HTN effects on the brain (25).     
Ischemic damage to the brain is perhaps the strongest mediator through which HTN 
causes volume reductions in gray matter. WMHL (also known as white matter hyperintensities, 
small vessel ischemic disease, or “leukoariosis”) are a well characterized biomarker of such 
damage and their main etiology is HTN (26-29). They typically manifest as areas of bilateral, 
diffuse, or patch-like areas of reduced density on computed tomographic scans or regions of 
higher intensity on T2 MRI (30, 31). Though first believed to be part of normal aging they were 
quickly found to be associated with HTN (32-34). 
Several factors support hypertensive vascular disease as a main cause of WMHL. First, 
cerebral white matter is located in the border zones of superficial and deep vascular territories, 
making it vulnerable to transient drops in regional cerebral blood flow (rCBF) (31) that can be 
seen with ischemia in the setting of long standing HTN. Second, arteriosclerosis and white 
matter pallor have been demonstrated in areas corresponding to radiologically identified white 
matter hyperintensities (34). Third, WMHL are correlated with stroke and the progression of 
lacunar infarcts – both of which are tightly linked to chronic HTN (35-38).  Fourth, WM 
components, namely oligodendrocytes and myelin, are highly sensitive to ischemia (39) and age-
related arteriolar tortuousity requires higher perfusion pressure for irrigation of WM. This 
increases vascular resistance, promotes ischemia, and leads to subsequent tissue damage. Finally, 
there is increased oxygen extraction in areas of WMHL, an indication that more oxygen is being 
consumed than is delivered by the circulation and an indicator of hemoydynamic compromise 
(40) and higher risk for ischemia and infarction –both of which are promoted by HTN 
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The link between WMHL and HTN related ischemia can be further refined by examining 
the morphology of these lesions.  WMHL can be morphologically grouped into 3 categories: 
caps and halos, punctuate lesions, and confluent lesions. Caps and halos are not lesions in a strict 
sense and often outline the cerebral ventricles in a symmetrical manner. The causes of these 
types of WMHL are non-vascular and include local redistribution of interstitial water flow, a 
loose network of myelinated fibers, and ependymitis granularis or disruption of the ependymal 
layer (31, 41, 42).  The neuropathological substrates of the caps and halos are disruption of the 
ependymal lining which results in CSF accumulation in the periventricular white matter. These 
findings also include a thin rim of subependymal gliosis and a wider band of white matter with 
reduced myelin staining around the lateral ventricles (23). Cap and halo WMHL do not have any 
associated arteriolar changes histopathologically and are thus not believed to have any vascular 
etiologies or clinical significance (43, 44).  
Punctate WMHL are thought to arise from impaired diffusion of nutrients through 
thickened blood vessel walls secondary to atherosclerosis, mechanical damage to the surrounding 
tissue from by a water hammer effect of pulsating arterioles with HTH, or both (45, 46).  
Punctate WMHL are most commonly associated with dilated perivascular spaces and do not 
represent lacunar infarcts (47).   
Confluent WMHL are caused by ischemia of white matter arterioles usually smaller than 
150 µm; by contrast, occlusion of arterioles larger than 400 µm usually results in lacunar 
infarcts. Confluent WMHLs are thought to result from: i) ischemia followed by reactive glial 
changes that the border between ischemic and health tissue ii) demyelination within that area, 
and finally, iii) gliosis (48, 49).  Chronic ischemia can result from vascular remodeling and 
vessel wall damage that is common in HTN. While some have suggested that anti-hypertensive 
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drugs cause confluent WMHL through alterations in perfusion pressure, the lack of white matter 
changes in patients with dilated cardiomyopathy would argue against this (42).  
Given the link between HTN and WMHL, it is likely that WMHL reflects the effects of 
HTN on reducing brain volume in the elderly. That is, WMHL represent the end organ effect of 
HTN on the aging brain. Consequently, age related changes in the brain can be secondary to 
hypertensive vascular disease. The next section will examine evidence that vascular disease, 
namely HTN and WMHL, and MCI are linked. 
1.2 EVIDENCE FOR A RELATIONSHIP BETWEEN VASCULAR DISEASE AND 
MILD COGNITIVE IMPAIRMENT 
Because the slow progressive nature of dementia implies the existence of prodromal state, MCI 
refers to a transition state that confers higher risk of converting from normal aging to dementia 
because in many cases it represents early neurodegenerative changes in the brain (50, 51).  Risk 
factors for MCI can therefore be potentially used as predictors for conversion to a future 
dementia. For the purposes of this dissertation, dementia is conceived as a behavioral proxy for 
advanced neurodegeneration and MCI is regarded as a series of subtle cognitive deficits that 
reflect comparatively mild or moderate neurodegeneration.  While considerations of amnestic 
versus non-amnestic manifestations of MCI are important, they warrant separate study and are 
thus beyond the scope of this dissertation. This section will review evidence that vascular risk 
factors, namely HTN and its end organ damage effect WMHL, contribute to the development of 
MCI and further progression to dementia. 
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1.2.1 HTN and MCI 
Midlife HTN is a significant predictor of subsequent cognitive deterioration (52-55).  Cognitive 
functioning is negatively correlated with the BP values measured 12 to 14 years prior (52) and 
midlife SBP is associated with poor cognition later in life (56). Such studies suggest that HTN is 
related to MCI and may even be a risk factor for the condition because of the predictive power 
blood pressure has on worsening cognitive function later in life. 
The link between HTN and MCI was suggested in one of the largest autopsy studies of 
MCI from the Religious Orders Study (57) in which 180 subjects, 37 of whom had MCI, were 
evaluated for the presence of vascular neuropathology. In the MCI group, 37% had cerebral 
infarctions, a significant risk factor of this being HTN. A prospective community cohort study 
with 334 MCI cases found HTN to be predictive of increased incidence of MCI (hazard ratio = 
1.40, p = .02, adjusting for age and sex) (58).   These findings were verified by work from the 
Italian Longitudinal Study on Aging showing that 33% of 113 cases of incident MCI went on to 
develop VAD, suggesting a vascular and most likely hypertensive component in their risk (59).  
A Chinese case control study of 423 MCI subjects compared to 925 controls showed that 
hypertension doubles the risk of having MCI (OR 1.97, 95% CI 1.44 – 2.69) (60).  In an Indian 
community cohort study of 960 subjects, 15% of which had MCI, hypertension was also 
identified as a putative risk factor regardless of the subtype (61).  Within the CHS-CS, outcomes 
of chronic HTN such as MRI-identified infarcts are associated with increased risk for MCI (OR 
= 1.4, 95% CI 1.12-1.82) (62). Finally, a longitudinal study found an OR of 1.2 (95% CI 0.7-2.2) 
for SBP ≥ 160 versus < 140 mm Hg for risk of developing Mayo Clinic defined criteria for MCI 
in 1449 persons (62% women) age ≥ 65 years with an average follow up of 21 years (54).    
 9 
Pharmacological reduction of BP reduces HTN associated cognitive impairment.  A 
prospective observational study of 6,206 persons with HTN and an average age of 66 assessed 
the effectiveness of the antihypertensive drug losartan on development of cognitive impairment 
(63). Following 1 year of treatment, systolic/diastolic BP fell from its baseline level of 
158.1/90.3 mmHg to 137.3/80.6 mmHg. The proportion of patients in this study with mild/severe 
cognitive impairment was reduced from 30.3%/39.7% at baseline to 28.1%/37.1%, a statistically 
significant alteration (p < .05). This observation was also reflected in the Study on Cognition and 
Prognosis in the Elderly trial of 4937 hypertensives (age range: 70-89) undergoing double blind 
treatment with candesartan or placebo (64). While not formally evaluated for MCI, almost half of 
these HTN subjects had MCI range Mini-Mental State Exam (MMSE) scores (24-28, n = 2070).  
In the group with lower MMSE scores, treatment with candesartan reduced the extent of 
cognitive decline over a 3-5 year period (mean difference 0.49 MMSE points, 95% confidence 
interval 0.02 to 0.97, p = .04). To the extent that HTN treatment can attenuate vascular 
remodeling of blood vessls in the brain, this can explain why such treatment can be useful for 
blunting cognitive decline. While some may assert that anti-HTN treatment in the elderly is 
deleterious because it could drop perfusion pressures, thus leading to syncope and other adverse 
event, recent data suggests that this is not the case. The HYVET study in Europe employed 
aggressive blood pressure lower medication treatment with a combined indapamide/perindopril 
regimen in 358 persons over age 80 and compared outcomes at 2 years to the age matched 
placebo group of 448 (65). The active treatment group had a 30% reduction in risk of fatal or 
non-fatal stroke, 39% reduction in death from stroke and 21% reduction in death from any cause. 
Most important, there were fewer adverse events reported in the treatment group compared to 
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placebo (p = .001).  Having reviewed how HTN and MCI are linked, I will now overview what is 
known about the WMHL and MCI. 
1.2.2 WMHL and MCI  
There are multiple works supporting a link between MCI and WMHL.  A prospective cohort 
study of 156 MCI and 67 healthy subjects followed for a mean of 6 years showed WMHL to be a 
significant predictor of conversion to MCI (adjusted hazard ratio [HR], 3.30; 95% confidence 
interval [CI], 1.33-8.17; p = .01) (66). Another prospective study found that confluent 
periventricular hyperintensities were related to an increased risk of AD within three years among 
individuals with MCI (HR = 1.59, 95 % CI: 1.24 - 2.05, p < 0.001), even after controlling for 
age, education and treatment with donepezil or vitamin E (67).  A combined MRI/EEG study of 
94 MCI subjects found a statistically significant correlation between WMHL induced damage to 
long range (capsular) and short range (medial and perisylvian) cholinergic tracts and 
abnormalities on the delta and theta power bands (68).  This study suggests that in the setting of 
MCI, comorbid vascular disease can exert damage to white matter tracts that are important in 
cognitive function.     
 
Combined, the studies reviewed in this section suggest that HTN and its end organ CNS 
marker, WMHL, may promote MCI which is itself a high risk state for future dementia. Thus, I 
have so far examined evidence supporting the concept that age related gray matter volume loss is 
moderated by HTN then end organ brain effects of which are WMHL. The following section will 
review the relationship between HTN, WMHL and dementia, with an emphasis on AD. 
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1.3 EVIDENCE FOR THE RELATIONSHP BETWEEN VASCULAR DISEASE AND 
DEMENTIA 
Environmental, personal, and genetic factors including age, family history of dementia, head 
trauma, cerebrovascular disease, have one of two copies of apolipoprotein E 4 (APOE-4) allele 
(4, 69-77) increase the risk to develop clinical dementia. In the context the present research, the 
relationship between HTN and dementia is especially important. Much about the synergistic 
mechanisms between these two processes is unknown but this section will review current 
knowledge. 
 
1.3.1 Hypertension effects on cognition 
The main basis for hypothesizing a link between HTN and dementia are the number of studies 
suggesting that HTN induces cognitive impairment. It is important to note that studies which 
examined the effects of HTN on cognition usually do not differentiate cases with MCI or 
dementia from those that have small changes in formal cognitive measures. The most common 
type of association tested has been between high SBP and lower scores on tests of 
neuropsychological function in cross-sectional investigations of non-demented elderly.  A UK 
study of 598 healthy elderly individuals age 70+ found an inverse correlation between high SBP 
and lower MMSE scores, controlling for intelligence quotient (78).  A study of 1339 persons 
aged range 69-95 years evaluated whether or not DBP was associated with having an MMSE 
score of less than 24. A 10 mm Hg increase in DBP corresponded to a 29% increase in risk for 
having an MMSE < 24 (79).   Another study of 13840 participants (age range: 45-69) showed 
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persons with BP of ≥160/95 mm Hg performed worse on the digit symbol substitution test and 
had poorer word fluency, controlling for ethnicity and occupation (80).  A Swedish study of 999 
men aged 69-75 with BP measured found that each 1 standard deviation increase in DBP 
translated to an OR = 1.45 (95% CI 1.20-1.75) for lowest quintile of MMSE scores. This study 
controlled for stroke, body mass index (BMI), cholesterol levels, serum glucose, and anti-HTN 
medications (53).  A community based investigation examined performance of 107 untreated 
hypertensives and 116 normotensive individuals aged 70-89 years and their performance on 8 
domain specific neuropsychological tests. The HTN group (BP 160-169/90-99 mm Hg) 
performed more poorly on 3/8 of these tests with slower speed of completion being the main 
reason for impaired performance (81).    A study of 158 community dwelling volunteers (age 
range 60-91) found that higher SBP predicted lower scores on both the MMSE and the 
Cambridge Cognitive Examination, controlling for plasma homocysteine levels.  In the 
Cardiovascular Health Study, a study of 5888 persons (≥65 years) showed that for every 1 
standard deviation increase in SBP (22 mm Hg), MMSE decline by 0.96 points every year for 7 
years (82).   
 
The severity of HTN may determine the subsequent effect on cognition. This was 
illustrated by of 500 men, mean age = 68, who were evaluated on a 5-test neuropsychological 
battery. Performance on this battery was worse in the more severe HTN group (≥180/110 mm 
Hg) than the less severe HTN group (140-159/90-99 mm Hg) (83).  Additionally, lower 
education status may exacerbate the effect of HTN on cognitive function. This was reflected in a 
study of 278 British African Caribbean people age 55-75; those with HTN and lower educational 
status (no college) had lower composite scores from 11 domain specific neuropsychological 
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tests, including those for episodic memory and executive function (84).  The relationship 
between HTN and lower executive function was also observed in a study of 70 persons age 65+ 
showing that SPB ≥ 145 mm Hg is related to deficits in executive function. Those findings held 
despite controlling for ethnicity, alcohol use, drug use, BMI, and total cholesterol (85).  It is 
important to note, though, that selective survival may remove the most severely hypertensive 
individuals from an elderly population. Consequently, any study of hypertension and vascular 
disease on brain structure and function may underestimate the extent of damage these conditions 
can impact on the brain. This is because persons with the most severe forms of these vascular 
diseases may die before they can reach advanced enough aged to be studied.     
In addition to the cross sectional studies cited above, considerable longitudinal evidence 
also exists linking HTN to reduced cognition. Such studies typically correlate mid-life BP with 
cognition later in life, often with a 10-30 year intervening time period. This approach is taken 
because it is believed to better reflect the cumulative effects of HTN than BP measurements 
taken later in life. The Framingham Heart Study, for example, found an inverse relationship 
between SBP and composite neuropsychological test scores obtained 20 year later in a cohort of 
1702 individuals (age range: 55-88 years) controlling for stroke, smoking, alcohol consumption, 
and occupation (86).   A study of 392 men aged 68-79 with SBP measured between 43-53 found 
that higher SBP (≥ 140 mm Hg) was related to poorer performance on MMSE and domain 
specific neuropsychological tests over 10 years, controlling for stroke (87). The same research 
group found that in 717 white males, SBP measured at age 45 was negatively correlated with 
measures of verbal learning and memory function obtained 30 years later, controlling for stroke, 
depression, and use of anti-HTN drugs (88).  The same Swedish cohort of 999 discussed earlier 
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also examined BP obtained at age 50 with MMSE at age 70 and found that DBP was the 
strongest predictor of cognitive decline over that 20 year time period (53).           
1.3.2 HTN and Dementia Risk 
Multiple epidemiological studies support a link between HTN and dementia.  The Honolulu-Asia 
Aging Study found in 3703 Japanese-American men (mean age = 65, BP obtained between age 
45-68) that un-medicated HTN conferred a higher risk for Possible and Probable AD by 
NINCDS-ADRA criteria (89) than those on treatment, controlling for stroke, APOE4, heart 
disease, and alcohol use (90).  A Finnish study of 1449 persons (age ≥ 65, 21 year follow up) 
found an OR for Possible and Probable AD of 2.0 (95% CI: 1.1-7.2) if midlife SBP was ≥ 160 
mm Hg and 1.7 (95% CI: 0.8-3.6)  if midlife DBP was ≥ 95 mm Hg (91).  That study controlled 
for BMI, stroke, myocardial infarction, smoking, and alcohol use.  A Chinese study of 602 
individuals (age ≥ 65), with SBP and DBP measured 15 years prior, found that HTN (defined as 
≥160/95 mm Hg) predicted higher risk of DSM-IV defined AD (OR = 2.0; 95% CI: 1.1-3.5) 
controlling for smoking and alcohol intake (92).    In Japan, a study of 1773 persons (73% 
women, age ≥ 60 with BP recorded 20 years prior) found that high SBP was related to DSM-IV 
defined VaD (OR per 10 mm Hg 1.33; 95% CI: 1.14-1.56) but not AD (93). Finally, a study of 
8845 persons (mean age 69 with midlife HTN defined at age 42) found that HTN (defined either 
by use of medication or BP ≥ 140/90 mm Hg) increased risk for all cause dementia (OR = 1.24; 
95% CI: 1.04-1.48) (94).  
 A connection between HTN and dementia can also be inferred from work showing that 
anti-HTN drugs lower risk for developing the syndrome. One study of 2418 subjects (age ≥ 60) 
was a randomized clinical trial with subjects receiving placebo versus nitrendipine or enalapril. 
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The outcome was development of AD, VaD, or mixed after 2 year follow up with entry DBP as a 
covariate. It was found that the anti-HTN medications reduced dementia risk by 50% (3.8 versus 
7.7 per 1000, p = .05) (95).  An extension of this study in 2902 treated subjects and placebo 
controls involved perindopril or plus indapamide with a median follow up of 3.9 years. The 
clinical outcomes were identical to the prior study and covariates included BMI, APOE4, 
alcohol, smoking, and MMSE (96).  It was found that the anti-HTN medication reduced 
dementia risk, specifically AD< by 55% (3.4 versus 7.4 per 1000 person-years).                          
1.3.3 Neuropathological Basis for HTN Promotion of Dementia 
The most frequent explanation for the effect of HTN on modifying dementia risk, especially 
vascular dementia, is HTN increases the risk of stroke due to large vessel cerebrovascular 
disease (CVD) (97, 98).  This has the effect of reducing brain reserve capacity due to tissue loss, 
thus leading to an “earlier” clinical expression of a degenerative process, with the resulting 
increase in disease prevalence (99-101).  Ischemic vascular lesions can cause the clinical 
expression of AD with fewer AD lesions (75, 102).  Amyloid beta peptide (Aβ) can cause 
cerebrovascular dysfunction (103, 104) by constricting blood vessels and attenuating the 
vasodilatation produced by the endothelium-dependent vasodilator acetylcholine (16, 104-106). 
This phenomenon may be exacerbated if HTN-related kidney dysfunction reduces the efficiency 
with which Aβ is cleared from the body (107). HTN, through deleterious effects on brain 
vasculature, appears to have the potential to mediate an additive effect with AD 
neurodegeneration to result in greater clinical severity of dementia at an earlier time.         
Additional evidence linking HTN with dementia, particularly AD, can be found in 
examining common neuropathological processes in both conditions. These processes typically 
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converge on the vasculature. Present in both HTN and AD are basement lamina thickening and 
collagen accumulation, hyalinosis, fibrinoid necrosis, and the presence of lobar and intracerebral 
hemorrhages (108-110). Characteristic in HTN and present in AD are WMHL, lacunar infarcts, 
microbleeds, large cerebral infarcts, and intima thickening in the blood vessels (23). Cerebral 
amyloid angiopathy, neurofibrillary tangles, and amyloid plaques, while characteristic of AD, are 
less commonly seen in HTN. Additionally, while endothelial degeneration is present in AD it is 
less so in HTN (23).  The link between AD and HTN can also be inferred from one particular 
study linking anti-hypertensive medication with attenuation of amyloid pathology. The study 
involved screening 55 clinically prescribed anti-HTN drugs based on their anti-beta amyloid 
activity in cortico-hippocampal neurons based on cultures from the Tg2576 AD mouse model 
(111).  Of these candidates it was found that one, valsartan, attenuated the oligomerization of 
amyloid peptides into neurotoxic oligomeric peptides. Additionally, valsartan improved spatial 
learning in the actual animals even when delivered at a dose that is twice less the level used to 
treat HTN in humans. This study suggests that since anti-HTN drugs may have AD-modifying 
activity, HTN and AD may share common pathogenic mechanisms.   
1.3.4 HTN and Neuroimaging 
Structural MRI studies have shown that elevated systolic pressures in untreated hypertensive, but 
cognitively normal subjects (mean age 61.3 years) correlate with decreased GM volumes in 
superior frontal, anterior cingulate, and middle temporal gyri (18). GM volume is associated with 
memory and executive function tests, and untreated midlife HTN is associated with decreased 
hippocampal volume 30 years later (112).   
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Positron emission tomography (PET) studies conducted in middle-aged cognitively 
normal subjects with HTN show a pattern of reduced rCBF (113, 114).  Cognitively normal 
hypertensive subjects had less activation when engaged in memory tasks than normotensives in 
the middle posterior watershed area, parietal lobes, and thalamus. Functional MRI studies have 
shown a negative correlation between activation in the anterior cingulate gyrus, insula, thalamus, 
and periaqueductal gray matter and measures of BP when cognitively normal subjects with HTN 
performed the Stroop test (115). A more extensive discussion of HTN effects on perfusion will 
be discussed in Chapter 8.  
All of these studies suggest that HTN can alter brain structure and function beyond the 
expected cerebral regions localized at the end lenticulostriate perforant arteries (116).  These 
limbic and paralimbic areas are critical for higher cognitive functions, and are also targeted by 
AD pathology (117, 118). Other studies suggest that the prefrontal cortex GM volume can be 
affected by HTN even when blood pressure is under pharmacological control (116). In rhesus 
monkeys, executive functions are reduced when HTN is artificially induced (119). These 
neuroimaging studies therefore hint at the existence of key strategic brain regions that may be 
jointly affected by aging, hypertensive vascular disease and neurodegenerative pathology such as 
that seen with AD. 
1.3.5 WMHL and Cognition 
Multiple studies suggest that WMHL may modify risk for cognitive impairment and decline. 
Gunning-Dixon and Raz compared the associations of visual ratings of WMHL on CT or MRI to 
cognition, as assessed by neuropsychological tests, across 16 different studies (120).  The 
combined associations between WMHL and global functioning (.22 ± .19, p < .001) and speed 
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(.22 ± .13, p < .001) were statistically significant. Nine of the studies found that WMHL were 
associated with deficits in executive function (.31 ± .26, p < .01) and 6 found WMHL were 
correlated with delayed memory performance (.20 ± .10, p < .01). Eleven studies found a 
smaller, but statistically significant, negative correlation between WMHL and immediate recall 
(.12 ± .16, p < .05).  Most important, however, was the finding that age did not influence the 
relationship between WMHL and cognitive index (all Fisher’s z-scores < 0.1) and choice of 
imaging study (CT versus MRI) did not affect the relationships. Additionally, the location of the 
WMHL (deep versus periventricular) did not affect the correlations with cognitive function.  
This review suggests that higher burden of WMHL on the brain are related to suboptimal 
cognition regardless of age and imaging modality. The influence of WMHL on cognition was 
confirmed by a CHS study of 3301 individuals, each with a visual grading of WMHL on a 10 
point (0-9) scale found a progressive decline in the Modified Mini-Mental State Exam score 
(3MSE) in both men and women (36).  
 
1.3.6 WMHL and Dementia  
WMHL have also been shown to modify cognition in those with dementia. This was illustrated 
in a study of 88-nondemented controls and 68 persons with clinically adjudicated AD.  An 
interaction was found between periventricular WMHL and AD clinical status on global 
cognition, suggesting that the cognitive effects of WMHL can vary as a function of co-morbid 
dementia (121).  Another study of 115 persons with dementia found that those with higher 
WMHL burden had even lower scores on tests of episodic and working memory compared to 
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demented persons free of such lesions (122). With VaD, WMHL predicts lower scores on tests of 
executive function, episodic memory, and global function (48).     
WMHL have also been independently linked to increased dementia risk. Progression to 
non-AD dementia in 152 MCI subjects was predicted by both deep (HR = 5.7; 95% CI: 1.2 – 
26.7) and periventricular WMHL (HR = 6.5; 95% CI: 1.4 – 29.8) (123). WMHL predict 
conversion from MCI to VAD and mixed dementia over a 3.8 year time period (HR = 1.14; 95% 
CI: 1.06-1.24) (124). However, other work has suggested that WMHL can accelerate conversion 
to AD.  Progression to Probable AD from MCI within 3 years was predicted by the presence 
WMHL (HR = 1.59; 95% CI: 1.24 – 2.45, p < .001) (67).  
In assessing the importance of WMHL for dementia risk is it important to recognize the 
difficulty in separating “pure” VaD and “pure” AD, especially in very old (> 85 years) 
populations.  In the CHS-CS, for example, it was found that there was considerable overlap 
between NINCDS-ARDA AD criteria and VaD as determined by modified State of California 
Alzheimer's Disease Diagnostic and Treatment Centers criteria in identifying incident dementia 
in 3,375 participants followed for 5.7 years (125).  This overlap is also mirrored by 
neuropathology studies identifying prevent co-existence of both vascular and AD 
neuropathology, hence the concept of mixed dementia (126).  
1.4 CONTEXT OF RESEARCH OBJECTIVES 
In this chapter, I have reviewed pertinent literature regarding the role of hypertensive vascular 
disease in raising risk for cognitive impairment and dementia. In doing this, I have also reviewed 
the link between hypertensive vascular disease and normal cognitive functions. I specifically 
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highlight the role of HTN and its end organ marker of brain damage, WMHL because they 
represent well described relationships between age, vascular disease, and dementia risk. The 
main concept I present in this dissertation consists of several parts. First, that the effect of age on 
the brain is moderated by the presence of WMHL, which in turn reflects the long term effects of 
HTN on the brain. The implication of this concept is that it is not the mere passage of 
chronological time by itself that reduces brain volume but the underlying vascular pathologies, 
namely HTN, which themselves are more commonly observed in the elderly. If one draws this 
concept further, it also suggests that if vascular disease were prevented or attenuated that brains 
would not appear “older” for a given chronological year. This was illustrated in an autopsy case 
of the world’s oldest woman who died at 115. Despite her advanced chronological age and being 
born weighing only 1600 g, her brain at autopsy showed no signs of atherosclerosis, myelin 
pallor, amyloid plaques, atrophy and her Braak Stage was 2 (127). Not surprisingly, her 
cognitive scores – last obtained when she was 113 - were above those of adults age 60-75. What 
makes this one particular case intriguing is that is suggests that while brain volume and cognition 
do decline with age they do not necessarily always have to and vascular disease could be one 
determinant of such an outcome. Second, the gray matter volume loss (GMVL) - the imaging 
marker I use to infer underlying brain atrophy – is associated with WMHL in brain regions that 
are also responsible for cognitive function.  The significance of this concept is that it provides 
neuroanatomical specificity by with one can understand how hypertensive vascular disease can 
have potentially deleterious consequences on cognition. Third, GMVL that is associated with 
WMHL overlap with areas of the brain that are targeted by neurodegenerative processes, namely 
those affected by MCI and dementia. The key implication of this concept is that it defines a 
common neuroanatomical framework for how age, vascular and neurodegenerative pathologies 
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may overlap by identifying strategic areas targeted by all three processes. Whereas the first three 
concepts focus on the relationships between age, vascular disease, neurodegeneration, and brain 
structure the fourth deals with the relationship between vascular disease and perfusion. 
Specifically, hypertensive disease is associated with perfusion deficits in the brain effects areas 
of cognitive relevance, such as the hippocampus. This fourth concept is important because it 
entails using a fairly new imaging modality to provide a lens through which one can understand 
the mechanistic basis for how vascular disease can induce GMVL.  
1.4.1 Concept of Strategic Brain Areas and Key Strategic Regions 
To summarize, hypertensive vascular disease can overlap with and modify brain aging 
and neurodegeneration in key strategic regions. The concept of such regions was suggested by 
Mesulam (128) who divided the brain into the following functional areas: limbic areas that 
include the substantia innominata and hippocampus; paralimbic areas that include the temporal 
pole, insula, orbital frontal cortex, and parahippocampal gyrus; heteromodal association areas 
which include the precuneus, and unimodal regions such as the primary motor and sensory 
cortices.  Many of the brain regions I hypothesize to be jointly affected by age, hypertensive 
vascular disease, and neurodegeneration in this dissertation are encompassed in limbic, 
paralimbic, and heteromodal association areas. Using the functional areas of Mesulam as a 
general guide, one can represent strategic (with respect to cognitive function and thus dementia 
risk) and non-strategic regions of the brain in Figure 1, taken from the publication of Zekry and 
colleagues (129). This figure summarizes the concept that there are vital strategic areas of the 
brain with respect to cognitive functions, including memory and executive function. Factors that 
induce atrophy in these areas such as age, vascular disease, and neurodegeneration could 
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therefore be expected to raise risk for dementia. This dissertation will extend this concept by 
adding that these brain areas can also act as sites of synergy whereby brain atrophy associated 
with age may potentially add to that of hypertensive vascular disease and co-morbid 
neurodegeneration, thus considerably amplifying the risk for dementia. Thus, the strategic areas 
outlined in dark can be conceived as sites of multiple “hits” from age, HTN, and 
neurodegeneration.  From these strategic areas, I will specifically focus on what I refer to as key 
strategic brain regions: orbital frontal cortex, anterior cingulate gyrus, the posterior cingulate 
gyrus, the precuneus, hippocampal formation, thalamus, caudate, putamen, globus pallidus, and 
basal forebrain.  
All of these 10 key strategic brain regions are relevant because they are known to be 
involved in higher order cognitive functions (128) but each has its own relevance to vascular and 
or neurodegenerative pathology that makes it eligible for emphasis. The orbital frontal cortex 
plays an important role in executive function, a cognitive domain that is often affected early in 
the course of AD and with hypertensive vascular disease (116, 130). Additionally, the orbital 
frontal cortex has been shown to have high levels of amyloid in the setting of AD (131). The 
anterior cingulate gyrus is also a key region that I highlight because it has reduced metabolic 
output with aging (132), loss of perfusion and volume with hypertensive vascular disease (133), 
and is also affected by the amyloid pathology of AD (134). In addition, the anterior cingulate 
gyrus also contributes to executive function, especially attention (135). The posterior cingulate 
gyrus and precuneus are highlighted because these regions are involved in some of the earliest 
pathological changes in AD (136-138) and are important association cortices involved in 
cognitive function (128, 139). The hippocampal formation, which I define here as inclusive of 
the hippocampus and parahippocampal gyrus, is perhaps the most frequently implicated brain 
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regions in the pathology of neurodegeneration – particularly AD and its neurofibrillary tangle 
pathology (117, 140, 141). The hippocampus also has well defined roles in memory and learning 
(142-145). The inclusion of the caudate, putamen, globus pallidus, and thalamus in the list of key 
regions is for two reasons. First, all of these regions are well known to be affected by vascular 
disease in terms of having a higher proportion of lacunar infarcts and strokes (146). This is due 
to the delicate lenticulostriate artery distribution that is especially vulnerable to damage 
secondary to chronically elevated mean arterial pressure (33, 147). The second reason for 
including the regions is because they are implicated in frontal-subcortical networks that help 
serve executive functions (148-150). The basal forebrain, particularly the substantia innominata 
which is defined as GM inferior to the anterior commissure, is included because of it is a key site 
of cholinergic production in the brain (151). This is important because part of AD pathology 
involves the loss of this production which is also known to contribute to cognitive symptoms 
(152, 153).  The orbital frontal cortex, anterior cingulate gyrus, the posterior cingulate gyrus, the 
precuneus, hippocampal formation, thalamus, caudate, putamen, globus pallidus, and basal 
forebrain therefore represent the most important key strategic brain regions within the strategic 
areas of Figure 1 because damage to any of them for any one or multiple reasons incurs the most 
severe consequences in terms of cognitive decline and risk for dementia. Areas that would 
therefore not be included are primary visual, motor, and sensory areas and the cerebellum.  This 
dissertation will also present data asserting the notion that hypertensive vascular disease 
adversely affects cerebral perfusion in key strategic brain areas.  
The data presented here were investigated using subjects drawn from a population based 
community cohort, Cardiovascular Health Study Cognition Study, and MRI modalities that allow 
for analysis of brain structure and function. This, combined with extensive clinical data on each 
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subject, allowed for more detailed investigations than in many of the studies reviewed. The study 
subjects utilized are also draw from the community, thus minimizing the referral biases of 
specialty clinics and more accurately representing the structural and functional changes that are 
likely to be observed in a general elderly population. The following chapter will review the 
general methods used in the CHS-CS.     
 
 
 
Figure 1: Conceptual Model of Strategic Brain Areas in black versus non-strategic areas in gray. The 
strategic areas represent brain regions that are likely to bet the subject of multiple “hits” from aging, 
hypertensive vascular disease, and neurodegeneration. These areas include regions such as the orbital frontal 
cortex, hippocampus, posterior cingulate gyrus, and precuneus.  
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2.0  BACKGROUND AND DESCRIPTION OF METHODS 
Having identified the research objectives of interest, three components are needed to achieve 
them. First, I require a group of human subjects that has extensive information on their state of 
vascular disease, WMHL, and dementia diagnoses. Such a sample should ideally be drawn from 
the community to most broadly represent the vascular, MCI, and dementia being investigated 
and thus avoid the referral bias of specialty clinics. This is achieved in the work discussed by use 
of participants in CHS-CS, the description of which will occupy the first section of this chapter. 
Second, imaging methods are needed to provide detailed structural and functional information on 
the brains of these participants. This methodological requirement is accomplished by employing 
advanced 3-D volumetric structural MRI (SPGR) and a relatively new technique for perfusion 
imaging, arterial spin labeled (ASL) MRI. Third, computational imaging analyses are necessary 
to provide whole-brain information on the regionally specific effects of age, hypertensive 
vascular disease, and neurodegenerative states (MCI and dementia) on brain structure and 
function. This is achieved using the Statistical Parametric Mapping (SPM, v. 2; SPM2) software 
and its extension, Voxel Based Morphometry (VBM, v. 2; VBM2). Description of these methods 
will be done in the third and final section of this chapter.        
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2.1 THE CARDIOVASCULAR HEALTH STUDY COGNITION STUDY (CHS-CS) 
The CHS-CS is derived from the larger multi-site CHS. The CHS is a population-based, 
longitudinal study of coronary heart disease and stroke in person age 65 and older (154). Its 
recruitment is based on Medicare eligibility lists in: Forsyth County, North Carolina; Sacramento 
County, California; Washington County, Maryland; and Pittsburgh, Pennsylvania. By drawing 
participants from the community, CHS avoids the referral biases that often plague studies of 
subjects from specialty clinics. The study was initiated in 1989 and began with a total of 5888 
subjects. Extensive physical and laboratory evaluations were performed at baseline to identify 
the presence and severity of such vascular diseases as HTN.  Periodic follow up examinations (1-
3 years) further ascertained the severity of hypertensive vascular disease.  This section will 
overview the composition of the CHS-CS arm, including information on cognitive diagnoses, 
and definition of HTN and WMHL.  
2.1.1 Description of the CHS-CS 
In 1997/99, dementia was diagnosed in 3,602 CHS participants as part of the CHS-CS (155, 
156). All participants completed an informed consent and Institutional Review Board approvals 
were received at all sites. A separate DNA consent was obtained for genetic studies. The CHS-
CS participants were included in the study based on completion of brain MRI (MRI at time 1 or 
MRI 1) and 3MSE in 1992/94.  These subjects were further screened using neuropsychological 
data obtained at the clinical visit closest to MRI 1 to identify those at increased risk for dementia. 
A participant was regarded to be at high risk for dementia if he or she had: i) previously scored 
less than 80 or had a decrease of 5 or more points on 3MSE completed at previous exams ii) a 
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prior Telephone Interview for Cognitive Status (TICS) (157) score <28 iii) an Informant 
Questionnaire on Cognitive decline in the Elderly (IQCode) (158) score > 3.6, iv) incident stroke 
v) medical records indicating dementia diagnosis by their primary care physician (PCP) vi) or 
current residence in a nursing home.   
For those agreeing to revisit the clinic or receive an in-home visit the following 
neuropsychological tests were administered: the Digit Symbol Substitution test (DSST), the 
America version of the National Reading test, the Benton Visual Retention test (BVRT), Raven’s 
Colored Progressive Matrices, the California Verbal Learning Test (CVLT), the Rey-Osterreith 
figure, Immediate and Delayed Recall, modified Boston naming test, Verbal fluency test, Block 
design (modified from the revised Wechsler Adult Intelligence Scale), Stroop test, Trail Making, 
Trails A and B, Digit Spans, and the Baddeley and Papagno Divided Attention Task (155, 159). 
Domain specific neuropsychological tests were then transformed into age and education (college 
versus no college) adjusted t-scores for the following cognitive functions: executive function, 
motor function, language, processing speed, and visual-constructional/visual-spatial functions 
(159). The mean of these 5 t-scores are referred to as a composite cognitive score (CCS) and will 
later be used for correlations between cognitive function and brain structure in Chapter 5. For 
persons who declined the full neuropsychological battery, TICS, IQCode, 3MSE, DSST, and 
BVRT, were still available from the multiple follow up visits during the course of the CHS-CS. 
Neuropsychological test results were considered abnormal (>1.5 standard deviations below 
individuals of comparable age and educational level) based on normative data collected from a 
sample of 250 unimpaired subjects in Pittsburgh. 
Additional information available to the CHS-consensus committee were activities of 
daily living, instrumental activities of daily living, physical function measures (gain, speed, 
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balance, grip strength, etc), known medications, and documentation of all hospitalized medical 
events such as stroke, myocardial infarctions, etc. that had transpired. Psychiatric information 
was obtained with the Center for Epidemiologic Studies–Depression Scale 10-item version (160) 
and the Neuropsychiatric Inventory (161).  
A neurological exam for each subject included a brief mental status examination, cranial 
nerve testing, motor tone, abnormal movements, strength, deep tendon reflexes, release signs, 
plantar response and clonus, cerebellar testing, primary sensory testing, gait, postural stability, 
the Unified Parkinson’s Disease Rating Scale (162) and the Hachinski Ischemic Scale (159, 
163).  All of these data were compiled into packets that were then later reviewed by a consensus 
panel of neurologists, psychiatrists, and neuropsychologists for the purposes of classifying each 
subject.    
2.1.2 Classification of MCI in the CHS-CS 
While delineating between MCI subtype effects on brain structure and function is beyond the 
score of this dissertation, a description of how MCI was identified in the CHS-CS is included for 
completeness. A minimum of 5 neuropsychological measures, encompassing 3 cognitive 
domains, one of which must be memory, had to be done for an MCI evaluation to be complete. 
MCI was identified as either amnestic type (AT) or multiple cognitive deficits (MCD). Persons 
with MCI-AT had impairments in delayed verbal or nonverbal recall that had to represent a 
decline from a previous level of comparatively higher function as detected with standard CHS 
neuropsychological evaluations.  This diagnosis did not exclude individuals with mild defects on 
IADLs.  To be classified with MCI-MCD, a subject needed to have had deterioration in at least 1 
cognitive domain (not including memory), or 1 abnormal test result in at least 2 other domains, 
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without sufficiently severe cognitive function impairment for classification of dementia, or loss 
of instrumental activities of daily living to constitute dementia. As with the MCI-AT diagnosis, 
these deficits had to represent a decline from a previous level of higher function.  
The certainty of MCI diagnosis was represented by the categories probable (greater 
certainty) and possible (lesser certainty).   Participants were classified as having probable MCI if 
they met the following criteria: i) participants or their families reported cognitive problems and 
ii) there were no neurological, psychiatric, or systemic illnesses that could explain their presence 
of cognitive deficits. To be identified with possible MCI, two considerations were: i) neither 
participants nor their families reported cognitive problems ii) there were neurological, 
psychiatric, or systemic illnesses that might explain the presence of cognitive deficits.  
It is important to note that I conceive of MCI as a behavioral and cognitive proxy for a 
relatively earlier or less advanced level of neurodegeneration compared to dementia. Referral 
clinic studies have provided evidence to support this notion (164) but the particular population 
under study here is drawn from the community.   Thus, multiple potential causes of MCI could 
be at work in including systemic disease (i.e. cancer), polypharmacy, and psychiatric conditions 
such as major depressive disorder. While my ability to study MCI subjects representing early 
neurodegeneration may have been aided by selecting those with Probable MCI, this would have 
resulted in a large (> 25%) reduction in sample size. Concurrently, there is still a non-trivial 
likelihood that subject with Possible MCI may still have early neurodegenerative changes. Thus, 
to maximize statistical power and to avoid potentially excluding anyone with early 
neurodegenerative changes I used both Probable and Possible MCI subjects in my analyses. In 
doing so, I fully acknowledge that this makes the interpretation of the data potentially more 
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challenging but this is a tradeoff that I have judged to be acceptable.  This same logic applies 
with the use of possible dementia subjects in all of my analyses.  
2.1.3 Classification of Dementia in the CHS-CS 
AD was classified as Probable or Possible using NINCDS-ARDA criteria (89). Briefly, this 
diagnosis of dementia was based on deficits in two or more cognitive domains severe enough to 
hinder ADLs in the context of a history of normal intellectual function before the onset of 
cognitive symptoms. An abnormal domain was present when at least two tests of the same 
domain were below standard cutoffs.  This clinical diagnosis of dementia has been successfully 
used over the last two decades, and it has shown 98% sensitivity and 88% specificity for AD in 
the context of a referral based clinic (165). The diagnosis of dementia was independent of the 
MRI findings, although the MRI was used to exclude other pathologies. The diagnostic certainty 
was grouped into Probable versus Possible with the main difference being that Possible AD 
concedes that other pathologies (vascular, tumor, psychiatric) could be accounting for the 
dementia syndrome whereas with Probable AD this confound is less likely.  
VaD classification was done in two steps. First, the consensus committee provided a 
diagnosis based on the clinical evidence: non-VaD, VaD, or mixed (VaD with AD, or other 
cause of dementia). This was done using only the clinical and neuropsychological data available 
but not the MRI. In a second step, the adjudication committee applied a set of diagnostic criteria 
to classify VaD: DSM-IV, State of California Alzheimer’s Disease Diagnostic and Treatment 
Centers ADDTC, and National Institute of Neurological Disorders and Stroke-Association 
Internationale pour la Recherche et l’Enseignement en Neurosciences NINDS-AIREN and this 
step involved input from MRI scans (7).  In this dissertation, vascular dementia will be defined 
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using ADDTC criteria. This is preferred over other criteria because it allows for a subject to have 
both a secondary AD diagnosis whereas other standards require exclusion of AD in order for 
VaD to be diagnosed. Given the intimate associations between AD and vascular pathology in the 
brain, it was therefore felt that the ADDTC criteria best captured subjects with both pathologies 
– a group that would be undesirable to exclude. As with AD, the diagnostic certainty of ADDTC 
defined VaD is classified as either Probable or Possible.  
2.1.4 Identification of HTN and WMHL in the CHS-CS 
HTN in CHS-CS subjects is considered present when: i) they are diagnosed by their 
physicians as having HTN ii) are placed on antihypertensive treatment or iii) have SBP ≥ 140 or 
DBP ≥ 90 mm Hg in two separate measurements.   
Small vessel vascular disease, a reflection of HTN end-organ damage to the brain, was 
indexed by measurements of WMHL using standard CHS criteria of visual white matter grade 
(WMG) done by experienced neuroradiologists at MRI I and MRI II (166). These criteria 
estimated total extent of subcortical and periventricular WM signal hyperintensities on axial 
spin-density images. These hyperintensities were graded by successive increase from none to 
nominally detectable (grades 0 and 1) to involvement of almost all WM (grade 9). Excellent 
intrareader agreement (96.9%) has been found with the WMG scale (167). Examples of different 
WMG visual manifestations can be seen in Figure 2 from Longstreth et al (36).  Large infarcts on 
MRI were judged as an area of abnormal signal change of greater than 3 mm in diameter (168).  
 32 
  
Figure 2: Classification of WMHL using CHS WMG scale on either proton density or T2 weighted 
MRI. The numbers in each box are the corresponding rating from the CHS WMG scale.  WGM of 3 is when 
subcortical WMHL are visible and a WMG of 9 involves all WM (not shown). Confluent WMHL are first 
appreciable at grade 5. 
2.2 IMAGING MODALITIES USED IN CHS-CS 
2.2.1 Basic Concepts in Magnetic Resonance Imaging 
MRI is an imaging technique that produces computerized images of tissue hydrogen using 
magnetic fields (169).  This process is done in a scanner that surrounds the human body with 
electromagnets super cooled by liquid helium and generating a magnetic field that is, at minimal 
field strengths, 60,000 time as powerful as the magnetic field of the Earth. This field in turn 
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substantially affects the body tissue protons, the nuclei of hydrogen atoms. Protons typically 
wobble, or precess at a specific rate or frequency and this is known as the Lamor frequency, the 
equation of which is: 
Equation 1:  
Where  is the angular frequency and B represents the magnitude of the external magnetic field 
applied to the organ or tissue of interest (170). The north/south axis of each proton is typically 
represented by a magnetic moment, and these moments usually point in random directions as the 
protons precess (see Figure 3). Inside an MRI scanner, these proton magnetic moments align in 
the direction of the field’s poles (Figure 4). Even in alignment, however, the protons still precess 
at a specific frequency and the magnitude of this frequency increases in relation to the strength of 
the magnetic field, as per the Lamor equation.  
 
Figure 3: Magnetic moments of protons at rest, with no external magnetic field applied. At rest, all of 
the protons point in random directions.  Figure from www.e-mri.org . 
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 Figure 4: Within a large external magnetic field (called B0, represented by the magnet), nuclear spins 
align with the external field. Some of the spins align with the field (parallel, up arrows) and some align 
against the field (anti-parallel, down arrows). Figure from www.e-mri.org . 
 
When the MRI scanner subsequently excites these protons with a radiofrequency (RF) 
pulse timed to the same frequency of precession, it knocks the protons out of alignment and 
within several milliseconds they spiral back into their original configurations, producing a faint 
electrical signal of their own that is then detected by a computer. The computer then processes 
this signal into an image by creating a grid of tiny boxes, called voxels, in three dimensions 
(x,y,z). A voxel is therefore a 3-D pixel. 
The process of creating an MRI can therefore be summarized in three basic steps (169). 
First, the magnetic field is varied in the z direction to define a plane of interest in, for example, 
the brain. Within this plane, protons precess at a given frequency and are knocked out of 
alignment by the RF pulse tuned to the frequency of precession. Second, before the protons can 
realign themselves, other magnetic coils in the MRI scanner briefly vary the magnetic strength in 
the y axis. This causes protons to precess at different rates in the entire imaging plane. Detecting 
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these differences over hundreds of RF pulse and signal detection cycles, the computer locates 
voxels in the y-direction. Third, the MRI scanner coils vary the magnetic field from left to right 
in the x direction, causing protons to resonate at different frequencies as they realign themselves. 
Having now located each voxel in the x, y, and z directions, the computer assigns each voxel a 
coordinate on a computer screen. The signal intensity, or brightness of the spot, varies as a 
function of the number of protons and the magnetic properties of the tissue. Consequently, GM 
will have different properties and appearance on the image than WM or CSF. This tissue contrast 
forms the basis of readable MRI images and makes subsequent computational analysis possible. 
By varying the delay between the RF pulse and the refocusing pulse, distinct magnetic properties 
of the tissues examined can be emphasizes and these tissue can subsequently appear different 
upon visual examination. This is the basis of the different visual appearance of T1-weighted MR 
images in which CSF is dark versus T2 weighted sequences in which CSF shows as bright. The 
number of slices acquired during a scan also determines the extent to which detailed volumetric 
analyses can be done. 
To understand basic concepts in MRI, it is also necessary to briefly review the different 
classes of pulse sequences to better understand the neuroimaging techniques used in the CHS-
CS. Spin echo pulse sequences are a type of MRI in which tissue is exposed to a 90° RF 
excitation pulse then 180° RF refocusing pulse to obtain an MR signal.  T1-weighted 
conventional spin-echo is used for acquiring anatomic images in moderate time periods and at 
high resolution whereas T2-spin echo images are rarely acquired with this technique due to long 
scan times (171).   Gradient echo pulse sequences use a gradient to generate an RF echo, rather 
than a 180° refocusing pulse, as is the case in spin-echo sequences. Gradient-echo sequences 
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consequently allow faster imaging than spin-echo sequences and are frequently used in fast 3D 
imaging.   
The spoiled gradient echo (SPGR) pulse sequence is a type of gradient echo pulse 
sequence used by General Electric (GE) medical systems for 3-D volumetric sequences (169). 
Whereas a typical T1 weighted image of the brain only has 52 slices, 3-D T1 SPGR has 124 
slices acquired. This allows for whole brain coverage of all GM structures, subcortical nuclei, 
and WM tracts. This 3-D volumetric acquisition also allows for superior delineation between 
different brain tissues such as at GM-WM borders and GM-CSF boundaries, a feature that will 
become very important in subsequent discussions about MRI image segmentation.  
2.2.2 Details of 3-D Volumetric Imaging Acquisition in CHS-CS 
While structural imaging methods in the CHS have been previously described (168) they 
are briefly reviewed here. All MRI data were acquired at the University of Pittsburgh Medical 
Center MR Research Center using a 1.5 T GE Signa scanner (GE Medical Systems, Milwaukee, 
WI, LX Version). A 3D volumetric spoiled gradient recalled acquisition (SPGR) sequence was 
obtained for the whole brain (TE/TR = 5/25, flip angle = 40°, NEX = 1, slice thickness = 1.5 
mm/0 mm interslice gap) set parallel to the AC-PC line with an in-plane acquisition matrix of 
256x256 image elements, 250 x 250 mm field of view and an in-plane voxel size of 0.98 x 0.98 
mm.  All images produced from the scanner were in Digital Imaging and Communications in 
Medicine (DICOM), the standard default file format for handling, storing, printing, and 
transmitting information in medical imaging (169).  The DICOM format is written such that 
every image slice is generated as a separate file, resulting in 124 separate files per one scan 
acquisition. To simplify the number of files involved for subsequent image analysis the DICOM 
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images are compiled into the Analyze image file format 
(http://mayoresearch.mayo.edu/mayo/research/robb_lab/analyze.cfm).  This reduces 124 files to 
two files: a header file (.hdr) and an image file (.img). The .img file contains numbers conveying 
information about the image such as image intensities or in the case of perfusion images, blood 
flow values. The .hdr file contains information about the .img file, such as the volume 
represented by each number in the image (voxel size) and the number of voxels in the x, y and z 
directions. Analyze format images are the default file type used for all computational image 
analyses in this dissertation.   
2.2.3 Basic Concepts of Perfusion MRI imaging ASL 
The main purpose of perfusion MRI is to generate an image contrast that provides information 
on regional cerebral blood flow (rCBF), a key physiological metric of brain function. In 
evaluating the relative merit of a perfusion MRI method for both clinical and research use, it 
should be: i) Totally non-invasive and thus completely safe of use in elderly patients ii) Provides 
information on brain physiology that is known to be altered early in the course of 
neurodegeneration iii) can detect rCBF changes known to occur in the setting of hypertensive 
vascular disease. ASL perfusion MRI has the ability to fulfill both criteria.  
ASL MRI works through the application of radiofrequency pulses to magnetically label 
water proton spins in blood flowing through the carotid arteries (172, 173). These labeled spins 
exchange with unlabeled spins in brain tissue to yield a quantifiable map of regional cerebral 
blood flow with no requirement for radiolabled or contrast agents. Practically, this is achieved by 
subtracting a labeled plane from an unlabeled plane (Figure 5), yielding a signal change on the 
order of 2-8%, higher than the 1% signal change seen with fMRI (174). Another advantage over 
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fMRI is that ASL provides actual units of rCBF, making it a fully quantitative type of 
neuroimaging.  This makes ASL MRI an attractive choice for perfusion imaging in elderly 
persons, whom have been shown to be a higher risk for such adverse contrast reactions as 
nephropathies, hypotension, and nephrogenic systemic fibrosis (175-177). Perfusion imaging 
with ASL has been validated against quantitative perfusion techniques such as O15 PET (178). 
ASL MRI has also been utilized in research studies of AD and other dementias to show that 
perfusion abnormalities occur very early in the course of neurodegeneration (179-182). This 
makes ASL MRI compelling for studying dementia because it can detect perfusion alterations 
that are subtly altered early in the disorder. Because ASL MRI images rCBF it is also a sound 
imaging method for detecting perfusion alterations secondary to hypertensive vascular disease 
(183). 
 
Figure 5: Summary of ASL Perfusion MR imaging. 
ASL perfusion MRI can be typically applied in two forms: pulsed ASL (PASL) and 
continuous ASL (CASL). With PASL, an imaging slice of blood is labeled upstream of the 
region of interest by a short RF pulse, typically delivered to the base of the carotid and vertebral 
arteries. Signal acquisition is then carried out after a delay of typically 1-2 seconds. The 
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difference in signal the labeled and unlabeled imaging slices reflect the amount of labeled blood 
arriving in the volume of interest during the delay, and this allows for subsequent calculations of 
rCBF (184, 185). A major drawback to PASL is the limited lifespan of the endogenous tracer, 
since the magnetization of the labeled blood bolus returns to equilibrium after about 1-2 seconds. 
This can limit detailed perfusion MRI of structures which might not be reach reached by the 
tracer in time such as the inferior temporal lobe and the hippocampus.  
With CASL, an adiabatic inversion pulse is applied to the blood upstream of the slice 
using a continuous radiofrequency associated with a gradient applied in the direction of flow. 
Consequently, the signal of the labeled slice of interest will reach steady state and rCBF is 
calculated by comparing with the signal from the same, unlabeled slice. The main strength of this 
method is that it allows for greater whole brain coverage, including in the hippocampus and 
inferior temporal lobes (184, 185). Its main drawback is the amount of RF energy delivered, and 
this has led to the development of sequences with pseudo-continuous labeling or the use of two 
coils: one for labeling, with a reduced signal intensity centered on the carotids, and one for signal 
reception (186).  With both PASL and CASL, it is imperative that blood can flow unhindered 
through the main arteries such as the carotids because this enables the subsequent endogenous 
labeling and rCBF calculations. Consequently, carotid stenosis can result in labeled blood 
flowing through collateral vessels to have a delayed arrival time in the brain tissue that results in 
an underestimation of the CBF. This underestimation is worse in patients with severe carotid 
stenosis (172).  
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2.2.4 Details of Perfusion ASL MRI Acquisition in CHS-CS 
All MRI data were acquired using the same 1.5 T GE Signa system (Milwaukee, WI, LX 
Version) as was used for the structural MRI scans and this was achieved in 187 CHS-CS 
subjects. Of these 187 scans, 74 were analyzed for the purposes of this dissertation. The rest 
were excluded from the analysis for the following reasons:  a) history of clinical stroke or carotid 
stenosis as assessed with standard CHS criteria (187) b) radiological or clinical evidence of 
structural brain lesions (e.g. tumors, trauma, or surgery), c) history of head trauma or 
encephalitis d) no consumption of caffeine within 8 hours prior to exam, e) inability to process 
images using semi-automated tools, f) placement of the labeling place was not orthogonal to both 
carotid arteries and/or the difference between left and right carotid arterial mean velocities 
exceeded 20% of the mean, leading to acquisition of perfusion data in only half of the brain g) 
excessive patient motion as evidenced in structural images, or h) excessive image artifact (e.g., 
secondary to hair oil or dental implant).   
Multi-slice continuous ASL was done using ramp-sampled echo-planar imaging to 
acquire 19 contiguous axial slices (64x64 matrix, 20 cm FOV, 5 mm slice thickness, 0 spacing, 
21 ms echo time (i.e., minimum full), 76 kHz effective receiver bandwidth, 1 s acquisition time, 
700 ms transit delay, 90° flip angle).  The alternating single adiabatic inversion label and double 
adiabatic inversion control pulses were developed to cover the entire cerebrum and repeated 50 
times for signal averaging the pairs of acquisitions. All perfusion images were registered to a 
common stereotactic space in the Standard Single Subject Montreal Neurological Institute 
template using a fully deformable registration method (188).  This was done to atrophy correct 
the perfusion images, thus reducing the likelihood that any analyzed hypoperfusion patterns were 
secondary to cerebral volume loss (189).  
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2.2.5 Summary of Imaging Modalities used in CHS-CS 
The imaging methods employed in the CHS-CS provide complementary information on brain 
structure and function. An axial section from both an SPGR MRI and a perfusion ASL scan are 
displayed in figure 6. Having outlined the subjects and imaging modalities used for this work, I 
will now review the image analyses techniques used. 
 
Figure 6: This figure shows two axial MRI images from the same CHS-CS control subject, taken at 
the level of the thalamus. On the right is a 3-D volumetric SPGR which provides information on brain 
structure. On the left is an ASL MRI image in a hot iron (hotter = more blood flow, range: 0-100 mL blood/g 
tissue/minute) scale that provides a map of rCBF. 
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2.3 METHOD OF STASTICIAL IMAGE PROCESSING AND ANALYSIS 
Having identified subjects with extensive information on their state of vascular disease, cognitive 
status, and other factors and having obtained structural and functional imaging on this group, I 
now require a method for analyzing this data in a systematic way. This framework is provided by 
statistical parametric mapping (SPM) and this section will focus on analysis of structural images, 
with perfusion MRI processing reserving its own methods section in Chapter 8. SPM is a method 
for applying linear (parametric statistics) to the analysis of MRI images at a voxel-by-voxel 
level. This can be done in both a univariate (one independent or predictor variable and one 
dependent or response variable) or a multivariate fashion (one independent variable, multiple 
confounding variables or covariates, and one dependent variable). The general linear model 
(GLM) is summarized in the following equation: 
Equation 2: y = mx + b 
In its simplest univariate form, y is the variable I want to predict (GM for example), m is 
the slope of a straight line, x is the predictor variable (age for example), and b is the y intercept 
of the straight line. This equation can be subsequently expanded into a multivariate model 
represented by Equation 2: 
Equation 3: y = m1x1 + m2x2 + b1 + b2 + e 
This equation has the same variable I seek to predict (GM) but now has additional terms. 
The term m1 refers to the slope of x1 (age from Equation 1) and m2 is the slope of line 2 
corresponds to a second variable in this case one that could be confounding the relationship 
between age and GM. This variable is x2 which in this example is gender. The intercepts for 
each line is are represented by b1 and b2 and e is the error term for the equation. Equation 2 
therefore represents a multiple regression model. If one wants to test an interaction, that is if the 
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effect of age on gray matter varies as a function of gender, one would multiply the age and 
gender terms (age by gender interaction). Statistically, this is how one tests moderation, whether 
or not one variable alters the strength of a relationship between two others. In statistically testing 
mediation, one seeks to determine if the effect of x on y may in fact be accounted for by another 
variable. SPM is consequently nothing more than the application of these different statistical 
concepts at a voxel level, in this case in structural and perfusion MRI scans. To do this, though, 
all scans have to first be processed for statistical analysis. This is done using VBM, which is 
described in the next section.  
2.3.1 Introduction to Voxel Based Morphometry 
The basic principles of VBM are displayed in Figure 7 and VBM itself is fully described in 
previously published work (190). First, all MRI scans were processed using Smallest Univalue 
Assimilating Nucleus (SUSAN) from the FMRI Software Library (FSL; 
http://www.fmrib.ox.ac.uk/fsl/) for 3-D non-linear noise reduction, which improves the 
resolution of an MR image by only averaging a voxel with local voxels which have similar signal 
intensity. Second, I invoked the Brain Extraction Tool (BET) from FSL to automatically strip the 
scull and scalp from the images (http://www.fmrib.ox.ac.uk/analysis/research/bet/) and this has 
been shown to improve the quality of subsequent segmentation (191). Third, Voxel Based 
Morphometry (VBM2) (http://dbm.neuro.uni-jena.de/vbm/vbm2-for-spm2/) was utilized in 
Statistical Parametric Mapping (SPM2) (http://www.fil.ion.ucl.ac.uk/spm/) running in MATLAB 
v 7.0 (The MathWorks, Natick, MA, USA) to normalize all images use a 12-parameter affine 
transformation and non-linear registration with 16 iterations to spatially normalize and scale the 
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individual magnetic resonance images to the custom Pittsburgh Elderly Template of 419 brains 
(69 ± 7.5 years) (192). 
 
Figure 7: Outline of VBM. See text for details. 
During this step, images were visually inspected to ensure that no registration errors 
occurred. The Pittsburgh Elderly Template was selected due to it large sample size representing 
the most likely variations in healthy aging that could be observe in the population. Fourth, SPGR 
images were segmented into grey matter (GM), white matter (WM), and cerebrospinal fluid 
(CSF) based on registered spatial priors from our template.  A hidden Markov random field 
threshold of 0.3 was used in the segmentation step to remove isolated voxels of one tissue type 
that are unlikely to reside in that particular tissue. Additionally, volumes for each tissue type 
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were calculated by multiplying all voxels by the inverse of the Jacobian determinant of their 
spatial transformation matrix to correct for any changes in the size of the individual voxels 
during the normalization step and this process is known as modulation in VBM.  The volumes of 
GM, WM, and CSF obtained from this were summed to compute total intracranial volume (TIV), 
a measure of head size. Fifth, modulated, normalized, segmented images were smoothed using a 
10 mm isotropic Gaussian kernel (full width at half maximum) to increase statistical power and 
preparation for parametric statistical analysis.  The use of a 10 mm smoothing filter in particular 
is also recommended to minimize confounding results that could occur due to normalization 
errors (193). The use of modulation and the hidden Markov random field allows for full 
volumetric information of SPGR images to be obtained and ensures a more accurate 
segmentation process. Because of this, the version of VBM used in this study is known as 
optimized VBM and has also been described previously (194), with main modifications in our 
method being i) prior image processing with SUSAN and BET ii) use of a general elderly 
template instead of a study specific template iii) application of the hidden Markov random field.  
The VBM pipeline used in CHS-CS is described in Table 1.  
Table 1: VBM protocol steps with associated software. 
Step Software 
3-D Non-linear Noise Reduction  SUSAN http://www.fmrib.ox.ac.uk/fsl/ 
Smallest Univalue Segment Assimilating 
Nucleus 
Skull/Scalp Removal  BET http://www.fmrib.ox.ac.uk/analysis/research/bet/ 
Brain Extraction Tool 2 
Normalization to Pittsburgh Elderly  SPM2 http://www.fil.ion.ucl.ac.uk/spm/ 
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Template (419 subjects, 69 ± 7.5 years) Statistical Parametric Mapping 2 
Gray Matter Segmentation with 
Hidden Markov Random Field Threshold 
of 0.3 
VBM2 http://dbm.neuro.uni-jena.de/vbm/   
Voxel Based Morphometry 2 
Modulation by Inverse Jacobian 
Determinant to obtain tissue volumes. 
VBM2 
Smooth with 3-D 10 mm Gaussian 
Filter 
SPM2 
Statistical Analysis of GM images VBM2/SPM2 
While VBM methods have advantages relative to studies that focus on a restricted 
number of regions of interest, there are some important limitations to the technique.  Registration 
errors can occur during spatial normalization due to the increased variability encountered with 
atrophic brains; such errors depend greatly on template selection. We addressed this problem by 
using a custom template of 419 normal elderly brains (69 ± 7.5 years) (192) for the 
normalization step, which can produce more biologically plausible inter-group comparisons than 
the use of a “standard” template image (195). I did not use separate templates for the controls 
and AD subjects because this can result in an overestimation of GM volume loss by over 300% 
and a misclassification of the location of volume loss (196). I further minimize the effects of any 
registration errors by using a GM mask derived from the Pittsburgh Elderly Brain template to 
restrict the statistical search space to gray matter voxels. The use of a large smoothing kernel (10 
mm) also reduces the probability that the volumetric differences found are due to registration 
error (193). Thus, while I cannot completely rule out registration errors in the data, I have taken 
multiple precautions at different levels of the analysis to minimize these confounds.  
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It has been suggested that the unified segmentation method of SPM5 (197) provides 
better normalization results than SPM2. However, a recent paper from that same group shows 
that in fact the quality of normalization is the same between SPM2 and SPM5 using 
mathematical formulas to describe surface overlap, volume similarity, and distance measures 
(198). Thus, I have no compelling reason to use SPM5 normalization, an additional drawback of 
which is that it uses an iterative approach to minimize the use of customized templates. While 
this may work well for smaller studies of normal subjects it may also fail in cases of age related 
brain atrophy (http://www.fil.ion.ucl.ac.uk/-spm/software/spm5/SPM5_new_features.pdf; SPM5 
graphical user interface). Thus, I do not use SPM5 for my analysis of this data that consists of 
elderly or atrophied brains. The same paper also suggests that the newest SPM image processing 
toolbox, the Diffeomorphic Anatomical Registration Through Exponentiated Lie algebra or 
DARTEL offers superior spatial normalization (http://www.fil.ion.ucl.ac.uk-
/~john/misc/dartel_guide.pdf). There are three reasons I do not use DARTEL. First, it requires 
that images be down sampled from 1 mm to 1.5 mm resolution, which may obscure important 
volumetric results in smaller structures such as the hippocampus. Second, the fundamental 
approach of DARTEL requires that all brains be warped to custom templates of the subjects 
being studied and the disadvantages of this have already been discussed above and investigated 
in prior work (196).  Third, “In practice though, because DARTEL uses a constant velocity 
framework, it means that the further it has to deform something, the less accurate are the 
resulting warps.” (John Ashburner, SPMlistserv, 01/26/2009). In other words, because DARTEL 
uses an iterative approach for normalization (warps) there is a greater the probability that it may 
overmatch fine cortical anatomical details, leading to normalization results that could 
underestimate the actual extent of tissue loss.  
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 2.3.2 Statistical Concepts of Mediation and Moderation 
Mediation and moderation are two statistical concepts with relevance for the present work. This 
separate section defines them so that it is clear that when such language is used it refers to 
specific statistical ideas and not other concepts.  
Mediation is the process by which the Main Effect of an independent variable on a 
dependent variable is completely accounted for by a third mediator variable does not have a 
direct statistical test as is the case with moderation. However there are several criteria 
(http://davidakenny.net/cm/mediate.htm#WIM) that can be used to guide whether or not 
mediation is occurring.  They are:   
    Step 1:  Show that the candidate mediator is correlated with the dependent variable. 
This can be done using a simple bivariate Pearson correlation coefficient r. 
       
    Step 2: Show that the independent variable is correlated with the candidate mediator 
variable, which can also be established using a bivariate correlation.  
       
    Step 3:  Show that the candidate mediator variable reduces the effect size of the 
independent variable when both are included in a multiple regression model that predicts the 
dependent variable. For complete mediation, the effect size of the independent variable should 
go to zero when the candidate mediator variable is included in the model. For partial mediation, 
the independent variable effect size does not have to go to zero but it should be reduced to the 
extent where it is no longer statistically significant in predicting the dependent variable.  
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An example of mediation is shown in the following diagram in Figure 8. Part a is a 
conceptual model of partial mediation in which the relationship between the X and Y variables is 
in fact accounted for in part but not fully by the variable Z. The black arrow reflects the 
correlation between X and Y. The blue arrow shows the correlation between the X and Z 
variables and the red arrow shows that the candidate mediator variable is associated with the 
outcome variable Y. Part b replaces this model with the ideal posited by this dissertation: that the 
association of age and GM may be accounted for in part by WMHL.  This is identical to saying 
that WMHL partially mediate the association between age and GM. 
 
Figure 8: This figure has two parts. Part a depicts a partial mediation in which changed in variable X 
are correlated with changes in variable Y (black arrow) and changes in X are also correlated with changes in 
variable Z (blue arrow). The red arrow shows that changes in Z also correlated in those in Y, thus showing a 
partial mediation. Where complete mediation to exist, the black arrow would vanish once Z is entered into 
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the model. Part b replicates the partial mediation model of part a, with actual variables of interest: age, 
WMHL, and GM. In this case of mediation, changes in age are associated with those in GM; specifically, as 
age increases, GM goes down in volume (black arrow). Concurrently, as age increases WMHL also increase 
in magnitude (blue arrow) and such lesions are themselves inversely associated with GM (red arrow). Thus, 
one can conclude in this case that the inverse association of age on GM is partially mediated by WMHL. With 
complete mediation, the black arrow between age and GM would no longer exist once WMHL are entered 
into the model.  
 
Moderation in statistics is defined in terms of an interaction. Interactions assess if the 
Main Effect of an independent variable on a dependent variable varies as a function of a third 
variable. If this is the case, it is an example of moderation (199). Another way of defining 
moderation is that the Main Effect of a certain variable, such as age and its relationship with 
GM, varies as a function of gender. Thus, gender would be said to moderate the Main Effect of 
age on gray matter volume. With respect to this work, moderation can be hypothesized in terms 
of WMHL strengthening the association between age and GM. This is depicted in Figure 9. 
Figure 9 shows a red arrow drawn from WMHL to the black arrow linking age to GM. What this 
means is that WMHL is strengthening the association between age and GM, thus moderating it. 
Another way of expressing this relationship is that the main effect of age in those with WMHL 
will be stronger than in those without such lesions. A practical consequence of moderation in this 
case would therefore be that persons with WMHL would have “older” looking brains in terms of 
having a higher magnitude of age associated GMVL.  
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 Figure 9: This figure depicts moderation of the inverse association of age and GM (black arrow) by 
WMHL (red arrow). Specifically, the red arrow means that in persons with WMHL, the magnitude of the age 
association is higher than in those without. 
   
2.3.3 Statistical Modeling in SPM 
For the purposes of structural MRI analyses, I analyze only GM voxels. Whether nor not 
a voxel is classified as GM or not is determined in VBM by how likely those voxel intensity 
values match those in the Pittsburgh Elderly Brain template. Therefore, a voxel was only 
analyzed statistically if it displayed a GM value greater than corresponding WM and CSF values. 
To additionally protect against inclusion of WM or CSF voxels in my statistical analyses, I also 
applied an absolute voxel intensity threshold of 0.1 (range 0 – 1) according to standard VBM 
guidelines (http://dbm.neuro.uni-jena.de/vbm/vbm2-for-spm2/) so that any voxel below that 
value is automatically excluded from the analysis. This measure is to especially exclude those 
voxels that are WM or CSF but may be mistakenly classified as GM voxels due to their locations 
at GM-WM or GM-CSF borders.  
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I conducted statistical analysis in SPM by applying the general linear model on a voxel-
by-voxel level in the subjects MRIs of the specific groups I examined (controls, MCI, dementia, 
etc). The main model I use in SPM multiple regression, which allows the specification of one 
dependent variable (GM) and multiple independent variables. So, for example, one could assess 
the relationship between age and GM while controlling for such potential confounders as gender, 
race, and education. In doing this, an investigator can determine whether or not increasing age 
predicts a decrease in gray matter (an inverse association or negative correlation) or if higher age 
is associated with larger tissue volumes (a positive relationship). Such associations of the 
independent variable with the dependent variable are called Main Effects. Thus, if higher age is 
positively or negatively associated with GM volume that is the Main Effect of age on GM. In 
SPM, building statistical models is achieved through the construction of a design matrix. An 
example of a multiple regression design matrix is seen in Figure 10. This figure shows the 
independent or predictor variables in an SPM multiple regression model. The context of this 
model it is possible to test, for instance, if age is associated with GM while controlling for the 
potentially confounding influences of head size (TIV), gender, or race.  
When a design matrix is constructed, the Main Effects of each independent variable on 
GM are specifically determined using contrast modeling. Contrast modeling entails the 
specification of contrast vector weights. Thus, if I wanted to assess the Main Effect of age on 
GM in the Figure 10 design matrix I would code a contrast vector weight of -1 (testing for an 
inverse relationship) and I would code the covariates as 0 so as to control for their confounding 
effects. Were I to be interested in a positive relationship between age and GM the contrast vector 
weight would be 1.  
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 Figure 10: Four columns model the Main Effects of age, total intra-cranial volume (TIV), gender, 
and race on gray matter, all independent variables. Values for each variable are represented by a grayscale 
color scheme (ex. 0s are white, 1s are gray in group columns and continuous variables are varying shades of 
white, gray and black in the age and TIV columns).  Each row corresponds to a smoothed modulated 
normalized segmented gray matter MRI, GM being the dependent variable.  
Statistical interactions can also be evaluated within the SPM framework. A specific 
example of an interaction or moderation that could be tested in SPM is to assess if the Main 
Effect of age on GM varies as a function of whether or not an individual has AD. Such an 
interaction may hypothesize, for instance, that age has a stronger Main Effect in persons with 
AD. In the SPM design matrix, this would be represented with the following design matrix in 
Figure 11, which shows specific columns for an age by group interaction with control and AD 
subjects. If one wanted to therefore test whether or not an Age by AD interaction is predictive of 
lower GM volume a -1 contrast vector weight would be coded for that column in the design 
matrix. In other words, this would allow for a test of whether or not age moderates or in this case 
strengthens the inverse association between AD and GM volume. Continuous variable are 
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centered around their overall means (overall mean – continuous variable) to reduce confounding 
due to multicollinearity – a problem in statistics in which correlation between independent 
variables leads to faulty statistical output from a multiple regression model. 
 
Figure 11: Interaction analysis design matrix with separate columns for the two groups (controls and 
AD) and their respective interaction terms with age. Interaction terms are calculated by multiplying the two 
independent variables that are hypothesized to interact in columns 3 and 4. Remaining columns model the 
effects of gender, race, and TIV as nuisance covariates. The column marked µ models the mean data across 
all subjects. 
Mediation cannot be evaluated directly in SPM but will be tested in several ways. First, it 
will be formally evaluated using total GM volume obtained from VBM as the dependent variable 
in multiple regression models using Statistical Package for Social Science (SPSS, SPSS Inc, 
Chicago, IL.). Within SPM itself, a candidate mediator variable will then be added to a model 
with the independent variable. If the independent variable is no longer statistically significant 
when the candidate mediator variable is added, this will interpreted as evidence for complete 
mediation. Should the Main Effect of the independent variable remain statistically significant but 
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is attenuated on visual exam using the overlay of the r-images that include and exclude the 
candidate mediator variable, then this will be taken as evidence to support partial mediation. 
Mediation analyses will only be referred to if they are statistically significant and full all criteria 
for either partial or complete mediation. The reader should therefore assume that no mediation 
effects are seen unless they are specifically described.  
A third type of statistical analysis that I will be conducting in SPM is what is called a 
conjunction analysis (200).  A conjunction is a statistical test for determining whether two 
independent variables have Main Effects in the same brain areas. This kind of analysis therefore 
allow me to identify, for example, if age and WMHL both exert Main Effects in the 
hippocampus or any other brain region encompassed by the scan. Conjunction analyses will be 
very important in subsequent chapters and multiple results will be presented regarding them. As 
with mediation, the reader should assume no conjunctions unless they are described.  
2.3.4 Statistical Thresholds in SPM 
A statistical threshold is typically a cutoff value by which results are deemed as statistically 
significant. A common challenge in defining statistical thresholds, however, is the problem of 
multiple comparisons, a common dilemma in statistics that is especially pertinent to SPM 
analyses of brain images.  The problem of multiple comparisons states that a statistically 
significant result can be obtained by sheer virtue of conducting large numbers of statistical tests 
simultaneously. Thus, if an MRI volume contains 10 million GM vowels and one conducts 
separate univariate tests at each voxel with SPM, then a p-value of .05 would mean .05 * 10 
million = 500,000 false-positive voxels due to chance alone. The multiple comparisons problem 
can therefore  amount to almost a half a liter of false positive (type I error) volume per MRI scan. 
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 An early approach to correcting for multiple comparisons was the Family Wise Error 
correction, which functioned as a Bonferroni style (p-value/number of tests) correction using 
Gaussian Random Field Theory (201). This method, however, was regarded as being too 
stringent – thus increasing the risk of false negatives (type II error). Newer approaches 
consequently emerged and the most successful one in neuroimaging has been the innovation of 
the False Discovery Rate (FDR) (202).  Rather than control chance of any false positives as is the 
case with random field theory, FDR controls the expected proportion of false positives among 
statistically significant voxels. FDR thresholds are therefore determined from the p-value 
distribution the actual data set and consequently adapts to the amount of signal within that data; 
this makes FDR more sensitive signal than other methods that correct for multiple comparisons. 
If there are truly no statistically significant results in an analysis, FDR achieves similar results to 
random field theory thus minimizing type I error (203).  The most common FDR threshold 
applied in SPM is the FDR = .05 (p < .05) that means that no more than 5% of the statistically 
significant voxels in an image cluster are the result of type I error. For all structural image 
analyses presented here, this is the method used. Correction for multiple comparisons of 
perfusion images will be discussed in Chapter 8.  
 Finally, another type of threshold in SPM is the extent threshold (k). This threshold refers 
to how many contiguous (bordering or adjacent voxels) need to pass a statistical threshold for the 
entire cluster to be statistically significant. The extent threshold is typically signified in terms of 
the number of voxels. Thus, if I establish an extent threshold of 10 voxels (k = 10) this means 
that 10 continuous voxels must exceed statistical threshold in order for the overall cluster to be 
regarded as significant. For the majority of structural statistical analyses, the extent threshold is 
100 for Main Effects, 100 for conjunction, and 30 for interactions. For perfusion analysis the 
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extent threshold is 30 for all analyses.  As there are no published guidelines for what extent 
thresholds to use, my choice of how large to make these thresholds is largely arbitrary.  
2.3.5 Statistical Output in SPM 
Statistical output in SPM is represented both visually and quantitatively. The most common 
statistical output of SPM is the t-statistic, which can be obtained from most type of parametric 
statistical analyses including multiple regressions.  In SPM, each cluster of statistically 
significant voxels has individual voxel level t-values that represent the highest effect sizes. These 
are called peak maxima and have an associated FDR-corrected p-value, all of which are reported 
in default SPM output tables (200).  Visually, t-statistics generated by converting them into brain 
images that are then projected onto a template brain. This allows for subsequent anatomical 
localization of Main Effects. The most common template brain used for this purpose is the 
Standard Single Subject Montreal Neurological Institute brain (204). Such rendering can be done 
either in volume/surface rendered images or in orthogonal sections (sagittal, coronal, and axial) 
and these will be also referred to as section renderings. With respect to section renderings, t-
values can be converted to a more intuitive measure of statistical effect size: the point biserial 
correlation (205) or correlation coefficient r.  The formula used to achieve this in SPM is shown 
below:  
Equation 4: r = sign (t)/sqrt((df/t2) + 1) 
Where t = the t-statistic in an individual voxel and df = the degrees of freedom in the 
multiple regression model. Because the r-value is calculated using a t-value obtained form a 
multiple regression model, it is a partial correlation (rp). Thus, if I were correlating age to GM 
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while controlling for gender, the correlation from that analysis is a partial correlation because it 
is the correlation between age and GM that accounts for the correlation between gender and GM.   
Because r values can only range between -1 and 1, they represent a more intuitive measure of 
effect size than the t-statistic which can take on a wide array of values (206).  For this reason, all 
section renderings presented in this dissertation will be done using the r-value. The only 
exception to this will be Main Effects that are masked for other Main Effects as r-images cannot 
be produced in such a manner using SPM. Volume rendering will be done with the t-statistic as 
that is default and only option for doing so in SPM. Additionally, volume rendering of all 
structural results will be done using the Standard Single Subject MNI template.  
2.3.6 Anatomical Localization in SPM Analyses  
A key component in SPM output is defining anatomical locations of statistically 
significant voxels. This is commonly done by identifying the peak maxima in a given cluster, 
those voxels with the highest effect sizes, and mapping their locations onto a stereotactic grid. 
The standard stereotactic space used in neuroimaging is the Montreal Neurological Institute 
(MNI) space. Thus, the purpose of normalization in VBM was to warp all subject scans into the 
spatial system of the Pittsburgh Elderly Brain Template which itself had been constructed in 
MNI space. Thus, a coordinate system of (x = -10, y = -15, z = 12) would correspond to the same 
anatomical location in each subject. For MNI space, an atlas called the Automated Anatomical 
Labeling (AAL) atlas was constructed to define the locations of brain areas (207) using MNI 
spatial coordinates and the AAL toolbox for SPM (http://www.cyceron.fr/freeware/).  The AAL 
atlas is shown in Figure 12 (top row) and its overlay onto the Standard Single Subject MNI 
template (bottom row). For display purposes only, I overlay all section rendered results onto 
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orthogonal sections of this image (204) and this is done using the MRIcron image viewer 
software (208). With very large clusters (k > 50,000 voxels) considerably more local maxima 
will be listed than for smaller clusters in all SPM statistical output tables. 
 
Figure 12: The top row shows color coded brain regions defined by the AAL. The bottom row depicts 
the overlay of this atlas onto the Standard Single Subject MNI template.  
There has been much debate regarding how appropriate it is to overlay group data onto 
single subject images.  Overlaying group results onto a single subject brain may deceptively 
imply that the resolution of the data is higher than in reality and this debate has mainly been 
carried out with respect to non-quantitative functional MRI activation studies (209). Such studies 
typically use small numbers of subjects (n = 10-30) and attempt to make statements regarding 
brain function in relatively focal brain areas in which case precise anatomical localization takes 
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on added importance. I present my work on the Standard Single Subject MNI template because 
to use an average template for an overlay would be less precise due to inter-subject 
morphological variability blurring anatomical landmarks.  Consequently, the Standard Single 
Subject MNI template serves as a useful high resolution visual guide one can use to understand 
the general anatomical location of Main Effects.  Another reason for using the Standard Single 
Subject MNI template for overlay purposes is that it enhances comparability with the number of 
studies has have used the template for this purpose (210-212). Thus, projecting our results onto 
the Standard Single Subject MNI template is methodologically consistent with other studies of 
elderly brains. Indeed, were every study to use their own average templates for overlaying results 
it would quickly lead to confusion in visual comparisons of such data due to lack of consistency 
in the basic display. Ideally, different standard high resolution templates would exist for various 
demographic and age groups and would be the standard of visualizing neuroimaging results but 
consensus regarding this has not been reached in the field (209).   
That stated, it is important to understand that the Standard Single Subject MNI template 
serves only as a guide for general visualization of the anatomical locations targeted by Main 
Effects of such variables as age and WMHL. It is not meant to provide absolutely precise 
anatomical localization but rather is meant to support a general description of such anatomical 
locations. The same caveat applies to the use of the AAL, which itself was defined from the 
Standard Single Subject MNI template. Additionally, caution should be taken with inferring the 
resolution of the data I present from that of the template – they are not the same.  Ultimately, the 
final resolution of the data that will be presented is limited by the size of my smoothing filter (10 
mm) but in general neuroanatomical regions of interest defined on MRI tend to be quite large 
and thus have low anatomical resolution compared to what is obtainable with microscopic 
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neuropathological methods. Thus, optimally precise resolution of neuroanatomy is neither the 
goal nor the capability of the methods I use. My methods for neuroanatomical localization and 
display, however, are sufficient enough to determine and illustrate if gross structures represented 
by key strategic brain regions (hippocampal formation, precuneus, etc.) are affected by variables 
of interest.  
2.3.7 Emphasis on Key Strategic Brain Regions in SPM Output 
SPM provides whole brain analysis of GM and the main advantage of this aspect of the program 
is that it avoids the bias of region-of-interest studies. Because of this, for every analysis done I 
provide a table that documents the stereotactic coordinates of the strongest statistical results in a 
cluster volume, the actually size in cubic mm of the cluster volume, the t-score from the multiple 
regression and it’s more parametric counterpart, the z-score, the correlation effects size and the 
voxel level p-value. This table is very important in any analysis because it quantitatively 
compliments the visual information provided in the volume and section renderings.  As such, it is 
presented in an unabridged form but there are certain markers that will aide the reader in its 
interpretation. First, all regions reported in an SPM output table are rank ordered from the most 
negative correlation effect size (largest absolute value of the partial correlation coefficient) to the 
smallest. This provides the reader with an understanding of which of a potentially large number 
of brain regions most strongly show the statistical relationship being tested.  
In addition to rank ordering the regions, the reader will find that several regions are in 
bold. These are 10 key strategic brain regions, a subset of the key strategic brain areas 
highlighted in black in Figure 1. To reiterate, the key strategic brain regions that will be in bold 
in all SPM output tables are orbital frontal cortex, the anterior cingulate gyrus, the posterior 
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cingulate gyrus, the precuneus, hippocampal formation (hippocampus and parahippocampal 
gyrus), thalamus, caudate, putamen, globus pallidus, and basal forebrain.  However, they will be 
highlighted in the context of a rank order of statistical main effects so that the reader understands 
how strongly these areas are affected in the context of other brain regions.  
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3.0  WHITE MATTER HYPERINTENSE LESIONS ARE PREDICTED BY AGE AND 
BLOOD PRESSURE IN THE CARDIOVASCULAR HEALTH STUDY COGNITION 
STUDY 
3.1 INTRODUCTION 
Having established the context and methods for the work in this dissertation, I now begin with 
presenting data pertinent to the model in Figure 1. To reiterate: I will first show in this chapter 
that WMHL are vascular in nature and are also associated with aging. In the next chapter I will 
provide results to support a main hypothesis: that the Main Effects of age on GM vary as a 
function of WMHL and that this moderation takes place in brain areas relevant to cognitive 
function such as the hippocampus and cingulate gyrus.  In Chapter 5, I will show a conjunction 
between WMHL and cognitive function as assessed with domain specific CHS-CS 
neuropsychological tests in key strategic brain regions. In Chapters 6 and 7, I will examine 
conjunctions and interactions of WMHL with MCI and dementia respectively. In Chapter 8, I 
will present results regarding the relationship between hypertension, a key predictor of WMHL, 
and rCBF abnormalities key strategic brain areas. Finally, I will conclude in Chapter 9 with an 
overall discussion of the results of this dissertation and avenues for future investigation.  This 
chapter, however, will seek to relate the main predictors of WMHL in the CHS-CS cohort. My 
specific hypothesis is that age and blood pressure, a quantitative measure used for HTN 
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diagnosis, are the main predictors of these lesions.  Chapter 1 established that age and HTN are 
key predictors of WMHL using studies reviewed from the literature. The purpose of this chapter 
is to therefore establish that this is also the case in those CHS-CS subjects whom were scanned 
with structural MRI.  This is important because if WMHL are to be used as a proxy measure for 
long term HTN damage to the brain, it is imperative that HTN is actually identified in this 
sample as a main predictor of WMHL.  
3.2 MATERIALS AND METHODS 
The subjects used for this study are drawn from the CHS-CS as described in Chapter 2. In all, 
456 subjects were scanned with 3-D volumetric SPGR MRI from 1997-1999.  From this group, 
relevant demographic variables, WMG, and blood pressure values were available for 410 
participants. For the purposes of establishing the predictive value of age and HTN on WMHL, 
only controls were examined (n = 302). Including dementia classification as a predictor variable 
of WMHL would not be logical as WMHL often precede the onset of dementia. Thus, dementia 
and MCI subjects were not included in the analysis. From the group of 302 control subjects, 
clinical data on all of them, including blood pressures in the year of structure MRI were available 
for 284 subjects.  The demographics of the subjects analyzed are provided in Table 2. The 
average systolic and diastolic blood pressures were below hypertensive range and majority of the 
subjects studied were female, educated, and Caucasian.  
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 Table 2: Demographic Variables of the 284 Control Subjects Analyzed 
Variable Mean, Standard Deviation, Range, Percent 
Age 77.92 ± 3.58 (70-89) 
WMG 2.28 ± 1.39 (0-8) 
Systolic Blood Pressure 132.36 ± 19.22 (87-197) 
Diastolic Blood Pressure  68.05 ± 10.84 (30-104) 
Gender (M/F) 40% M (112)/60% F (172) 
Education (Beyond 12th Grade/12th Grade) 65% (184)/ 35% (100) 
Race (Caucasian/African American) 82% (234)/18% (51) 
  
 
Multiple regression analysis was performed using SPSS. CHS WMG values were used as the 
dependent variable. Independent variables were age, gender, education, race, systolic blood 
pressure at MRI2 (averaged from two visits over that same year), and diastolic blood pressure 
(also averaged).  
3.3 RESULTS 
The results of the multiple regression are displayed in Table 3.    
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Table 3: This table shows independent variable and their correlation with WMHL, the dependent 
variable, from a multiple regression model in SPSS. The first column lists the independent variables in the 
model. The next three columns provide information t, p, and partial correlation coefficient values.  
Independent Variable t-value p-value Partial 
Correlation 
Value (rp) 
Age 3.63 < .001 .21 
Diastolic_Blood_Pressure 4.28 < .001 .25 
Systolic_Blood_Pressure -.95 .34 -.06 
Gender 1.19 .24 .07 
Race -1.08 .28 -.07 
Education .41 .69 .02 
 
As is evident in Table 3, variables that were positively correlated with  WMHL as 
defined by CHS WMG are age (t(277) = 3.63, rp =  .21, p < .001) and diastolic blood pressure 
(t(277) = 4.28, rp =  .25, p < .001). Age accounts for over 4% of the variance in WMG (Figure 
13) and DBP accounts for over 6% of the variance in WMG (p < .001) as shown in Figure 14. 
DBP is therefore the most strongly correlated with of WMHL in the CHS-CS cohort scanned in 
1997-1999.  
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 Figure 13: Scatter plot of age at MRI 2 and its correlation with WMG. Age accounts for 4.4% of the 
variance in WMG. 
 
 
Figure 14: Predictive power of diastolic blood pressure on CHS WMG. DBP accounts for 6.3% of the 
variance in WMG. 
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The main outcome of these results is to establish that in the CHS-CS cohort that was 
scanned in 1997-1999, older age and higher blood pressure are positively correlated with 
WMHL. No other variable entered, including presence of MCI or dementia, served as 
statistically significant predictors of WMHL. Thus, in constructing a model on the complex 
relationships between hypertensive vascular disease, brain aging, neurodegeneration, and 
cognition, the data presented in this chapter establishes the following paths in Figure 15: 
 
Figure 15: This figure summarizes the main findings of this chapter in terms of building a model 
towards understanding how hypertensive vascular disease related to aging and neurodegeneration in the 
brain. This figure in particular shows that age and hypertension are positively correlated with a greater 
magnitude of white matter hyperintense lesions in the brain.  
 
 
 Having established that age and hypertension are correlated with WMHL, I will next 
describe both the conjunction and the interaction between age and WMHL in gray matter in the 
next chapter.  
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4.0  CONJUNCTION AND INTERACTION BETWEEN WMHL AND AGE IN GRAY 
MATTER OF COGNITIVELY NORMAL ELDERLY PERSONS 
4.1 INTRODUCTION 
The main hypothesis that will be tested in this chapter is that the Main Effect of age on GM 
overlaps with WMHL and varies as a function of such lesions. This question is important to 
examine because of the risk for dementia that older age confers. It is not well understood, 
though, how this risk is applied but it is my assertion that it is not only the passage of 
chronological time itself that reduces GM volume in the brain; rather the presence of age-
correlated vascular disease, expressed as WMHL, that induces atrophy. This chapter will present 
evidence to support this hypothesis.  
4.2 MATERIALS AND METHODS 
This analysis was done in all 302 cognitively normal subjects scanned with structural SPGR 
MRI. I included all controls, including those who progressed to MCI or dementia. My main 
reason for doing so was to maximize the sample size, and thus statistical power since this 
optimizes detection of interactions (206). To confirm that conversion would not confound my 
analyses, I investigated for any statistically significant Main Effects of either MCI or dementia 
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conversion on GM in three steps. The first was to perform a partial correlation of MCI 
conversion status to GM in 235 CHS-CS subjects (169 controls who stayed cognitively normal 5 
years after MRI2 and 66 controls who converted to MCI) controlling for the metric of head size, 
TIV. The relationship between MCI conversion and GM was again test in a multiple regression 
model in SPSS that had total GM volume as the dependent variable and TIV, MCI conversion, 
age, gender, race, MRI infarcts and education as independent variables. Finally, the Main Effect 
of MCI conversion was assessed at the voxel level in SPM2 using TIV as the sole covariate with 
a standard FDR threshold. This process was repeated for controls whom remained normal and 
dementia converters (n = 56). Table 4 shows the demographic and vascular variables of controls 
subjects whom remained normal 5 years after their MRI scans in 1997-1999 versus those control 
who progressed to MCI. No statistically significant differences are noted (p < .05).  
 Table 4: Demographic and vascular characteristics of controls that remained normal versus 
MCI converters. 
Variable  Controls who 
Remained Controls 
(n = 169) 
MCI Converters (n = 
66) 
χ2 or t-value/ p-
value* 
Age 77.57 ± 3.62 78.06  ± 3.44 -.95, .34 
Gender 73/96 23/43 1.37, .31 
Race 139/30 54/12 .01, .54 
Education (Beyond 
Grade 12/Grade 12) 
108/61 43/23 .03, .49 
MRI Infarcts (N/Y) 129/40 48/17 .16, .41 
WMG 2.18 ± 1.32 2.46 ± 1.63 -1.38, .69 
* df = 234 
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The demographic and vascular variables of persons who progressed to dementia versus 
controls who did not convert are shown in Table 5. Persons who converted to dementia were 
more likely to be older and female (p < .05) than stable controls.  
 
Table 5: Demographic and vascular characteristics of controls that remained normal versus 
dementia converters.  
Variable  Controls who 
Remained Controls 
Dementia 
Converters 
χ2 or t-value/ p-
value* 
Age 77.57 ± 3.62 79.0  ± 3.78 -2.54, .01 
Gender (M/F) 73/96 14/50 5.13, .03 
Race 139/30 45/9 .03, .86 
Education (Beyond 
12th Grade/12th Grade) 
108/61 31/23 .74, .39 
MRI Infarcts (N/Y) 129/40 35/19 2.79, .07 
WMG 2.18 ± 1.32 2.43 ± 1.39 -1.38, .69 
*df = 223 
Having established that conversion to MCI and dementia did not affect my outcome 
measures, I assessed the Main Effects of age and WMHL on GM volume.  Covariates in the 
model were gender, race, education, and MRI identified infarcts. Masked Main Effects were 
produced for age by visualizing only those voxels in which there was an age Main Effect and not 
a WMHL Main Effect using a mask threshold of p < .05. The same procedure was done to show 
only those voxels that has a WMHL Main Effect and not an age Main Effect. Figure 16 shows 
the SPM design matrix used for the evaluation of the independent Main Effects of age and 
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WMHL (labeled as wmg2 in the design matrix) on GM volume. This design matrix is also the 
same used for assessing the conjunction of age and WMHL Main Effects.  
 
Figure 16:  SPM Design Matrix for Age-WMHL conjunction analysis. 
To determine whether or not age Main Effects on GMVL are moderated by WMHL, an 
interaction between age and WMG was coded in SPM by multiplying the centered (variable – 
overall mean) variables.   This interaction is depicted in the SPM design matrix in Figure 17.  
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 Figure 17: SPM design matrix showing the interaction between age and WMHL in the 4th column 
from the right. The interaction column is produced by centering age and wmg2 values around their overall 
means and then multiplying the two centered variables by each other.  
To summarize the methods applied in this chapter, a combination of SPSS and SPM 
multiple regression models were applied to verify that conversion to MCI and dementia exert no 
Main Effects on GM at MRI2. Table 6 shows the demographic characteristics for the 302 
controls in which the conjunction and interaction between age and WMG were assessed. 
Table 6: Demographics of CHS-CS Controls from MRI2 (n = 302). 
Variable Mean, Standard Deviation, Range, Percent 
Age 77.96 ± 3.63 (70-90) 
WMG 2.30 ± 1.43 (0-8) 
MRI Infarcts (N/Y) 74% (223)/26% (79) 
Gender (M/F) 40% (120 M)/60% (182 F) 
Education (Beyond 12th Grade/12th Grade) 63% (191)/37% (111) 
Race (Caucasian/African American) 83% (250)/17% (52) 
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4.3 RESULTS 
4.3.1 MCI and Dementia Conversion Main Effects on Gray Matter 
The was no correlation between MCI conversion and total GM volume, controlling for TIV 
r(232) = -.04, p = .57. The multiple regression model with additional covariates also failed to 
reveal any relationship between MCI conversion and total GM volume (t(227) = -.14, rp = -.01, p 
= .89), though age and TIV were statistically significant predictors as shown in Table 7.  
Table 7: This table shows the SPSS output of a multiple regression model, with total GM volume in 
mL as the dependent variable, showing no statistically significant relationship between MCI conversion after 
5 years and total GM volume. 
Independent Variable t-value p-value Partial 
Correlation 
Value (rp)* 
Age -4.15 < .001 -.27 
MCI Conversion -.14 .89 -.01 
Gender -.36 .72 -.02 
Education -1.88 .06 -.12 
Race -1.58 .16 -.11 
MRI Infarcts -1.07 .29 -.07 
TIV 19.53 < .001 .79 
* df = 227 
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Additionally, there was no correlation between MCI and GM at the voxel level in SPM, 
controlling for TIV. Thus, there were no focal effects of MCI conversion on GM that could be 
detected. 
In examining conversion to dementia, there was no correlation between dementia 
conversion and total GM volume, controlling for TIV r(222) = -.06, p = .35. This was confirmed 
in a multiple regression model with additional covariates (t(215) = -.10, rp = -.01, p = .92).    
Table 8: This table shows the SPSS output of a multiple regression model showing no statistically 
significant relationship between dementia conversion after 5 years and total GM volume. 
Independent Variable t-value p-value Partial 
Correlation 
Value (rp)* 
Age -4.75 < .001 -.31 
Dementia Conversion -.11 .92 -.01 
Gender -.36 .71 -.03 
Education -2.12 .04 -.14 
Race -1.08 .28 -.07 
MRI Infarcts -.97 .34 -.07 
TIV 19.75 < .001 .81 
* df = 215 
As was seen with MCI conversion, there was no Main Effect of dementia conversion on 
GM volume in SPM. Having established that MCI/dementia conversion do not influence gray 
matter either on a whole volume or voxel level, I will now present the results showing the 
separate Main Effects of age and WMG before presenting results pertaining to their conjunction 
and interaction.  
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4.3.2 Main Effect of Age on GM 
The Main Effects of age on GM are shown on Figure 18, projected onto a volume rendered 
Standard Single Subjects MNI template (PFDR = .05, k = 100). This figure conveys how 
substantially widespread age-related gray matter volume loss (GMVL), or atrophy, is. There is 
age associated reduction in GM in the frontal lobe, motor cortex, temporal lobe, medial temporal 
lobe, parietal cortex and cerebellum controlled for WMHL, gender, race, education, and MRI 
identified infarcts. Hotter colors denote a stronger Main Effect in those voxels. These can be 
seen in the right frontal lobe, cerebellum, and mesial temporal lobe. A positive correlation was 
tested to see if higher age is associated with larger GM volumes in any areas of the brain. No 
such regions were found even when uncorrected p-value thresholds (.0001, .01, and .1) were 
applied.  
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 Figure 18: Volume rendered projection of age associated GM volume loss on the Standard Single 
Subjects MNI template. In the first column, the middle rendering portrays Main Effects in the right 
hemisphere and the second column these effects are shown in the left hemisphere.  
Figure 19 shows these same Main Effects projected onto orthogonal sections of the 
Standard Single Subject MNI template. In panel 1, the Main Effect of age is clearly visible in 
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both hippocampi (double headed arrow). This age related hippocampal volume loss is localized 
to the anterior hippocampus on the left (Panel 2) and the anterior and posterior hippocampus on 
the right (panel 3). Panel 4 shows age related GMVL in the posterior cingulate (red arrow) and 
the anterior cingulate (blue arrow). The precuneus is also reduced in volume with increasing age 
(Panel 5, black arrow, right hemisphere). Additionally, both caudate nuclei are observed to be 
lower in GM volume with older age (Panel 6, red arrows).  Partial correlation coefficient values 
on the above color scale range from 0 to .30 and were rendered on MRIcron using the classic 
overlay option with red colors corresponding to higher values. Correlation effect sizes and 
corresponding spatial coordinates fro the regions shown here are listed in Table 9. 
 
 
Figure 19: Age related GMVL projected onto orthogonal sections of the Standard Single Subject 
MNI template (PFDR = .05, k = 100).  Areas that show lower volume with increasing age include such key 
strategic brain areas as the hippocampus, parahippocampal gyrus, posterior cingulate, and caudate.  
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 Table 9 shows the contents of an SPM statistical output table that include the anatomical 
location of those voxels with the largest partial correlation effect sizes (rp values) and these are 
collectively referred to as peak maxima. They can be conceived as locations in which the Main 
Effect of age is strongest. The table is rank ordered in descending direction with the largest 
absolute partial correlation values on top. If multiple peak maxima were listed for a given cluster 
volume the value of that cluster volume is written only once, with blank boxes denoting that 
same volume until a new on is written. If any peak maxima was located in any one of the 10 key 
strategic brain areas or their subdivisions (i.e. inferior (inf), superior (sup), anterior (ant), 
posterior (post)), then they are highlighted in bold. To reiterate, the key strategic brain regions 
are:   orbital frontal cortex, the anterior cingulate gyrus, the posterior cingulate gyrus, the 
precuneus, hippocampal formation (hippocampus and parahippocampal gyrus), thalamus, 
caudate, putamen, globus pallidus, and basal forebrain.   Sixteen of the peak maxima were 
located in key strategic brain regions with the strongest age Main Effect being in one of these 
areas, the right posterior parahippocampal gyrus.  
 
Table 9: This table provides the location and quantitative information on brain regions with 
strongest Age Main Effect. Key strategic brain regions are highlighted in black.  
Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value PFDR 
R_Post_Parahippocampal 33, -41, -4 696 6.49/6.27 -.35 < .001 
R_Fusiform 33, -49, -3  3.85/3.80 -.22 .004 
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R_Mid_Hippocampus 19, -21, -11 188122 5.34/5.21 -.30 .001 
R_Sup_Temporal 46, -13, -3  5.25/5.12 -.29 .001 
R_Crus1_Cerebellum 26, -65, -35  5.11/4.99 -.29 .001 
R_Insula 37, -22, 10  5.08/4.97 -.28 .001 
L_Sup_Temporal_Pole -24, 5, -19  5.05/4.94 -.28 .001 
L_Caudate -14, 21, 3  4.96/4.85 -.28 .001 
R_Caudate 11, 18, 5  4.72/4.63 -.28 .001 
L_Mid_Hippocampus -18, -19, -15  4.72/4.63 -.28 .001 
R_Inf_Frontal_Operculum 41, 11, 7  4.66/4.57 -.26 .001 
R_Calcarine 9, -66, 7  4.61/4.53 -.26 .001 
L_Sup_Temporal -43, 0, -7  4.56/4.48 -.26 .001 
R_Sup_Temporal_Pole 31, 10, -24  4.52/4.44 -.25 .001 
L_Ant_Hippocampus -21, -15, -17  4.52/4.44 -.25 .001 
L_Calcarine -19, -56, 7  4.42/4.34 -.25 .001 
R_Inferior_Frontal_Operculum 57, 18, 20  4.34/4.26 -.25 .001 
L_Thalamus -7, -12, 0  3.48/3.46 -.20 .005 
R_Thalamus 8, -12, 0  3.82/3.80 -.22 .007 
L_Amygdala -23, -2, -14  2.96/2.94 -.17 .02 
R_Amygdala 20, 1, 14  2.65/2.63 -.15 .03 
L_Mid_Cingulate -12, -27, 37 1827 4.72/4.63 -.27 .001 
L_Post_Hippocampus  -35, -35, -6 216 4.07/4.01 -.23 .001 
L_Inf_Frontal_Trigone -44, 26, 26 5900 3.83/3.78 -.22 .004 
R_Postcentral 47, -8, 33 1346 4.02/3.96 -.23 .003 
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R_Precentral 41, -16, 42  3.28/3.25 -.19 .01 
L_Mid_Temporal -60, 6, -23 1111 3.67/3.63 -.21 .005 
L_Postcentral -27, -36, 60 1892 3.65/3.60 -.21 .006 
L_Inf_Parietal -37, -43, 40  3.54/3.50 -.20 .007 
L_Sup_Parietal -29, -45, 59  3.14/3.11 -.18 .01 
R_Inf_Parietal 46, -53, 53 1445 3.64/3.60 -.21 .006 
R_Angular 27, -58, 46  2.46/2.45 -.14 .04 
L_Mid_Occipital -50, -72, 6 3099 3.62/3.58 -.21 .006 
L_Post_Cingulate -10, -58, 28  2.81/2.79 -.16 .02 
R_Post_Cingulate 5, -42, 24  2.82/2.80 -.16 .02 
L_Precuneus -9, -53, 19  2.67/2.65 -.15 .03 
R_Precuneus 5, -45, 22  2.69/2.64 -.15 .03 
L_Mid_Frontal -30, 63, 6 831 3.47/3.43 -.20 .008 
L_Sup_Frontal -19, 41, 43 339 3.45/3.41 -.20 .008 
R_Mid_Cingulate  13, 6, 41 415 3.42/3.38 -.20 .009 
R_Mid_Temporal 46, -55, 5 372 3.23/3.20 -.19 .01 
R_Ant_Cingulate 6, 35, 1 1186 3.10/3.07 -.18 .02 
L_Ant_Cingulate -4, 34, 6  2.82/2.80 -.16 .02 
L_Precentral  -25, -14, 63 257 2.94/2.91 -.17 .02 
R_Sup_Temporal 67, -5, 5 119 2.87/2.85 -.17 .02 
R_Mid_Orbital_Frontal 27, 43, -20 281 2.85/2.83 -.16 .02 
L_Sup_Parietal  -24, -68, 41 466 2.80/2.78 -.16 .03 
R_Medial_Sup_Frontal 3, 60, 15 266 2.68/2.66 -.15 .03 
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L_Medial_Sup_Frontal -6, 56, 24  2.49/2.47 -.14 .04 
L_Inf_Occipital -29, -78, -8 259 2.67/2.65 -.15 .03 
L_Lingual -25, -66, -8  2.51/2.50 -.14 .04 
 
4.3.3 Main Effect of WMHL on GM 
WMHL lesions had more extensive Main Effects on GM than age, affecting larger portions of 
the frontal, temporal and parietal lobes.  Figure 20 shows the projection of the Main Effect of 
WMHL, as quantified by CHS WMG, on GM. These results are adjusted for age, gender, race, 
education, head size, and the presence of MRI identified infarcts. With higher WMG, there is 
lower GM volume in the areas highlighted with the hot colors. Hotter colors correspond to higher 
t-values obtain from the multiple regression and thus are brain areas with a stronger association 
between WMHL and brain atrophy. These associations are seen most impressively in the frontal 
lobes, particularly the orbital frontal cortex. The temporal lobes and are also exhibited lower GM 
volumes in relation to a higher grade of WMHL. The medial parietal and superior occipital lobes 
are largely spared from the Main Effects of WMHL. There were no positive correlations between 
WMHL and GM volume even using uncorrected p-value thresholds (.0001, .01, and .1). 
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 Figure 20: Main Effect of WMHL, as quantified by CHS WMG, on GM. This is a volume rendered 
figure with the t-values from the multiple regression model evaluating the association between WMHL and 
GM volume projected onto the Standard Single Subject MNI template. Hotter colors represent larger t-
values and are seen in areas such as the orbital frontal cortex which show a particularly strong relationship 
between WMHL and GM atrophy.    
 
Figure 21 shows the Main Effect of WMHL projected onto the Standard Single Subject 
MNI template, with an emphasis visually displaying key strategic brain areas that are lower in 
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GM volume in relation to a higher magnitude of WMHL. Panel 1 shows WMHL related gray 
matter volume loss in the right anterior hippocampus (arrow at rP = -.19 at x= -21, y= 0, z = -32). 
Panel 2 shows that this GMVL is also seen in the middle and posterior right hippocampus (arrow 
point to rp = -.21 at x = 29, y = -27, z = -9 and rp = -.19 at x = 29, y = -33, z = -4). Panel 3 shows 
a similar Main Effect in the left anterior hippocampus (arrow point to rp = -.15 at x = -21, y = -
18, z = -14).  Panel 4 shows that GM volume in the left precuneus is reduced with increasing 
WMHL burden (rp = -.29 at x = -10, y = -31, z = 3). This same panel also shows GM atrophy in 
the left orbital frontal cortex (asterisk at rp = - .31 at x = -10, y = 56, z = -40). Panel 5 shows that 
the GM atrophy associated with WMHL is also visible in the right precuneus (rp = -.34 at x = 9, y 
= -33, z = 3). Finally, as WMHL increased in magnitude there was decreased GM volume in the 
thalamus as delineated by the blue box in Panel 6 (left:  rp  = -.26 at x = -9, y = 4, z = -19 and 
right: rp = -.28 at x = 12, y = 1, and z = -19).  
 
 
Figure 21: This figure shows the Main Effect of WMHL projected onto the Standard Single Subject 
MNI template, with black arrows and an asterisk identifying the key strategic brain areas.  Red colors 
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indicate partial correlation effect sizes that are above 0.3 and the posterior cingulate, precuneus, orbital 
frontal cortex, and thalamus are all in that range of values.  
 
In examining the actual effect sizes, the partial correlation coefficient values were 
approximately double those of the age Main Effects and were seen most impressively in the 
orbital frontal cortex (Table 10). Note that while key strategic brain areas were affected by 
WMHL as shown in Figure 21, not all of them were peak maxima of GM volume decline and are 
thus not included in the table. This highlights the complimentary value of both the SPM output 
figures and tables.  All peak maxima shown in the following table were located within the same 
cluster volume.  
 
Table 10: Peak GM volume declines in association with higher magnitude of WMHL.  
Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value PFDR 
R_Med_Orbital_Frontal 9, 66, -8 737055 8.70/8.68 -.45 < .001 
L_Med_Orbital_Frontal -12, 63, -4  8.62/8.60 -.45 < .001 
L_Postcentral -57, -13, 28  8.57/8.55 -.45 < .001 
L_Mid_Temporal -60, -37, 7  8.37/8.34 -.44 < .001 
R_Supramarginal 59, -16, 23  8.36/8.33 -.44 < . 001 
L_Sup_Frontal -15, 62, 7  8.08/7.66 -.43 < .001 
R_Inf_Frontal_Trigone 53, 35, 0  8.05/7.64 -.42 < .001 
R_Sup_Temporal 61, -34, 8  8.03/7.63 -.42 < .001 
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L_Sup_Temporal -58, -44, 13  7.96/7.57 -.42 < .001 
L_Inf_Orbital_Frontal -34, 30, -5  7.85/7.47 -.42 < .001 
R_Sup_Frontal 18, 62, 11  7.66/7.31 -.41 < .001 
L_Rolandic_Operculum -56, 0 , 11  7.57/7.23 -.40 < .001 
R_Medial_Sup_Frontal 15, 61, 14  7.52/7.18 -.40 < .001 
L_Mid_Cingulate -12, -12, 46  7.46/7.13 -.40 < .001 
R_Rolandic_Operculum 38, -14, -19  7.32/7.01 -.39 < .001 
R_Mid_Temporal -57, -26, -11  7.31/7.00 -.39 < .001 
R_Heschl 37, -24, 9  7.28/6.97 -.39 < .001 
R_Supp_Motor_Area 9, -19, 56  7.24/6.93 -.39 < .001 
R_Mid_Cingulate 15, -22, 46  7.23/6.93 -.39 < .001 
4.3.4 Age Main Effects Masked for WMHL 
To better conceptualize with areas of GM are affected only by an age main effect, a Main Effect 
image showing voxels that are solely associate with age and not WMHL was generated. Thus, 
Figure 22 shows only those voxels affected by age Main Effects and not WMHL Main Effects. 
In viewing this figure, one can observe that when the WMHL is masked out there are no longer 
any observable age Main Effects in the frontal lobes. Thus, those voxels with both an age and 
WMHL Main Effect were excluded from this graphic. Age Main Effects exist only in the 
anterior temporal lobe, parietal lobe, and cerebellum.  
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 Figure 22: Age Main Effects in 302 cognitively normal CHS-CS controls projected onto the Standard 
Single Subject MNI template and masked for WMHL Main Effects (PFDR = .05, k = 100, uncorrected p-value 
mask < .05). 
Because masked r-images cannot be produced in SPM, I show the section rendering for 
the masked Main Effect of age on GM as a t-image in Figure 23. This picture shows an SPM 
produced t-image of age Main Effects masked for WMHL Main Effects. T-values range from 0 
to 6 with hotter colors corresponding to higher values. While age Main Effects are still observed 
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in the caudate, anterior cingulate, and hippocampus they are absent from the posterior cingulate 
and precuneus because these are areas also affected by WMHL and were thus masked from the 
image. This image can therefore be thought of showing those voxels with “age-only” effects in 
the context of concurrent WMHL Main Effects.   
 
Figure 23: This figure is an SPM t-image of Age Main Effects masked for WMHL Main Effects. 
Even when excluding regions with GM atrophy associated with WMHL, there are this still age related 
atrophy in such key strategic brain regions as the anterior cingulate, caudate, and hippocampus.  
 
Table 11 shows the peak maxima for the WMHL masked Main Effects of age on GM. 
The right posterior parahippocampal gyrus is still the location of the strongest age Main Effect 
and in all, 6 of the peak maxima are located in key strategic brain regions.  
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Table 11: Peak locations of age related GM volume loss masked for WMHL. 
Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value PFDR 
R_Post_Paraphippocampal 32, -38, -4 291 6.03/5.85 -.33 < .001 
L_Caudate -14, 21, 3 6330 4.96/4.85 -.28 .001 
L_Amygdala -23, 3, -18  4.95/4.85 -.28 .001 
R_Cerebellum 37, -84, -32 17860 4.21/4.14 -.24 .002 
R_Hippocampus 23, -16, -15 9889 4.81/4.71 -.27 .001 
R_Inf_Frontal_Operculum 41, 11, 7  4.66/4.57 -.26 .001 
R_Insula 42, 4, -3  4.48/4.41 -.25 .001 
L_Crus_Cerebellum -37, -85, -31 10664 4.73/4.64 -.27 .001 
Vermis_Cerebellum 2, -72, -17  3.45/3.41 -.20 .008 
R_Caudate 11, 18, 5 854 4.72/4.63 -.27 .001 
L_Mid_Cingulate -10, -29, 42 469 4.50/4.43 -.25 .001 
L_Calcarine -20, -57, 8 6386 4.39/4.31 -.25 .002 
R_Lingual 6, -66, 7  4.17/4.11 -.24 .002 
R_Sup_Occipital 15, -91, 20  4.17/4.10 -.24 .002 
R_Mid_Occipital 31, -79, 19 913 3.79/3.74 -.22 .004 
L_Mid_Temporal -60, 6, -23 761 3.67/3.63 -.21 .005 
R_Mid_Cingulate 13, -29, 41 259 3.67/3.62 -.21 .005 
R_Inf_Parietal 46, -53, 53 1429 3.64/3.60 -.21 .006 
R_Angular 27, -58, 46  2.46/2.45 -.14 .04 
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L_Inf_Parietal -37, -43, 40 1351 3.54/3.50 -.20 .007 
L_Sup_Parietal -29, -45, 59  3.14/3.11 -.18 .007 
R_Sup_Parietal 24, -78, 48 340 3.28/3.25 -.19 .01 
R_Cuneus 18, -58, 22 240 3.22/3.19 -.18 .01 
R_Mid_Temporal 46, -55, 4 225 3.18/3.15 -.18 .01 
L_Ant_Cingulate -10, 16, 30 254 2.87/2.85 -.17 .02 
R_Ant_Cingulate 6, 35, 1 670 3.10/3.07 -.17 .02 
L_Inf_Frontal_Trigone -38, 28, 25 114 3.03/3.00 -.17 .02 
L_Precentral -24, -13, 64 155 2.39/2.91 -.17 .02 
4.3.5   WMHL Main Effects Masked for Age 
The Main Effect of WMHL on GM was largely unchanged even after masking out voxels that 
were also affected by age as shown in Figure 24. The orbital frontal cortex is still a site of strong 
WMHL related GM atrophy as reflected by the hotter colors but there is some lack of WMHL 
Main Effect in the lateral frontal lobe. Also, while WMHL associated GM volume loss is still 
very much observed in the temporal lobe, there is and this is some comparative absence in the 
lateral temporal lobe and this is attributable to concurrent age Main Effects in that area. There is 
also a conspicuous lack of WMHL Main Effect in the cerebellum and this is expected given the 
age Main Effect in that area that was masked out.  
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 Figure 24: This figure shows the projection of WMHL effects, masked for age, onto the Standard 
Single Subject MNI template. Some of the frontal lobe effects of WMHL are no longer visible because of 
concurrent age Main Effects. This is also the case in the temporal lobes and especially evident in the 
cerebellum.  
 
In examining the section rendered t-images, the age masked WMHL Main Effects still 
persist in key strategic brain areas such as the hippocampus, posterior cingulate, and anterior 
cingulate gyrus as is seen in Figure 25. Part a shows that the Main Effects of WMHL persist in 
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the middle portion of the right hippocampus (crosshairs) even after masking out the Main Effect 
of age (PFDR = .05, k = 100). Part b shows that the Main Effect of WMHL also persist in the 
posterior cingulate (yellow arrow) and the anterior cingulate (green arrow) despite masking out 
the Main Effect of age. 
 
Figure 25: This figure shows the Main Effect of WMHL after masking out voxels that are also 
encompassed by an age Main Effect. Part a shows the presence of WMHL GM atrophy in the hippocampus 
and in the posterior cingulate gyrus (part b, yellow arrow) and anterior cingulate (green arrow).  
In examining the peak maxima of WMHL Main Effects, it is interesting to note that the 
left hippocampus becomes a location of a peak maximum when the age effect is masked out 
(Table 12). Otherwise the majority of peak maxima of the WMHL Main Effect are unchanged, 
especially in the orbital frontal cortex – the left and right medial subdivision of which exhibit the 
strongest areas of WMHL atrophy.  
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Table 12: Age-masked Main Effect of WMHL presented as peak areas of statistical significance. 
Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value PFDR 
R_Med_Orb_Frontal 9, 66, -8 455461 8.70/8.68 -.45 < .001 
L_Med_Orb_Frontal -12, 63, -4  8.62/8.60 -.45 < .001 
L_Postcentral -57, -13, 28  8.57/8.55 -.45 < .001 
L_Mid_Temporal -60, -37, 7  8.37/8.34 -.44 < .001 
R_Supramarginal 59, -16, 23  8.36/8.33 -.44 < . 001 
L_Sup_Frontal -15, 62, 7  8.08/7.66 -.43 < .001 
R_Sup_Temporal 61, -34, 8  8.03/7.63 -.42 < .001 
L_Sup_Temporal -58, -44, 13  7.96/7.57 -.42 < .001 
R_Inf_Frontal_Trigone 53, 38, -1  7.76/7.39 -.41 < .001 
R_Sup_Frontal 18, 62, 11  7.66/7.31 -.41 < .001 
L_Rolandic_Operculum -56, 0 , 11  7.57/7.23 -.40 < .001 
R_Sup_Temporal 62, -25, 5  7.55/7.21 -.40 < .001 
L_Inf_Orbital_Frontal -35, 31, -6  7.53/7.20 -.40 < .001 
R_Medial_Sup_Frontal 15, 61, 14  7.52/7.18 -.40 < .001 
L_Inf_Frontal_Trigone -50, 26, 11  7.51/7.18 -.40 < .001 
R_Mid_Temporal -57, -26, -11  7.31/7.00 -.39 < .001 
R_Heschl 37, -24, 9  7.28/6.97 -.39 < .001 
R_Supp_Motor_Area 9, -19, 56  7.24/6.93 -.39 < .001 
R_Mid_Cingulate 15, -22, 46  7.23/6.93 -.39 < .001 
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L_Mid_Cingulate -12, -15, 46  7.25/6.94 -.39 < .001 
L_Supramarginal -54, -29, 34  7.18/6.88 -.39 < .001 
R_Rolandic_Operculum 60, -5, 13  7.09/6.81 -.38 < .001 
R_Postcentral 62, 2, 17  7.08/6.80 -.38 < .001 
R_Crus_Cerebellum 13, -53, -46 308 2.13/2.13 -.12 .03 
L__Crus_Cerebellum -39, -56, -36 2404 3.02/3.00 -.17 .003 
L_Parahippocampal -21, -24, -18 229 2.86/2.84 -.16 .005 
L_Hippocampus -26, -26, -12  2.21/2.21 -.13 .02 
  
4.3.6 Conjunction between Age and WMHL  
The conjunction of age and WMHL represents voxels in the 302 brains examined that have both 
a Main Effect of age and of WMHL.  This is represented on a volume rendered projection in 
Figure 26 and shows the projection of age-WMHL conjunction onto the Standard Single Subject 
MNI template. Age and WMHL Main Effects are jointly statistically significant in the frontal 
lobes, temporal lobes, mesial temporal lobe, and the inferior cerebellum. 
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 Figure 26: This displays the conjunction of age and WMHL Main Effects in all 302 control subjects.  
  
Figure 27 shows Sectioned rendered t-images showing the conjunction between age and 
WMHL Main Effects key strategic brain areas. Parts a and b show that the age and WMHL Main 
Effects are jointly statistically significant in the left parahippocampal gyrus and right middle 
hippocampus respectively (crosshairs). Part c shows and age/WMHL conjunction in the right 
precuneus (crosshairs) and part d also shows a conjunction in the thalamus. All coordinate 
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locations and effect sizes for these areas can be found in table 13.  T-values range from 0 to 5 
with larger values corresponding to hotter colors. 
 
Figure 27: SPM t-images showing the conjunction between age and WMHL main effects. Key 
strategic brain regions affects both by age and WMHL related brain atrophy are the hippocampal formation 
(parts a and b; crosshairs), the precuneus (part c, crosshairs), and the thalamus (part d, crosshairs).  
 
Table 13 shows peak local maxima that correspond to the conjunction between age and 
WMHL Main Effects. These areas show both a statistically significant Main Effect on GM from 
both age and WMHL. The top three conjunction sites with the largest effect sizes are in key 
strategic brain regions: the right middle hippocampus, right thalamus, and left thalamus. In all, 6 
of the peak maxima were located in key strategic brain regions.  
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 Table 13: The conjunctions between age and WMG Main Effects on GM are shown in Table 13. This 
table shows areas of the brain where both age and WMG are correlated with lower GM volume, controlling 
for head size, gender, education, race, and MRI infarcts. Key strategic brain regions are highlighted in bold.  
Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value PFDR 
R_Mid_Hippocampus 18, -22, -11 4120  5.25/5.13 -.29 .007 
R_Thalamus 6, -17, -5 4120  4.94/4.83 -.28 .007 
L_Thalamus -3, -16, -5 4120  4.85/4.76 -.27 .007 
Heschl_R 37, -22, 10 7124  5.08/4.97 -.28 .007 
R_Sup_Temporal 48, -13, -2 7124  4.97/4.87 -.28 .007 
R_Sup_Temporal 58, -18, 7 7124  3.92/3.87 -.22 .02 
L_Postcentral -43, -14, 40 2552  4.58/4.50 -.26 .007 
L_Postcentral -43, -10, 47 2552 3.99/3.93 -.23 .02 
L_Postcentral -60, -12, 38 2552 3.42/3.38 -.20 .03 
L_Parahippocampal -17, -21, -14 434 4.40/4.32 -.25 .009 
R_Mid_Cingulate 5, -12, 29 1451 4.39/4.32 -.25 .009 
L_Post_Cingulate -4, -29, 26 1451 3.56/3.52 -.20 .03 
R_Lingual 10, -64, 4 4793 4.33/4.26 -.24 .009 
R_Calcarine 13, -68, 11 4793 4.20/4.14 -.24 .01 
L_Crus_Cerebellum -21, -69, -35 4277 4.16/4.10 -.24 .01 
L_Heschl -37, -28, 12 9059 4.15/4.09 -.24 .01 
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L_Sup_Temporal -44, -21, 6 9059 4.08/4.02 -.23 .01 
R_Inf_Frontal_Trigone 55, 20, 21 4936 4.06/4.00 -.23 .02 
R_Insula 38, 24, 5 4936 3.86/3.81 -.22 .02 
R_Postcentral 47, -8, 33 529 4.02/3.96 -.23 .02 
R_Precentral 41, -16, 42 529 3.28/3.25 -.19 .03 
L_Precentral -44, 4, 27 915 3.91/3.85 -.22 .02 
L_Inf_Frontal_Operculum -53, 9, 19 915 3.34/3.31 -.19 .03 
R_Crus_Cerebellum 31, -67, -37 3927 3.89/3.84 -.22 .02 
L_Inf_Frontal_Trigone -44, 26, 26 1069 3.83/3.78 -.22 .02 
R_Precuneus 15, -55, 21 334 3.72/3.68 -.21 .02 
L_Lingual -14, -58, 3 1319 3.65/3.61 -.21 .02 
L_Calcarine -10, -76, 8 1319 3.46/3.42 -.20 .03 
L_Mid_Occipital -50, -72, 6 808 3.62/3.58 -.21 .02 
L_Mid_Temporal -51, -68, 13 808 3.15/3.12 -.18 .04 
R_Supp_Motor_Area 10, -21, 54 235 3.53/3.49 -.20 .03 
L_Mid_Frontal -29, 62, 6 239 3.45/3.42 -.20 .03 
R_Mid_Frontal 35, 49, 4 334 3.27/3.24 -.19 .03 
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4.3.7 Interaction between Age and WMHL in GM 
This section will display results regarding statistical interaction, or moderation of age 
Main Effects on GM by WMHL. Figure 28 shows areas of the brain in which the Main Effect of 
age on GM varies as a function of WMHL magnitude. Specifically, this graphic shows the 
projection of the interaction between age and WMHL as an rp image onto orthogonal sections of 
the Standard Single Subject MNI template in MRIcron (PFDR = .05, k = 30).  Part a shows that the 
Main Effect of age on GM is moderated by WMHL lesions in the right posterior hippocampus (rp 
= -.22, x = 36, y = -28, z = -9). This interaction is also observable in part b in the mammillary 
bodies (red box, left: rp = -.21, x = -6, y = -4, z = -15 and right: rp = -.22, x = 6, y = -4, z = -15) 
on coronal projection. This interaction is also visible in part c which shows more impressively 
the moderation of age by WMHL in the anterior cingulate gyrus (left: rp = -.22, x = -4, y = 27, z 
= 20 and right: rp = -.25, x = 5, y = 25, z = 20). The interaction also extends into the middle 
cingulate gyrus (left: rp = -.25, x = -3, y = 1, z = 33 and right: rp = -.26, x = 4, y = 2, z = 33).  
 
 
Figure 28: This figure shows areas of the brain in which the Main Effect of age on GM varies as a 
function of WMHL. This is seen in such key strategic brain areas as the left posterior hippocampus (part a) 
anterior cingulate (part c) and also in the mamillary bodies (part b, red box).     
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The peak local maxima of the interaction between age and WMHL are displayed in Table 
14. The top three most strongly affected areas in terms of this interaction are in key strategic 
brain areas.   
 
Table 14: Local Peak Maxima of the Moderation of Age Main Effects on GMVL by WMHL. 
Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value PFDR 
L_Ant_Cingulate 0, 8, 29 4242 5.24/5.12 -.29 .003 
R_Ant_Cingulate 5, 26, 18 4242 4.32/4.25 -.24 .008 
R_Post_Hippocampus 37, -29. -8 173 4.08/4.02 -.23 .02 
L_Mid_Cingulate -1, 30, 33 207 3.94/3.89 -.22 .02 
L_Mid_Temporal -67, -38, 4 172 3.84/3.79 -.22 .03 
R_Rolandic_Operculum 41, 1, 18 33 3.79/3.75 -.22 .03 
L_Inf_Temporal -59. -36, -19 65 3.71/3.67 -.21 .03 
 
 
This chapter has several main findings. First, age and WMHL both separately and jointly 
affect large portions of GM with particular emphases on key strategic brain regions, namely the 
hippocampus, precuneus, and anterior and posterior cingulate gyrus. These conclusions are based 
on data regarding the Main Effects of WMHL and age and their conjunction. The interaction 
between WMHL and age suggests that the relationship between higher age and lower GM is 
moderated by co-morbid WMHL which in turn reflects end organ brain damage from 
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hypertensive vascular disease. That that interaction took place in key strategic brain areas such as 
the hippocampus suggests that one mechanism by which age can confer higher risk for dementia 
is because vascular disease is more likely to occur in older age and thus induce brain atrophy in 
these areas.  Thus, if vascular disease could be prevented or better controlled this may reduce 
risk for dementia by lower the extent of age related brain atrophy in areas relevant to cognitive 
function such as the hippocampus and cingulate gyrus. With respect to building the model on the 
relationships between vascular disease, brain aging, neurodegeneration and cognition, the 
contributions of this chapter to that model are shown in Figure 29. 
 
 
Figure 29: This figure shows the progressive construction of the overall model of this dissertation 
with contributions from chapter 4 added. Age and hypertension are correlated with WMHL. More WMHL 
are correlated with gray matter atrophy in key strategic brain regions as is older age.  The conjunction 
between age and WMHL in terms of this atrophy is symbolized by both arrows from each of those boxes 
pointing to the circle that represents GM atrophy in key strategic regions. The red arrow drawn from the 
WMHL lesions box to the older age arrow symbolizes how these lesions moderate the relationship between 
age and GM volume.  
This concludes the chapter detailing the Main Effects of age, WMG, their conjunction, an 
interaction in GM in the CHS-CS cohort of 302 controls. Having examined the Main Effect of 
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WMHL and it’s moderation of age Main Effects on the brain, I will now present results 
pertaining to the relationship between WMHL and cognition.  
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5.0  COGNITION MAIN EFFECTS ON GRAY MATTER OVERLAP WITH THOSE 
FROM WHITE MATTER HYPERINTENSE LESIONS AND ARE MEDIATED BY CO-
MORBID NEURODEGENERATION 
5.1 INTRODUCTION 
Having identified that WMHL moderate the effects of age on GM atrophy, it now becomes 
relevant to inquire whether or not these lesions have implications for cognitive function. The 
data presented in this chapter will seek to answer this question in several ways. First, I will 
present data showing that WMHL is a statistically significant predictor of lower scores on a 
composite cognitive score (CCS) of domain specific neuropsychological tests and that this is 
mediated by GM volume. Next, I will show SPM data pertaining to areas of the brain that are 
higher in volume better CCS scores and the overlap of these areas with the Main Effects of 
WMHL. I hypothesize that WMHL Main Effects target brain areas that are themselves correlated 
with improved cognitive function, such as the hippocampus. Verifying this hypothesis will 
provide an appropriate context for next investigating the overlap between MCI and dementia, 
which I use as behavioral proxies for underlying neurodegeneration, in Chapters 6-7.  
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5.2 MATERIALS AND METHODS 
All subjects were drawn from the CHS-CS as described in Chapter 2. The metric of cognition 
used in these analyses was a composite cognitive score (CCS) and was derived, as described in 
chapter 2, from age and education adjusted t-scores from domain specific tests of executive 
function, motor function, language function, processing speed, and visual-spatial functions. Of 
the 456 subjects scanned with SPGR MRI in 1997-1999, detailed domain specific 
neuropsychological data and thus CCS scores were available for 350. A regression model 
designed to predict CCS was constructed in SPSS with WMG, gender, and race as the 
independent variables. This model was then re-run with GM as a proportion of total head size 
included as a covariate in order to determine if the Main Effect of WMHL on CCS was mediated 
either partially or completely by brain structure.  
SPM analyses were then conducted. First, CCS correlated with GM while controlling for 
TIV and WMHL to yield both the unmasked and masked Main Effects of CCS to determine 
which areas of GM have higher volume in relation to better CCS performance and the SPM 
design matrix for this is seen in Figure 30. This figure shows the SPM design matrix used in 
examining the correlations of CCS and WMHL with GM volume. Age and education were not 
covariates in this model because CCS was already adjusted for them. Gender, race, and MRI 
infarcts were not included in the model either because neither were correlated with GM volume 
(gender: rp (347) = .02, p = .73, TIV covariate); (race: rp (347) = -.03,  p = .61, TIV covariate); 
(MRI infarcts rp (347) = -.09,  p = .08, TIV covariate).   With this model, a conjunction analysis 
was also performed to reveal voxels with both a CCS and WMG Main Effect. The conjunction 
analysis is the most important one conducted in this chapter because it shows which areas of the 
brain atrophy in relation to WMHL and are correlated with higher CCS. In doing this, I will 
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therefore show that WMHL affect brain areas that are specifically correlated with cognition in 
the CHS-CS. To maximize sample size and statistical power, control, MCI, and dementia 
subjects were included in the analysis. However, because MCI and dementia are outcomes of 
impaired cognition, they are highly correlated with CCS in this sample (r(350) = -.69, p < .001).  
To avoid multicollinearity, we therefore did not use MCI or dementia as predictor variables of 
CCS in this analysis.  
 
 
Figure 30: This figure shows the SPM design matrix used in examining the Main Effect of CCS (2nd 
column) and WMHL in the third column.  
 
Table 15 shows the demographic characteristics of the subjects utilized in this analysis. 
There were statistically significant differences in age between normals and MCI, normals and 
dementia, and MCI and dementia with the demented subjects having the oldest average age. 
There were also demographic differences in education and race with the MCI group having the 
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highest percentages of African-American persons, and those with only a high school education. 
Demented persons had the highest burden of WMHL, statistically different from controls but not 
those with MCI. Finally, with respect to CCS, there was progressive worse cognitive function 
along the spectrum of normal, MCI, and dementia.  
Table 15: Demographic characteristics of CHS-CS subjects with domain specific cognitive scores at 
MRI2 in 1997-1999. 
Variable Normal (n=248) MCI (n=70)  Dementia (n=32)  T-test(t, p)/χ2 
Age 77.77 ± 3.59 79.42  ± 4.66 82.72  ± 4.85 *-2.75, .007 
** -5.57, < .001 
*** -3.27, .001 
Gender (F) 61% (151) 56% (39) 63% (20) .70, .72 
Education (12th 
Grade only) 
35% (86) 53% (37) 44% (14) 7.89, .02 
Race 22% (44) 49% (23) 32% (10) 9.02, .01 
Infarcts 27% (66)  31% (22) 41% (13) 2.99, .24 
WMG 2.23  ± 1.35 2.37  ± 1.73 3.06  ± 1.79 * -.75, .46 
** -3.16, .002 
*** 1.85, .07 
CCS 50.22  ± 4.98 40.71  ± 8.18 32.13  ± 9.19 * 12.04, < .001 
** 16.75, < .001 
*** -4.28, < .001 
• *Normal compared to MCI 
• **Normal compared to dementia  
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• ***MCI compared to dementia 
5.3 RESULTS 
5.3.1 Mediation of WMHL Main Effects on CCS by Brain Structure 
Table 16 shows the results of the first SPSS model in which CCS is the dependent variable and 
WMHL, gender, race, and MRI infarcts were the independent variables. The strongest predictors 
of CCS were WMHL and race.  
Table 16: Predictors Composite Cognitive Score 
Independent Variable t-value p-value Partial 
Correlation 
Value (rp) 
WMHL -2.62 .009 -.14 
Gender -.09 .93 -.01 
Race -2.68 .008 -.15 
MRI Infarcts -1.39 .17 -.07 
 
To determine if the correlation between WMHL and CCS was mediated by GM volume 
itself, GM as a fraction of TIV was inputted into the model as an independent variable. The 
results of this model are shown in Table 17. When GM volume as a proportion of TIV is 
included in the analysis, the correlation between WMHL and CCS is no longer statistically 
significant. The Main Effect of WMHL on CCS is therefore partially mediated by brain 
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structure.  This is represented by Figure 31 which shows that the manner in which WMHL 
affects cognition is through brain structure, which is logical given the known Main Effects that 
such lesions have on GM volume based on the data presented in Chapter 4.  
Table 17: Predictors of Combined Cognitive Score with Mediation Effect by Brain Structure 
Independent Variable t-value p-value Partial 
Correlation 
Value (rp) 
WMHL -1.52 .13 -.08 
GM/TIV 2.69 .007 .19 
Gender -.53 .59 -.03 
Race -2.68 .008 -.14 
MRI Infarcts -1.51 .13 -.08 
 
 
Figure 31: This figure shows how the relationship between WMHL and cognition is partially 
mediated by GM volume. That is, the reason that WMHL are related to cognition is through their Main 
Effect on GM volume. That is, WMHL induce changes in GM volume (blue arrow) and it is those alterations 
that  themselves results in the changes in cognition. The red arrow reflects how increases in GM volume 
translate to increases in CCS and the red arrow shows the negative correlation between WMHL and CCS. 
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5.3.2 Positive Correlation between CCS and GM volume 
Figure 32 shows the positive correlation between CCS and GM volume at the voxel level. It is 
very important to understand that in showing this figure, I do not mean to imply that increasing 
CCS is causing higher GM volume. Rather, what I am trying to convey in this figure is that if 
CCS is higher it is most likely attributable to higher GM volume in the areas highlighted.  
 
Figure 32: This figure shows the positive correlation between GM and CCS, observed in all four 
lobes of the cerebrum including the frontal and temporal lobes.  
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The section renderings of this correlation are shown in Figure 33. It shows areas of the 
GM that are higher in correlation with higher CCS scores, controlling for WMHL and TIV (PFDR 
= .05, k = 100). Panel 1 shows a coronal image indicating higher GM volume in the highlighted 
areas translates to better scores on CCS. This is evident in both hippocampi (double headed 
arrows). Panel 2 shows that in the left hippocampus, this relationship is localized in the anterior 
hippocampus (rp = -.17, x = -24, y = -11, z = -19). By contrast, Panel 3 shows that the right 
hippocampus has higher volumes throughout the extent of the hippocampus in correlation to 
higher CCS (posterior: rp = -.15, x = 32, y = -33, z = -5). Panel 4 shows that the left posterior 
cingulate gyrus (red arrow: rp = -.18, x = -9, y = -50, z = 24), left precuneus (black arrow: rp = -
.17, x = -9, y = -65, z = 37) and the left anterior cingulate gyrus (blue arrow) all have higher GM 
volume and that these larger volumes translate to a better performance on CCS. Panel 5 shows 
that while this relationship is also observed for the right posterior cingulate (rp = -.19, x = 10, y = 
-48, z = 23) and precuneus (rp = -.24, x = 10, y = -55, z = 20) (red box) it is not for the right 
anterior cingulate. Panel 6 shows that larger GM volumes in both caudate nuclei and thalami 
(blue box) are positively correlated to better CCS results.  All remaining correlation effect sizes 
are provided in Table 18. 
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 Figure 33: This figures shows areas of the GM that are higher in correlation with higher CCS scores, 
controlling for WMHL and TIV (PFDR = .05, k = 100).  
The peak maxima of CCS Main Effects are displayed in Table 17.  
 
Table 18: Peak Maxima showing brain regions where larger GM volumes are correlated with higher 
CCS. 
Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value PFDR 
R_Postcentral 67, -6, 28 374634 6.14/5.98 .31 < .001 
L_Thalamus -10, 11, 8  6.03/5.93 .31 < .001 
R_Caudate 12, 14, 7  5.77/5.63 .30 < .001 
R_Inf_Temporal 64, -23, -22  5.59/5.47 .29 < .001 
 112 
R_Insula 34, -15, 12  5.42/5.31 .28 < .001 
R_Mid_Temporal 61, -15, -1  5.31/5.20 .27 < .001 
L_Mid_Temporal -46, -47, 16  5.29/5.19 .27 < .001 
R_Rolandic_Operculum 46, -1, 11  5.23/5.13 .27 < .001 
R_Angular 47, -66, 46  5.22/5.12 .27 < .001 
R_Inf_Frontal_Trigone 53, 43, 3  5.13/5.03 .27 < .001 
R_Inf_Frontal_Operculum 45, 10, 24  5.02/4.93 .26 < .001 
R_Sup_Temporal 59, -9. 0  4.87/4.79 .25 < .001 
L_Inf_Frontal_Operculum -41, 14, 29  4.86/4.78 .25 < .001 
R_Precuneus 13, -55, 27  4.82/4.74 .25 < .001 
R_Ant_Hippocampus 28, -11, -15  4.81/4.73 .25 < .001 
L_Sup_Occipital -27, -70, 39  4.75/4.67 .25 < .001 
L_Inf_Parietal -32, -43, 45  4.70/4.63 .25 < .001 
L_Mid_Cingulate -12, 6, 42 1156 3.22/3.19 .17 .007 
L_Ant_Cingulate -10, 31, 24  2.83/2.82 .15 .01 
L_Crus_Cerebellum -54, -59, -42 817 3.04/3.02 .16 .01 
L_Cerebellum -31, -64, -47 1805 3.02/3.00 .16 .01 
R_Mid_Cingulate 14, 22, 35 192 2.91/2.89 .15 .01 
L_Mid_Occipital -32, -92, -6 405 2.83/2.81 .15 .01 
L_Fusiform -25, -81, -9  2.69/2.68 .14 .02 
R_Fusiform 28, -78, -11 101 2.34/2.35 .13 .03 
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5.3.3 Positive Correlation between GM Volume and CCS with WMHL Main Effects 
masked out 
The positive correlation between GM volume and CCS is now presented having excluded 
any voxels statistically significant in terms of having a Main Effect of WMHL (Figure 29).  
 
Figure 34: The positive correlation between GM volume and CCS are confined largely to the, 
temporal, parietal and occipital lobes when masking out the Main Effects of WMHL (PFDR = .05, k = 100). 
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The section rendering of the positive correlation between GM volume and CCS masked 
for WMG are shown in Figure 35. Part a shows that even after masking, there is still an 
independent correlation of GM volume and CCS in the right hippocampus (crosshair). This is 
also the case for the left anterior hippocampus as shown in part b (crosshair). Part c reveals that 
both the left (crosshair), right precuneus and right anterior cingulate main affects still persist in 
this correlation though the posterior cingulate effect is no longer visible due to the fact that it was 
encompassed in the WMHL Main Effect and thus masked out.  Part d show that the correlation 
of GM volume and  CCS in the left (crosshair) in the right caudate nuclei is still present.   
 
Figure 35: Section rendering in SPM of the positive correlation between GM volume and CCS after 
masking out the Main Effect of WMHL.   
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The spatial coordinates corresponding to the highest correlations between GM and CCS, 
masking out the WMHL Main effect, are shown in Table 19. The top two peak maxima are in the 
key strategic brain area of the caudate and the anterior hippocampus is the fourth largest peak 
maximum in terms of effect size. In all, five peak maxima are located in key strategic brain 
areas. 
Table 19: This table shows the peak maxima  in GM in association with CCS while masking out 
WMHL Main Effects. 
Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value PFDR 
L_Caudate -10, 11, 8 8310 6.09/5.93 -.31 < .001 
R_Caudate 12, 14, 7 18257 5.77/5.63 -.30 < .001 
R_Inf_Frontal_Operculum 43, 11, 24  4.81/4.73 -.25 < .001 
R_Ant_Hippocampus 28, -11, 15  4.81/4.73 -.25 < .001 
R_Angular 46, -66, 46 31135 5.22/5.12 -.27 < .001 
R_Mid_Temporal 45, -57, 22  5.15/5.05 -.27 < .001 
R_Inf_Parietal 50, -53, 48  4.63/4.56 -.24 < .001 
L_Mid_Temporal -46, -48, 20 37442 5.09/5.00 -.26 < .001 
R_Precuneus 14, -54, 27  4.81/4.73 -.25 < .001 
L_Sup_Occipital -27, -70, 39  4.75/4.67 -.25 < .001 
R_Inf_Temporal 66, -20, -36 1022 4.69/4.62 -.24 < .001 
L_Med_Sup_Frontal -1, 62, 10 709 3.73/3.69 -.20 .002 
L_Inf_Temporal -69, -25, -25 416 2.93/2.91 -.16 .01 
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L_Calcarine 3, -88, 9 1195 2.83/2.81 -.15 .01 
L_Lingual -4, -80, 5  2.34/2.33 -.12 .03 
L_Ant_Cingulate -11, 33, 21 480 2.81/2.79 -.15 .02 
L_Sup_Temporal_Pole -40, 11, -20 125 2.58/2.56 -.14 .02 
5.3.4 Conjunction of GM Volume/CCS Correlation and WMHL Main Effects 
Voxels in which there is both a statistically significant CCS and WMHL correlations with GM 
are shown in Figure 36.    
 
Figure 36: This figure shows the conjunction of CCS and WMHL correlations with GM volume 
(PFDR = .05, k = 100). The conjunction is evident in the frontal, temporal (including mesial temporal), occipital 
lobes, and cerebellum. 
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 Figure 37 shows the conjunction between CCS and WMHL correlations with GM 
volumes. Part a shows that both CCS and WMHL are jointly significant in their correlations with 
GM in voxels residing in the left anterior hippocampus (part a, crosshairs). Part b shows a similar 
conjunction in the right posterior hippocampus. Part c indicates a CCS-WMHL conjunction in 
the posterior cingulate gyrus, with the crosshair located on the left side. Part d shows joint CCS 
and WMHL Main Effects in the thalamus. This figure therefore shows that WMHL are 
correlations with lower GM volume in the same brain regions in which larger GM volumes 
translate to better performance on neuropsychological evaluations of cognition.  
 
Figure 37: Section rendered SPM t-imaging showing brain areas in which both increased volumes 
translate to better cognitive scores and where WMHL related atrophy occurs.   
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 The peak maxima with respect to the CCS-WMHL conjunction are visible in table 20. 
This conjunction includes 7 peak maxima located in key strategic brain areas.   
Table 20: Peak Maxima of the Conjunction between CCS and WMHL Correlations with GM. 
Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value PFDR 
R_Postcentral 66, -7, 29 145310 6.12/5.96 -.31 < .001 
R_Insula 34, -15, 13  5.37/5.36 -.28 < .001 
R_Rolandic_Operculum 50, 8, 7  5.03/4.94 -.26 < .001 
R_Inf_Frontal_Trigone 53, 42, 1  4.95/4.86 -.26 .001 
R_Sup_Temporal 59, -9, 0  4.87/4.79 -.25 .001 
L_Inf_Frontal_Operculum -41, 14, 29  4.86/4.78 -.25 .001 
R_Mid_Temporal 56, -18, -7  4.79/4.71 -.25 .001 
R_Inf_Frontal_Operculum 49, 9, 22  4.77/4.69 -.25 .001 
L_Inf_Frontal_Trigone -47, 17, 5  4.59/4.52 -.24 .001 
L_Heschl -33, -27, 12  4.39/4.33 -.23 .002 
L_Sup_Temporal -49, -45, 18  4.38/4.31 -.23 .002 
R_Inf_Frontal_Trigone 49, 22, 5  4.34/4.28 -.23 .002 
R_Precentral 53, 2, 26  4.26/4.20 -.22 .002 
R_Sup_Temporal 61, -23, 5  4.25/4.19 -.22 .002 
L_Sup_Temporal -50, -45, 22  4.20/4.15 -.22 .003 
R_Precuneus 12, -55, 23 9084 4.69/4.61 -.24 .001 
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R_Calcarine 16, -62, 8  3.68/3.64 -.19 .006 
L_Precuneus -7, -52, 16 2689 4.43/4.37 -.23 .002 
L_Post_Cingulate -6, -44, 23  3.06/3.04 -.16 .02 
L_Lingual -11, -63, 2  3.04/3.01 -.16 .02 
L_Sup_Frontal -17, 41, 49 5031 4.09/4.04 -.21 .003 
L_Medial_Sup_Frontal -5, 65, 6  3.88/3.83 -.20 .005 
L_Mid_Frontal -41, 25, 46 547 3.81/3.77 -.20 .005 
R_Post_Cingulate 11, -38, 31 287 3.69/3.66 -.19 .006 
L_Cuneus -13, -72, 20 2016 3.69/3.65 -.19 .006 
L_Sup_Occipital -22, -74, 25  2.88/2.86 -.15 .02 
L_Inf_Temporal -58, -9, -30 1621 2.99/2.97 -.19 -.16 
L_Inf_Parietal -30, -42, 52 390 3.52/3.48 -.19 .008 
L_Sup_Parietal -29, -58, 50  2.81/2.79 -.15 .03 
R_Cuneus 12, -76, 27 1304 3.41/3.38 -.18 .01 
R_Sup_Occipital 25, -73, 29  2.96/2.94 -.16 .02 
L_Thalamus -19, -24, 8 590 3.37/3.34 -.18 .01 
R_Sup_Frontal 22, 54, 20 2186 3.33/3.30 -.17 .01 
R_Mid_Frontal 29, 50, 24  2.98/2.96 -.16 .02 
R_Med_Sup_Frontal 8, 36, 56 245 2.78/2.76 -.15 .03 
R_Mid_Occipital 30, -92, 12 1659 3.26/3.23 -.17 .01 
R_Inf_Occipital 32, -94, -6  3.18/3.16 -.17 .01 
L_Mid_Cingulate -12, 6, 42 317 3.22/3.19 -.17 .01 
L_Ant_Cingulate -11, 27, 28  2.78/2.77 -.15 .03 
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L_Mid_Temporal -63, -53, -2 1057 3.19/3.17 -.17 .01 
L_8_Cerebellum -31, -64, -47 834 3.02/3.00 -.16 .02 
R_Mid_Cingulate 11, -30, 36 114 2.99/2.97 -.16 .02 
R_Angular 32, -64, 45 942 2.95/2.93 -.16 .02 
R_Sup_Temporal_Pole 32, 10, -27 255 2.95/2.93 -.16 .02 
R_Paraphippocampal 23, 6, -21  2.41/2.40 -.13 .04 
 
While a conjunction existed between WMHL and CSS, there was no statistically 
significant interaction between the two. To summarize, domain specific tests of 
neuropsychological function can be combined to form a composite score that is positively 
correlated with brain areas that are known to be implicated in cognitive function, mainly in the 
temporal and parietal lobes. This relationship is present even when controlling for WMHL 
atrophy. Thus, WMHL have relevance for cognitive impairment because they are related to 
atrophy in the same brain areas in which larger GM volumes are correlated with better 
performance on CCS. The contribution of this chapter’s results to the overall model is displayed 
in Figure 38. 
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 Figure 38: This figure shows the contributions of the chapter 5 results to the overall model.  WMHL 
are correlated to impaired cognition and this is mediated mainly by alterations in the volume of key strategic 
brain regions  
 
Based upon this reasoning, I next investigated the interactions and conjunctions of 
WMHL with MCI and dementia. The results of these analyses occupy the contents of chapters 6 
and 7 with chapter 6 focused on the relationship between WMHL and MCI and chapter 7 
engaged with WMHL and dementia Main Effects on GM volume.  
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6.0  INTERACTION BETWEEN WHITE MATTER HYPERINTENSE LESIONS 
AND MILD COGNITIVE IMPAIRMENT IN GRAY MATTER 
6.1 INTRODUCTION  
I have identified WMHL as predictors of lower GM volume in areas of the brain that are known 
to be affected by aging and cognitive function. Having done this, I now focus on whether or not 
WMHL either conjunct or interact with behavioral proxies for neurodegeneration. As I have 
discussed in chapter 2, MCI is commonly acknowledged as a high risk state for dementia and 
thus potentially represents a relatively early phase of neurodegeneration. This chapter presents 
data that examines the interaction between WMHL and MCI. All MCI subjects were used for 
this analysis regardless of whether or not they progressed after 5-years. This chapter shows MCI 
effects on brain structure varies as a function of WMHL and this moderation is localized in the 
anterior cingulate gyrus: an area relevant to vascular disease, dementia pathology, and cognitive 
function.  
6.2 MATERIALS AND METHODS 
This analysis utilized 399 CHS-CS scans from individual participants in 1997-1999. Subject 
demographics are detailed in Table 21. MCI subjects tended to be older, less educated and more 
 123 
likely to be African-American compared to the control group (p < .05). The MCI group also had 
a higher percentage of MRI identified infarcts than the control group though this difference did 
not reach statistical significance (p = .06).  
 
Table 21: Demographics Characteristics of Control and MCI Subjects 
Variable Normal (n=302) MCI (n=97)  T-test(t, p)/χ2 
Age 77.96 ± 3.63 79.47  ± 4.56 -3.33, .003 
Gender (F) 60% (182) 56% (54) .64, .25 
Education (12th 
Grade only) 
37% (111) 30% (47) 4.20, .03 
Race 17% (52) 30% (29) 7.29, .006 
Infarcts 26% (79)  35% (34) 2.86, .06 
WMG 2.30  ± 1.43 2.49  ± 1.74 -1.08, .28 
 
Before testing the interaction between WMHL and MCI itself, I wanted to first assess the 
Main Effect of WMHL in the MCI group only to see if the distribution of this atrophy differed in 
these subjects compared to what was observed in Chapter 4 in the controls. The SPM statistical 
model that was used to test this Main Effect is seen in Figure 9. This model included standard 
covariates such as age, gender, race, education, and MRI infarcts (design matrix not shown). I 
next tested the Main Effect of MCI and WMHL in all 399 subjects with standard covariates and 
this model is shown in Figure 39, which depicts the SPM2 design matrix used to assess the Main 
Effects of MCI, WMHL, and their conjunction.  
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 Figure 39: This SPM2 design matrix shows columns modeling the Main Effect of MCI (2nd column) 
and WMHL (3rd column). The remaining columns model the confounding effect of head size, age, gender, 
education, race, and MRI identified infarcts.  
 
A separate statistical model was constructed to investigate the interaction between 
WMHL and MCI. This was done by centering the CHS WMG visual grading around its overall 
mean and multiplying that by the binary MCI variable. This interaction term then comprised its 
own column in the subsequent SPM2 design matrix shown in Figure 40. A contrast vector weight 
of -1 was applied to the interaction column to yield the subsequent areas of the brain that are 
reduced in GM volume in correlation with the interaction term. All analyses were done with an 
FDR threshold of 5% and an extent threshold of 30 voxels for the interaction analysis.  
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 Figure 40: This design matrix is identical to that presented in Figure 33 with the sole difference being 
the additional interaction term in the fourth column of the design matrix.  
 
6.3 RESULTS 
In all 399 subjects, there were no independent Main Effects of MCI on GM volume. The WMHL 
Main Effects were identical to those described in chapter 4.  For the Main Effect of WMHL in 
only the 97 MCI subjects, the volume rendered t-image is displayed in Figure 41. Like the Main 
Effects observed in Chapter 4 in the controls, the Main Effect of WMHL in the 97 MCI subjects 
was observed most impressively in the frontal lobes, including the orbital frontal cortex. This 
similarity also holds in viewing the temporal lobes in which there is atrophy in relation to 
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WMHL. Unlike the WMHL Main Effects in controls, however, there are fewer observable 
parietal lobe Main Effects in MCI group.   
 
Figure 41: This figure shows the Main Effect of WMHL in 97 MCI subjects from the CHS-CS, 
volume rendered onto the Standard Single Subject MNI template (PFDR = .05, k = 100). These Main Effects 
are most impressive in the paramedian frontal lobes, orbital frontal cortex, and the temporal cortices.  
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Figure 42 shows section renderings of the Main Effect of WMHL in only the MCI 
subjects. Correlation effects sizes in all regions are above .30 in magnitude.  Part a highlights 
how impressively the frontal lobes are lower in GM volume with increased WMHL burden. Part 
b shows that the Main Effects of WMHL are seen in both the putamen and the thalamus. Part c 
shows in the center of the crosshairs how higher WMHL is associated with lower GM volumes 
in the right precuneus. 
 
Figure 42: Main Effect of WMHL in 97 MCI subjects.  
Table 22 shows the peak maxima of the WMHL Main Effect in the MCI group. Eleven sites of 
these peak maxima are in key strategic brain areas and are highlighted in bold.  
Table 22: Peak Maxima of the WMHL Main Effect in the MCI Subjects 
Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value PFDR 
R_Sup_Frontal 15, 60, 21 74758 6.25/5.68 -.55 < .001 
R_Med_Sup_Frontal 11, 46, 45  6.12/5.58 -.54 < .001 
R_Mid_Frontal 38, 17, 47  5.36/4.98 -.49 < .001 
R_Mid_Cingulate 12, 26, 39  5.27/4.90 -.49 < .001 
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R_Rolandic_Operculum 61, -1, 11  5.24/4.88 -.49 < .001 
R_Supp_Motor_Area 9, -21, 57  5.00/4.68 -.47 < .001 
R_Postcentral 39, -24, 42  4.97/4.66 -.47 < .001 
R_Supramarginal 65, -20, 22  4.58/4.33 -.44 < .001 
R_Sup_Orbital_Frontal 16, 51, -15  4.52/4.27 -.43 < .001 
R_Mid_Orbital_Frontal 10, 67, -3  4.36/4.14 -.42 < .001 
R_Inf_Frontal_Trigone 51, 28, 9  4.34/4.12 -.42 < .001 
R_Sup_Temporal 65, 1, 2  4.16/3.96 -.40 < .001 
L_Postcentral -56, -8, 23 78470 5.87/5.38 -.53 < .001 
L_Inf_Frontal_Trigone -47, 28, 9  5.77/5.30 -.52 < .001 
L_Precentral -55, -2, 29  5.71/5.26 -.52 < .001 
L_Paracentral_Lobule -10, -23, 52  5.62/5.18 -.51 < .001 
L_Supp_Motor_Area -9, -10, 54  5.45/5.05 -.50 < .001 
L_Sup_Frontal -15, 61, 9  5.14/4.80 -.48 < .001 
L_Roladic_Operculum -59, 0, 10  5.01/4.69 -.47 < .001 
L_Mid_Cingulum -13, -22, 48  4.91/4.60 -.46 < .001 
L_Inf_Frontal_Operculum -16, 41, 38  4.78/4.50 -.45 < .001 
L_Supp_Motor_Area -15, -11, 64  4.61/4.35 -.44 .001 
L_Mid_Orbital_Frontal -13, 66, -1  4.57/4.32 -.44 .001 
L_Post_Cingulate -8, -35, 29  4.48/4.24 -.43 .001 
L_Medial_Sup_Frontal -11, 19, 42  4.39/4.17 -.42 .001 
L_Inf_Orbital_Frontal -39, 40, -7  4.25/4.04 -.41 .001 
L_Inf_Frontal_Operculum -50, 9, 15  4.19/4.00 -.41 .001 
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R_Thalamus 15, -14, 16 21825 5.57/5.14 -.51 < .001 
L_Thalamus -14, -15, 13  5.47/5.06 -.50 < .001 
R_Calcarine 11, -84, 16 7747 4.55/4.30 -.43 .001 
R_Inf_Occiptial 29, -95, -6  4.12/3.93 -.40 .002 
L_Lingual -14, -70, -1 2090 3.81/3.65 -.37 .004 
R_Crus_Cerebellum 38, 59, -41 1802 3.73/3.59 -.37 .004 
L_Inf_Temporal -51, -27, -19 3934 3.63/3.49 -.36 .006 
R_Sup_Temporal 50, -12, -9 2556 3.56/3.43 -.35 .006 
R_Cuneus 19, -72, 33 1207 3.32/3.21 -.33 .01 
R_Sup_Occiptial 18, -85, 37  2.90/2.83 -.29 .02 
L_Crus_Cerebellum -40, -65, -26 3520 3.28/3.18 -.33 .01 
L_Inf_Occipital  -37, -67, -9 3520 3.25/3.15 -.33 .01 
L_Angular -47, -49. -33  3.16/3.07 -.32 .01 
L_Putamen -25, 4, 5 472 3.20/3.10 -.32 .01 
R_Precuneus 12, -50, 21 226 3.17/3.08 -.32 .01 
R_Mid_Temporal 44, -65, 1 324 3.13/3.04 -.31 .02 
R_Putamen 27, 3, 9 694 3.10/3/02 -.31 .02 
L_Cuneus -8, -81, 22 105 3.00/2.92 -.30 .02 
L_Supramarginal -46, -33, 34 103 2.98/2.90 -.30 .02 
R_Supramarginal 65, -32, 39 107 2.95/2.87 -.30 .02 
L_Fusiform -27, -78, -10 636 2.75/2.68 -.28 .03 
R_Inf_Orbital_Frontal 39, 46, -1 244 2.85/2.78 -.29 .03 
L_Mid_Tepmoral_Pole -46, 20, -36 367 2.59/2.54 -.26 .04 
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L_Inf_Temporal -58, 0, -33 140 2.70/2.64 -.28 .03 
 
 The WMHL by MCI interaction is depicted in the volume rendered t-image of Figure 43 
which shows the moderation in the temporal, parietal, and frontal lobes – including orbital 
frontal cortex.  
 
Figure 43: This figure shows the volume rendered representation of the interaction between WMHL 
and MCI status. 
Figure 44 shows section renderings of the interaction between WMHL and MCI. Part a 
shows that WMHL moderates MCI in GM in the left anterior cingulate gyrus (rp = -.18, x = -5, y 
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= 39, z = -6). This interaction is also observed in the right anterior cingulate gyrus in part b (rp = 
-.18, x = 8, y = 43, z = 8). Finally, part c shows the interaction in the left posterior hippocampus 
as marked with the crosshairs (rp = -.17, x = -30, y = -30, z = -11). There was no such interaction 
in the right hippocampus. 
 
Figure 44: This figure brain areas in which WMHL moderate MCI in GM volume. All of the sites of 
this interaction are shown in key strategic brain areas: the left anterior cingulate gyrus in part a, right 
anterior cingulate gyrus in part b, and left posterior hippocampus in part c (crosshairs).   
 
The peak local maxima of the WMHL and MCI interaction are listed in Table 23. Eight 
peak maxima are located in key strategic brain areas and four out of the top 5 peak maxima are 
located in such areas.  
Table 23: Peak Maxima for the Interaction between WMHL and MCI 
Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value PFDR 
L_Gyrus_Rectus -13, 30, -12 5441 5.66/5.55 -.28 .005 
L_Med_Orbital_Frontal -3, 50, -8 5441 4.46/4.41 -.22 .01 
R_Med_Orbital_Frontal 13, 40, -3 5441 3.74/3.71 -.19 .02 
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L_Ant_Cingulate -5, 39, -6 5441 3.70/3.67 -.18 .03 
R_Ant_Cingulate 8, 43, 8 5441 3.58/3.55 -.18 .03 
L_Mid_Temporal -56, -56, 16 6258 4.83/4.76 -.24 .01 
L_Angular -55, -62, 30 6258 4.33/4.27 -.21 .01 
R_Inf_Temporal 53, -61, -16 2327 4.50/4.44 -.22 .01 
R_Mid_Temporal 59, -36, 4 887 3.93/3.89 -.20 .02 
R_Inf_Orbital_Frontal 41, 34, -18 225 3.84/3.80 -.19 .02 
R_Postcentral 41, -36, 57 38 3.48/3.45 -.17 .03 
L_Post_Hippocampus -30, -30, -11 61 3.47/3.44 -.17 .03 
R_Fusiform 39, -26, -29 36 3.42/3.39 -.17 .04 
L_Sup_Temporal -62, -36, 21 57 3.30/3.30 -.17 .04 
R_Rolandic_Operculum 39, -19, 17 59 3.31/3.29 -.17 .04 
 
Because age and WMHL have been shown to interact in Chapter 4, a separate age by 
WMHL interaction was tested but was not found to be statistically significant. Additionally, 
there was no Main Effect of age in the analysis of WMHL on only the MCI subjects. 
That no separate Main Effect of MCI was found on GM suggests that WMHL may 
mediate the effect of MCI on GM but the lack of MCI Main Effects was not noted until the SPM 
model was adjusted for gender, race, and education covariates. Thus, the lack of MCI Main 
Effects on GM is not due to mediation by co-morbid WMHL. However, there is an interaction 
between MCI and WMHL in GM in key strategic brain regions targeted by neurodegeneration, 
such as the hippocampus and this interaction is unchanged even when having MCI, WMHL and 
TIV as the only covariates in the analysis. This suggests that any MCI related brain atrophy, and 
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thus brain atrophy seen relatively early in neurodegenerative disease, may be moderated by 
comorbid vascular disease as reflected with WMHL. Consequently, WMHL may contribute to 
the pathophysiology of early neurodegeneration. The contributions of this chapter to the overall 
model are provided in Figure 45.  
 
Figure 45: This figure shows the contribution of Chapter 6 data to the overall model. The blue arrow 
symbolizes the interaction between WMHL and MCI on gray matter volume loss. In this case, both black 
arrows from WMHL and MCI to the circle of gray matter atrophy in key strategic brain areas reflects not a 
conjunction of the two Main Effects but rather the fact that WMHL predicts lower gray matter volumes in 
just the MCI subjects.  
 
 To see if WMHL may contribute to the brain atrophy of a more advanced neurodegenerative 
process, dementia, Chapter 7 examined the relationships between WMHL and dementia status.  
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7.0  CONJUNCTION BETWEEN WMHL GRAY MATTER VOLUME LOSS AND 
DEMENTIA ASSOCIATED ATROPHY 
7.1 INTRODUCTION 
Having identified the interactive patterns of WMHL and MCI associated GM volume loss, I now 
present results of my attempts to replicate this analysis with respect to WMHL and dementia. 
While this may seem redundant, it is not for several important reasons. The chapter 6 results 
suggest that MCI related brain atrophy varies as a function of co-morbid WMHL and this was 
shown to occur in such key strategic brain regions as the hippocampus and anterior cingulate 
gyrus. This suggests that early neurodegeneration, as reflected by MCI, is moderated by co-
morbid vascular disease, as indexed by WMHL. This chapter therefore seeks to establish 
whether or not advanced neurodegeneration is also moderated by co-existing vascular disease. I 
do not believe that such an interaction will be statistically significant because in a state of 
dementia, neurodegeneration is likely to be advanced and thus unlikely to vary as a function of 
co-morbid vascular disease.  A conjunction analysis between WMHL and dementia was also 
performed to determine if hypertensive vascular disease and advanced neurodegeneration overall 
in key strategic brain regions.  
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7.2 MATERIALS AND METHODS 
This study utilized 302 cognitively normal controls and 52 persons with dementia (34 Probable 
AD, 9 Possible AD, and 9 with ADDTC defined VaD). The controls and dementia subjects are 
compared in Table 22. Compared to controls, persons with dementia were older, less educated, 
African-American, and afflicted with more WMHL and MRI identified infarcts (p < .05).  
Table 24: Demographic Comparisons of CHS-CS Controls and Dementia Subjects 
Variable Normal (n=302) Dementia (n=52) T-test(t, p)/χ2 
Age 77.96 ± 3.63 82.56  ± 4.99 -6.34, < .001 
Gender (F) 60% (182) 65% (34) .49, .29 
Education (12th 
Grade only) 
37% (111) 54% (28) 5.43, .02 
African 
American Race 
17% (52) 28% (15) 3.91, .04 
MRI Infarcts 
Present 
26% (79)  40% (21) 4.43, .03 
WMHL visual 
grading (WMG) 
2.30  ± 1.43 3.21  ± 1.85 -4.03, < .001 
 
Six statistical analyses were done within SPM. The first analysis assessed for dementia 
associated atrophy while controlling for age, gender, race, education, WMHL and MRI identified 
infarcts. The second analysis also tested for dementia atrophy but masked out any voxels that 
were part of a WMHL Main Effect. The third analysis assessed WMHL Main Effects in just the 
dementia subjects. The fourth statistical analysis then re-evaluated WMHL Main Effects but did 
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so by masking out any voxels that were also part of a dementia Main Effects. The fifth analysis 
tested for a conjunction between WMHL and dementia related atrophy. The sixth and final 
analysis tested for the interaction between WMHL and dementia Main Effects in GM. 
7.2.1 Dementia Main Effects 
The Main Effect of dementia is observed in Figure 46. 
 
Figure 46: This figure shows the Main Effect of dementia on GM projected onto the Standard Single 
Subject MNI template (PFDR =  .05, k = 100). The distribution of these effects are seen notable in the temporal 
lobes, particularly the medial temporal lobes. They are also seen in the temporal-parietal junction and frontal 
lobes.   
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Figure 47 shows the section renderings of the Main Effect of dementia on gray matter. 
Part a shows that being demented is correlated with lower GM volumes in the left precuneus 
(crosshairs). Part b shows the main effect of dementia on the bilateral hippocampus. Part c shows 
that in the left hippocampus, this effect is localized mainly to anterior hippocampus. Part d 
shows that in the right hippocampus, the Main Effect of dementia spans the entire length of the 
hippocampus. Correlation effects sizes for each of these areas are provided in Table 25.  
 
 
Figure 47: This figure shows dementia related atrophy projected onto the Standard Single Subject 
MNI template.  
Peak maxima for the dementia Main Effect are displayed in Table 25. Ten of these peak 
maxima are in key strategic brain areas including the hippocampus, basal forebrain, and 
precuneus. Nine out of the top 10 largest effect sizes for the Dementia Main Effect are located in 
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key strategic brain areas.  The precuneus itself was the site of two different peak maxima, hence 
the delineations of upper and lower.  
Table 25: Peak areas of gray matter volume loss associated with clinical status of dementia. 
Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value PFDR 
R_Mammillary_Body 7, -7, -14 56024 7.46/7.18 -.37 < .001 
R_Ant_Hippocampus 28, -13, -18  6.33/6.16 -.32 < .001 
L_Ant_Hippocampus -31, -15, -21  6.01/5.85 -.31 < .001 
L_Caudate -9, 13, 2  5.83/5.69 -.30 < .001 
R_Caudate 10, 12, 2  5.61/5.49 -.29 < .001 
L_Parahippocampal -26, -11, -32  4.93/4.84 -.26 < .001 
R_Basal_Forebrain 5, 3, -7  4.75/4.68 -.25 < .001 
R_Post_Hippocampus 31, -35, -7  4.16/4.11 -.22 .002 
R_Parahippocampal 35, -28, -12  4.05/4.00 -.21 .002 
L_Insula -42, 13, -9  3.88/3.84 -.20 .003 
L_Inf_Temporal -49, -14, -33  3.88/3.84 -.20 .003 
L_Sup_Temporal_Pole -35, 9, -26  3.54/3.50 -.18 .008 
L_Fusiform -26, 6, -45  3.33/3.30 -.18 .01 
R_Mid_Temporal 53, -12, -11 26552 4.64/4.56 -.24 < .001 
R_Sup_Temporal 58, -9, 2 26552 4.43/4.37 -.23 < .001 
R_Insula 45, -7, 4 26552 4.33/4.27 -.23 .001 
R_Mid_Occipital 29 -70, 30 15837 3.91/3.86 -.21 .003 
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R_Inf_Temporal 52, -40, -20 1916 4.09/4.04 -.22 .002 
L_Mid_Occipital -29, -73, 29 17043 4.05/4.00 -.21 .002 
L_Angular -42, -61, 44  3.85/3.81 -.20 .004 
L_Mid_Temporal -47, -48, 20  3.61/3.57 -.19 .007 
R_Precentral 45, 8, 52 1761 3.61/3.57 -.19 .006 
R_Mid_Frontal 33, 14, 59  2.77/2.76 -.15 .03 
R_Sup_Frontal 18, 11, 69 267 3.51/3.48 -.19 .008 
L_Upper_Precuneus -6, -49, 73 181 3.41/3.38 -.18 .01 
L_Sup_Frontal -26, 59, 23 186 3.39/3.36 -.18 .01 
L_Lower_Precuneus -3, -68, 44 791 3.30/3.27 -.18 .01 
L_Crus_Cerebellum -53, -59, -38 286 3.22/3.19 -.17 .02 
L_Mid_Frontal -42, 26, 45 248 3.10/3.08 -.16 .02 
L_Calcarine -8, -48, 5 184 3.07/3.05 -.16 .02 
L_Inf_Parietal -58, -41, 43 329 3.03/3.01 -.16 .02 
R_Sup_Parietal  15, -53, 70 409 2.94/2.92 -.16 .03 
L_Postcentral -55, -17, 35 147 2.86/2.85 -.15 .03 
 
The Main Effect of dementia masked for the Main Effect of WMHL is visible on the volume 
rendered picture in Figure 48. Unlike the unmasked Main Effect, where some small clusters of 
statistically significant voxels could be seen in the frontal lobe, the masked Main Effect exhibits 
a classic temporal-parietal pattern of brain atrophy seen most often in AD. 
 140 
 Figure 48: This figure shows the Main Effect of dementia on GM when masking out voxels that are 
also statistically significant for a WMHL Main Effect.  The subsequent dementia main effect is representative 
of a typical temporal-parietal atrophy pattern seen most typical with AD in the temporal lobe, parietal lobe, 
and temporal-parietal junction.  
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Figure 49 shows the section rendering of the Main Effect of dementia atrophy masked for 
voxels also encompassed in a WMHL Main Effect. In viewing this, one can see that even after 
masking there is still dementia related atrophy in the left precuneus (part a, green arrow), caudate 
nuclei (part a, blue box), left anterior hippocampus (part b, crosshairs) and right anterior 
hippocampus (part c, cross hairs). 
 .  
 
Figure 49: This figure shows the section rendered t-image of the Main Effect of dementia atrophy 
masked for voxels also encompassed in a WMHL Main Effect and projected onto the Standard Single Subject 
MNI Template. Table 26 shows the corresponding effect sizes.  
Table 26 shows peak maxima of the dementia Main Effect with voxels affected by 
WMHL related atrophy masked out. Eight of the top ten effect sizes are in key strategic brain 
regions. In all, 9 of the peak maxima were located in key strategic brain regions.  
Table 26: Peak Maxima of Dementia Atrophy Masked for WMHL Main Effects 
Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value PFDR 
R_Ant_Hippocampus 28, -13, -18 4195 6.33/6.16 -.32 < .001 
R_Paraphippocampal 35, -28, -12 4195 4.05/4.00 -.21 .002 
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R_Post_Hippocampus 34, -36, -6 4195 3.89/3.84 -.20 .003 
L_Ant_Hippocampus -31, -15, -21 14860 6.01/5.85 -.31 < .001 
L_Parahippocampal -26, -11, -32 14860 4.93/4.84 -.26 < .001 
L_Caudate -9, 13, 2 1571 5.83/5.69 -.30 < .001 
R_Caudate 10, 12, 2 1147 5.61/5.49 -.29 < .001 
R_Putamen 22, 9, 0 1147 2.78/2.76 -.15 .03 
R_Mid_Temporal 50, -50, 17 11662 4.41/4.35 -.23 .001 
R_Sup_Temporal 48, -56, 23 11662 4.22.4.17 -.22 .001 
R_Mid_Occipital 29, -70, 30 11662 3.91/3.86 -.21 .003 
R_Insula 42, 14, -9 2227 4.21/4.16 -.22 .001 
R_Inf_Frontal_Operculum 44, 10, 23 2227 3.15/3.13 -.17 .02 
L_Mid_Occipital -29, -73, 29 8789 4.05/4.00 -.21 .002 
L_Angular -42, -61, 45 8789 3.83/3.79 -.20 .004 
L_Precuneus -6, -9, 73 181 3.41/3.38 -.18 .01 
R_Inf_Temporal 48, -42, -25 124 3.31/3.28 -.18 .01 
L_Crus_Cerebellum -53, -59, -38 286 3.22/3.19 -.17 .02 
R_Sup_Parietal 15, -53, 70 402 2.94/2.92 -.16 .02 
L_Inf_Parietal -33, -50, 41 143 2.82/2.81 -.15 .03 
L_Mid_Temporal -50, -39, -1 154 2.67/2.65 -.14 .04 
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7.2.2 WMHL Main Effects in the Dementia Group 
Figure 50 shows the Main Effect of WMHL in the 52 dementia subjects. There are lower GM 
volumes in relation to increasing WMHL in the frontal lobes, including the orbital frontal cortex.  
 
Figure 50: This figure shows the main effect of WMHL in only the dementia subjects. 
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Figure 51 shows the section rendered r-image of the Main Effect of WMHL in the 
dementia subjects. Part a shows that as WMHL increases in the dementia subjects, there is a 
decrease in GM volume in the right posterior cingulate and extending into the right precuneus 
(crosshairs). Part b shows a WMHL Main Effect in the right posterior hippocampus (crosshairs). 
Part c shows two boxes with a WMHL Main Effect. The red box is drawn around the left 
putamen and the blue box encompasses a WMHL Main Effect in the right thalamus.  
 
Figure 51: This figure shows the section rendered Main Effect of WMHL in the dementia subjects. 
WMHL are associated with atrophy in the right posterior cingulate/precuneus (part a, crosshairs), the right 
posterior hippocampus (part b, crosshairs), the left putamen (part c, red box) and the right thalamus (part c, 
blue box). Correlation effect sizes for these highlighted regions are provided in Table 27.  
 
Table 27 displays statistical information on the peak maxima of the Main Effect of 
WMHL in the dementia subjects. Eight of the peak maxima were located in key strategic brain 
regions and are highlighted in bold.  
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Table 27: Peak Maxima for the WMHL Main Effect in the Dementia Group 
 Structure Peak MNI 
Coordinates
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp 
value 
PFDR 
R_Thalamus 16, -10, 16 4320 5.89/5.03 -.66 .01 
L_Lingual 9, -30, -6  3.61/3.36 -.48 .03 
R_Rolandic_Operculum 67, -7, 14 2165 5.45/4.74 -.63 .01 
L_Rolandic_Operculum -65, -6, 13 5016 5.27/4.62 -.62 .01 
L_Precentral -59, 5, 28  4.69/4.20 -.58 .01 
R_Inf_Frontal_Trigone 44, 36, -1 6131 5.27/4.62 -.62 .01 
R_Mid_Orbital_Frontal 41, 53, -14  4.76/4.25 -.58 .01 
R_Insula 28, 24, -10  4.74/4.24 -.58 .01 
L_Medial_Sup_Frontal -15, 61, 12 2399 5.25/4.60 -.62 .01 
L_Mid_Orbital_Frontal -13, 62, 0  3.78/3.50 -.50 .02 
L_Putamen -25, -7, -6 1799 5.25/4.60 -.62 .01 
R_Supp_Motor_Area 11, -12, 59 302 4.74/4.24 -.58 .01 
R_Paracentral_Lobule 12, -28, 54  3.94/3.62 -.51 .02 
R_Sup_Frontal 16, 64, 10 4332 4.63/4.16 -.57 .01 
R_Sup_Orbital_Frontal 16, 67, -2  4.58/4.12 -.57 .01 
R_Medial_Sup_Frontal 11, 58, 27  4.24/3.86 -.54 .01 
R_Precuneus/R_Post_Cingulate 12, -49, 19 296 4.48/4.05 -.56 .01 
L_Precuneus -16, -43, 2 120 3.74/3.47 -.49 .03 
R_Hippocampus 23, -32, 3 122 3.65/3.38 -.48 .03 
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 7.2.3 WMHL Main Effects Masked for Dementia Main Effects 
Figure 52 shows the Main Effect of WMHL in all 354 subjects (controls and dementia) with 
exclusive masking for the dementia Main Effects. Compared to the Main Effect of WMHL seen 
in Chapter 4, masking for dementia Main Effects results in comparatively less observable 
WMHL Main Effects in the temporal lobes.  
 
Figure 52: Main Effect of WMHL in a combined group of 302 controls and 52 demented subjects 
with voxels in which dementia related atrophy is statistically significant being masked out. The effect of this 
masking is seen mainly in the temporal lobes.  
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Figure 53 shows the section rendered image of WMHL related atrophy with dementia 
related atrophy masked out. Even when masking is applied, WMHL related atrophy is still 
observed in the posterior cingulate gyrus (part a, black arrow), the thalamus (part b, blue square), 
and the hippocampus (parts c and d, black arrows). The large effect sizes in the frontal lobes 
(part a) are still present as well after masking out dementia Main Effects.  
 
Figure 53: This figure shows the Main Effect of WMHL masked for the Main Effects of dementia. 
Even after masking for dementia Main Effects, a greater WMHL burden is associated with lower volumes in 
the posterior cingulate gyrus (part a), basal ganglia (part b, blue box), left middle hippocampus (part c, 
arrow), and right posterior hippocampus (part d, arrow).  
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Table 28 shows the peak maxima of the Main Effect of WMHL masked for dementia 
diagnosis. The orbital frontal cortex remains the as key strategic brain region most strongly 
affected by WMHL related atrophy. In all, peak maxima were located in 7 key strategic brain 
regions (all in bold) and these included the orbital frontal cortex, precuneus, and thalamus. The 
posterior cingulate gyrus was also affected by WMHL atrophy but was not a peak local 
maximum and is thus not listed in Table 28.  
Table 28: Main Effect of WMHL on GM masked for Dementia Main Effects 
 Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value PFDR 
L_Medial_Sup_Frontal -15, 61, 13 501285 9.38/9.35 -.45 < .001 
R_Sup_Frontal 16, 66, 2 501285 9.31/9.28 -.45 < .001 
L_Mid_Orbital_Frontal -11, 61, -2 501285 9.13/9.10 -.44 < .001 
R_Inf_Frontal_Trigone 52, 34, 1 501285 9.04/9.02 -.44 < .001 
R_Mid_Orbital_Frontal 10, 66, -8 501285 9.00/8.97 -.44 < .001 
L_Rolandic_Operculum -59, -1, 14 501285 8.98/8.88 -.43 < .001 
L_Postcentral -56, -13, 26 501285 8.93/8.81 -.43 < .001 
R_Med_Sup_Frontal 11, 59, 27 501285 8.47/8.40 -.41 < .001 
L_Mid_Cingulate -12, -10, 46 501285 8.36/8.34 -.41 < .001 
R_Supp_Motor_Area 9, -19, 57 501285 8.33/8.29 -.41 < .001 
L_Inf_Frontal_Trigone -51, 27, 11 501285 8.18/7/80 -.40 < .001 
R_Precuneus 10, -50, 18 501285 7.83/7.50 -.39 < .001 
L_Inf_Orbital_Frontal -34, 29, -4 501285 7.80/7.48 -.39 < .001 
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L_Sup_Temporal -39, -28, 7 501285 7.76/7.45 -.39 < .001 
R_Inf_Orbital_Frontal 40, 37, -12 501285 7.73/7.42 -.38 < .001 
L_Mid_Temporal -59, -33, 6 501285 7.73/7.41 -.38 < .001 
R_Sup_Temporal 66, -23, 4 501285 7.69/7.39 -.38 < .001 
R_Heschl 35, -24, 14 501285 7.61/7.31 -.38 < .001 
R_Thalamus 17, -21, 0 149 6.81/6.59 -.34 < .001 
L_Thalamus -17, -14, 12 141 5.64/5.51 -.29 < .001 
R_Supramarginal 63, -35, 43 859 5.00/4.91 -.26 < .001 
L_Sup_Parietal -28, -60, 50 1117 3.60/3.56 -.19 .001 
L_Inf_Parietal -30, -43, 54 1117 2.32/2.31 -.12 .02 
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7.2.4 Conjunction between WMHL and Dementia Main Effects 
The surface rendering of the conjunction between WMHL and dementia Main Effects on GM are 
seen in Figure 54. Dementia and WMHL co-occur in the right temporal lobe and mesial temporal 
lobe.  
 
Figure 54: This figure shows that the conjunction between WMHL and dementia Main Effects in 
GM are seen mainly the right temporal lobe and the mesial temporal lobe. 
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 Figure 55 shows section renderings of several conjunctions between the Main Effects of WMHL 
and dementia on GM. Part a shows a small conjunction between WMHL and dementia atrophy 
in the right middle hippocampus (crosshairs). Part b shows a conjunction in the right basal 
forebrain substantia innominata area (red arrow) and the thalamus (green box).  
 
 
Figure 55: This figure shows section rendered t-images of the conjunctions between the Main Effects 
of WMHL and dementia on GM projected onto the Standard Single Subject MNI template.  
Peak maxima for the conjunction between WMHL and dementia is shown in Table 29. In 
this case, cluster specific local maxima are listed for any clusters above 100 voxels as the overall 
conjunction effect is relatively focal in distribution. The top two peak maxima for the overlap 
between dementia and WMHL related atrophy are in the left and right anterior hippocampus 
respectively. The hippocampus was the only key strategic brain regions identified in this 
analysis. There was no interaction between WMHL and Dementia Main Effects in GM.  
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Table 29: Peak Maxima of the Conjunction between WMHL and Dementia Atrophy  
 Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value PFDR 
L_Ant_Hippocampus -27, -12, -11 3868 4.33/4.27 -.23 .01 
R_Ant_Hippocampus 27, -10, -12 3868 4.02/3.97 -.21 .02 
R_Amygdala 23, -7, -13 3868 3.62/3.59 -.19 .03 
L_Amygdala -17, 1, -12 3868 3.50/3.47 -.19 .04 
R_Sup_Temporal 52, -9, -12 4273 4.50/4.43 -.24 .01 
R_Mid_Temporal 54, -15, -9 4273 4.44/4.37 -.23 .01 
R_Heschl 52, -5, 6 4273 3.93/3.89 -.21 .02 
R_Rolandic_Operculum 46, -5, 11 4273 3.77/3.73 -.20 .03 
R_Inf_Temporal 52, -40, -20 442 4.09/4.04 -.22 .02 
R_Supramarginal 58, -25, 38 621 4.05/4.00 -.21 .02 
R_Post_Hippocampus 29, -33, -6 115 3.82/3.77 -.20 .03 
R_Postcentral 63, -4, 22 324 3.79/3.75 -.20 .03 
 
This chapter had several major findings. First, the GM atrophy seen in demented CHS-
CS subjects follows a pattern of temporal-parietal atrophy most appreciated when WMHL Main 
Effects are masked out. Second, WMHL Main Effects still target AD specific structure such as 
the precuneus even when the Main Effects of dementia on GM are masked out. Third, both 
WMHL and dementia Main Effects are jointly significant in areas relevant to AD pathology, 
especially the anterior hippocampus and the basal forebrain.  The lack of an interaction of 
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dementia related brain atrophy suggests that WMHL might not play as important a role in later 
stage neurodgeneration than in a comparatively earlier time point, as was seen with MCI. 
However, the fact that WMHL are correlated in lower GM volumes even in dementia subjects, 
and that the areas affected include brain regions targeted by neurodegeneration, namely the 
hippocampus, suggests that prevention or better treatment of hypertensive vascular disease may 
lessen the magnitude of brain atrophy seen in dementia. The contribution of this chapter’s data to 
the model is displayed in Figure 51. 
 
Figure 56: This figure shows the contribution to the overall model by chapter 7 data. This can be 
seen in the Dementia box in the far right lower corner of the figure. The arrow drawn from that box to gray 
matter volume loss represents both the conjunction of WMHL and dementia effects on GM, specifically the 
hippocampus, and the predictive power of WHML on lower gray matter volumes in only the dementia 
subjects.  
 
This concludes all chapters focused on the structural aspect of vascular disease Main 
Effects on GMVL in the context of aging, MCI, and dementia. Chapter 8 will focus on the 
relationship between vascular disease and brain function, as assessed with perfusion MRI with an 
ASL pulse sequence. Rather than use WMHL as a proxy of vascular disease, as such measures 
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were not taken at the time of the perfusion MRI, the relationships examined will be between 
cerebral perfusion and hypertension, which was identified in Chapter 3 as a main predictor of 
WMHL. Other variables such as age and comorbid MCI and dementia will also be examined.  
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8.0  HYPERTENSION IS ASSOCIATED WITH LOWER PERFUSION IN BRAIN 
REGIONS RELEVANT TO NEURODEGENERATIVE DISEASE 
8.1 INTRODUCTION 
To this point, I have shown how vascular disease, as indexed by WMHL, is strongly associated 
with atrophy in key strategic brain areas. The WMHL I have used in these analyses are predicted 
by HTN. HTN is most commonly believed to result in WMHL through ischemic/embolic events 
in the brain (213, 214) and this is frequently facilitated through damage to the cerebral blood 
vessels itself. All of these processes have the effect of reducing regional cerebral blood flow 
(rCBF). Thus, a potential sequence of events by which long-standing HTN could lead to brain 
atrophy is damage to cerebral blood vessels leading to rCBF reductions. These reductions in 
rCBF can subsequently lead to ischemic changes most characteristic of WMHL that in turn have 
been shown to be strongly associated with gray matter volume loss. What this chapter will seek 
to establish is the relationship between HTN and lower rCBF as evaluated with ASL MRI. The 
main reason for examining HTN as opposed to WMHL is that data on HTN was available at far 
more time points in the CHS, including the year of ASL scan, but this was not the case for CHS 
scales of WMHL. Another reason for foregoing WMHL correlations with perfusion is because 
they may be an effect rather than a cause of lower rCBF (42, 215, 216) whereas HTN is more 
likely a viable etiological candidate for lower rCBF.  
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8.1.1 Evidence for a Relationship between HTN and Lower rCBF 
A small number of neuroimaging studies suggest that long-standing HTN is associated 
with lower rCBF. Dai and colleagues compared ASL MRI scans between 19 hypertensive 
cognitively normal individuals with HTN for an average of 30 years from CHS-CS and 22 
normotensive counterparts (217). Using voxel-level analyses, they found that the HTN group had 
lower rCBF compared to the non-HTN group in such key strategic brain regions as the anterior 
cingulate gyrus, left posterior cingulate, with extension into the medial precuneus, and left 
middle hippocampus. A longitudinal 7 year study of 14 cognitively normal persons with HTN 
and 14 age-matched control used biannual O15 –water PET scans to show decreased rCBF in the 
middle and inferior prefrontal cortex, anterior cingulate gyrus, and occipital-temporal cortices in 
the HTN group (218).  PET imaging studies conducted in middle-aged cognitively normal 
subjects with HTN showed a pattern of reduced resting rCBF (113, 114), as well as less 
activation in the thalamus when engaged in memory tasks than normotensives. Another study 
showed is also decreased metabolism in the striatum and thalamus in HTN (219, 220).   These 
studies suggest that HTN, either short term or long standing, is associated with perfusion 
reductions in key strategic brain regions. The work presented in this chapter will extend this field 
by examining that question in 74 control, MCI, and demented subjects scanned in the CHS-CS 
with ASL MRI.  Most importantly, the analyses presented in this chapter will extend my thesis 
by showing that HTN, which is the underlying vascular disease that targets brain structure, also 
adversely affects brain function – specifically cerebral perfusion. If this assertion is verified with 
the data analyzed it will suggest an important mechanism by which HTN can lead to atrophy in 
key strategic regions of the brain.  
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8.1.2 ASL Imaging Evidence of Lower rCBF in MCI and Dementia.  
Several ASL imaging studies suggest that clinical syndromes associated with 
neurodegeneration such as MCI and dementia are linked to lower rCBF. Dai and colleagues 
compared the extent of rCBF reductions in MCI (n = 19) and AD (n = 15) compared to 
cognitively normal controls (n = 19).  Both MCI and AD subjects had lower rCBF in the 
posterior cingulate gyrus that extended into the medial precuneus (221).     MCI subjects had a 
statistically significant increase in rCBF, or hyperperfusion, in left hippocampal, right amygdala, 
right head of the caudate nucleus, ventral putamen, and globus pallidus compared to controls. 
The majority of these subjects were right handed. AD subjects had lower rCBF compared to MCI 
and control subjects in the left inferior parietal, left lateral frontal, left superior temporal, and left 
orbital frontal cortices. Persons with AD had increased rCBF compared to controls only in the 
right anterior cingulate gyrus.  
The hippocampal hyperperfusion findings from the Dai study were also observed in a 
study of 22 AD subjects compared to 16 controls, albeit these findings were not statistically 
significant (182). This same study found lower rCBF in bilateral precuneus, parietal association 
cortex and the left inferior temporal lobe in the AD subjects.  An ASL study of 20 persons with 
AD, 18 with MCI and 23 cognitively normal subjects showed that persons with AD had lower 
rCBF in right inferior parietal lobe extending into the bilateral posterior cingulate gyri and left 
and right middle frontal gyri (181).  This study, however, did not reveal any statistically 
significant differences between the MCI group and the control and AD groups.  Finally, a study 
of 18 AD subjects and 11 age-matched controls showed statistically significant perfusion 
declines in temporal, parietal, frontal, and posterior cingulate cortices (179). Mini-Mental State 
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Examination in the AD subjects correlated most strongly with posterior parietal and posterior 
cingulate decreases but not temporal decreases.  These studies suggest that the perfusion 
alterations can be observed in MCI and dementia, making it the most logical covariate in 
examining the Main Effects of HTN on cerebral perfusion using ASL MRI with my analyses 
since I will be examining rCBF in controls, MCI, and dementia subjects. The next section will 
overview the specific methods for subject selection ASL MRI image processing, including 
missing data analysis, and SPM statistical modeling.  
8.2 METHODS 
Basic methods for subject selection and ASL image processing have also been described 
extensively elsewhere (217, 221) but are briefly discussed here, with additional methods of 
missing data analysis included.    In all, 74 subjects were available for analysis and had both ASL 
and SPGR imaging acquired in 2002/2003: 30 with HTN and 44 without. Subject demographics 
are outlined in Table 30 and include distribution of the 30 control normals, 21 MCI, and 23 
dementia subjects. There were no statistically significant differences between non-HTN and 
HTN persons in terms of age, gender, education, distribution of control, MCI, and dementia 
subjects or any of the other variables examined.  
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Table 30: This table shows the demographic characteristics of non-HTN versus HTN subjects in the 
CHS-CS 
Variable Non-HTN (n = 44) HTN (n = 30) T-test(t, p)/χ2 
Age 82.9 ± 3.47 83.2  ± 3.68 -.34, .74 
Gender (F) 52% (23) 57% (17) .20, .80 
Education (12th Grade 
only) 
34% (15) 37% (11) .05, 1.0 
Race 18% (8) 36% (11) 3.19, .07 
Infarcts at MRI2 18% (8)  17% (5) .02, 1.0 
WMG at MRI2 (1997-
1999) 
2.21  ± 1.49 2.63  ± 1.41 -1.17, .25 
Controls/MCI/Dementia 36%(16)/ 
32%(14)/32%(14) 
46.7%(14)/ 
23.3%(7)/30%(9) 
.93, .63 
 
8.2.1 ASL MRI Image Processing  
ASL image processing involves a series of steps designed to obtain perfusion values in 
GM.  First, each ASL MRI scan was coregistered (with no reslicing) to its corresponding SPGR 
scan in its native (not normalized) space in SPM2.  Second, manual tracing was done in 
MATLAB to remove the skull from the ASL scan but not from the SPGR. After using the phase-
contrast derived flow velocities to exclude persons with a greater than 20% difference in blood 
flow velocities between both carotid arteries, rCBF was calculated using a modified Buxton 
kinetic model (222).  Next, a fully deformable method for registration method (223) was used to 
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normalize both ASL and SPGR scans to the Standard Single Subject MNI template. The fully 
deformable method uses a higher dimensional algorithm than that used with SPM2 (224, 225). 
Consequently, a higher resolution template is needed for normalization than is the case with the 
Pittsburgh Elderly Brain template. Since the Standard Single Subject MNI template is the highest 
resolution image available for such a purpose and most widely available to researchers, this was 
the image employed for registration purposes. As part of the fully deformable registration 
method, a 6 mm smoothing filter was applied. This smaller smoothing filter was chosen due to i) 
The higher dimension normalization algorithm used ii) It corresponds roughly to the cross 
sectional dimensions of the hippocampus and thus increases the sensitivity for hippocampal 
findings in the relatively small number of 74 subjects examined in this chapter.  
8.2.2 Missing Data and ASL MRI Image Analysis 
Missing data in ASL MRI can occur because the signal of the endogenous tracer may degrade 
before it reaches certain areas of the brain such as the inferior temporal lobes (226). Such issues 
are not typically addressed in the literature (174) but warrant consideration. Thus, missing data 
was accounted for in ASL image analysis using the following steps. First, gray matter from the 
Standard Single Subject MNI template was segmented in SPM2 and used as a mask to define 
missing voxels in ASL MRI data. The Standard Single Subject MNI template was used because 
it was the template utilized for normalization and only GM from this template was used because 
ASL perfusion provides information on GM perfusion. This mask, segmented in SPM2, is shown 
in Figure 57.  
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 Figure 57: This figure shows the GM mask used for missing ASL MRI data analysis. The mask is 
segmented GM from the Standard Single Subject MNI template. 
The main criterion for defining whether or not a perfusion voxel was missing was to 
examine all 74 ASL images: If greater than 10% of these images lacked a voxel in the above GM 
mask, that voxel was considered to be missing data. From this data a mask was created of 
missing ASL perfusion voxels that could then be used in SPM analyses as an exclusive mask (i.e. 
voxels in those brain areas with missing perfusion voxels would be excluded from the analysis. 
This mask is shown as an overlay onto the Standard Single Subject MNI template in Figure 58. 
The regions with missing data are the cerebellum, periventricular areas, GM/WM border, and the 
inferior temporal lobe. However, key strategic brain regions such as the hippocampus, posterior 
cingulate, and precuneus have intact data. Thus, this assures me that ASL MRI can be reliably 
employed in the statistical models I am about to describe.  
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 Figure 58: This figure shows areas of missing perfusion data at the voxel level in greater than 10% of  
the 74 subjects scanned with ASL MRI projected as a red color map onto the Standard Single Subject MNI 
template. The sagittal view shows how much missing data is observed in inferior cerebellum but not in the 
frontal lobes, posterior cingulate gyrus or precuneus. The coronal view shows missing perfusion data in the 
inferior temporal lobes but not in the hippocampus. Finally, the axial view shows missing voxels in the 
GM/WM border and periventricular areas.  
8.2.3 Statistical Models in SPM for Analysis of HTN Effect on rCBF 
The analysis was done in three ways. The first was to correlate a binary categorical diagnosis of 
HTN with rCBF while controlling for MCI and dementia. The second was to correlate systolic 
and diastolic blood pressures separately with rCBF while also adjusting for MCI and dementia. 
The systolic and diastolic blood pressures were taken from baseline study entry in 1989, because 
blood pressure taken the furthest before the scan is more likely to reflect the long term burden of 
HTN in the brain as opposed to a value taken during the year of scan.  
Separate tests of the Main Effects of age, gender, race, Cystatin C - marker of glomerular 
function, education, MRI infarcts, WMHL, interleukin 6, heart disease (as defined by medical 
history of myocardial infarction or congestive heart failure), serum creatinine, left cardiac 
ventricular mass as assessed on echocardiogram, serum beta amyloid (both 40 and 42 amino acid 
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lengths), intima-media thickness, systolic blood pressure from year of ASL MRI scan, diastolic 
blood pressure form year of ASL scan, and APOE4. All of these variables were gathered using 
standard CHS methods (36, 37, 62, 154-156, 168, 227).  Each variable was entered as a variable 
in a multiple regression model with MCI/dementia classification as the only other covariate. If 
no Main Effect could be seen with an uncorrected threshold of p < .001 (FDR = 15%) then that 
variable was not used as a covariate in the statistical analysis of HTN and blood pressure effects 
on the brain.  None of the listed variables had a Main Effect on perfusion, even when the 
classification of MCI/dementia was removed as a covariate and the analyses were re-run as 
simple bivariate correlations with rCBF. Consequently, none of them were included as covariates 
in the analysis of HTN and baseline SBP and DBP Main Effects. Thus, the statistical analyses 
done were to separately identify the Main Effects of HTN, baseline SBP, and baseline DBP all 
controlling for MCI and dementia. All of these analyses were done as multiple regressions in 
SPM2 as previously described.         
Correcting for multiple comparisons was done using an FDR threshold set at a 
comparatively liberal threshold of 15%, meaning if a map has cluster of 30 statistically 
significant voxels (the extent threshold used), approximately 26 of them are valid and not false 
positives. This was done mainly because the sample size of the ASL images used was relatively 
low compared to what was used for structural analyses. Thus, as a compromise between being 
sensitive to statistically significant statistical effects, an FDR of p = .15 was adopted for ASL 
analyses. This approach was done based upon prior published literature in which an uncorrected 
threshold was used for voxel based ASL MRI analyses in AD (182).  Results are overlaid onto 
the Standard Single Subject MNI template using methods described in Chapter 2.  
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8.3 RESULTS 
8.3.1 Main Effect of HTN as a Binary Variable on rCBF 
The Main Effect of HTN as a binary variable, controlling for comorbid MCI and dementia, is 
shown in Figure 59. This figure shows areas of lower rCBF in HTN persons compared to non-
HTN persons in frontal lobes, including the orbital frontal cortex, and the temporal lobes.  
 
 
Figure 59: This figure shows the Main Effect of HTN on rCBF in 74 CHS-CS subjects projected onto 
the Standard Single Subject MNI template (puncorrected = .001, FDR < .15, k = 30). Persons with HTN have 
lower perfusion in the frontal and temporal lobes as visible from this surface rendering.  
 165 
 Figure 60 shows the Main Effect of HTN projected onto the Standard Single Subject 
MNI template (puncorrected < .001, FDR < .15, k = 30). Part a shows that HTN is associated with 
lower rCBF, even when controlling for comorbid MCI and dementia, in such key strategic brain 
areas as the left posterior cingulate. Part b shows a similar effect in the left anterior cingulate. 
Part c shows three areas of HTN associated reduction in rCBF relative to the non-HTN group. 
The crosshairs show lower rCBF in association with HTN in the right anterior cingulate gyrus. 
The red arrow points to a Main Effect of HTN on rCBF in the right posterior cingulate and the 
green arrow points to a similar effect in the right precuneus. All related statistics are provided in 
Table 31.    
 
 
Figure 60: This figure shows lower rCBF in the HTN group compared to non-HTN subjects. All 
related statistics are provided in Table 31.  Key strategic brain areas have lower rCBF in relation to HTN, as 
fully described in text. 
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Table 31 shows peak maxima of the HTN Main Effect in rCBF. Eleven of these peak 
maxima are located in key strategic brain regions. These include the putamen, orbital frontal 
cortex, anterior cingulate, posterior cingulate, precuneus and the thalamus. 
Table 31: Peak Maxima of HTN Main Effects on rCBF. Key strategic brain regions are highlighted 
in bold. 
 
 Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value Puncorrected 
R_Precentral 62, 10, 17 394 4.87/4.50 -.50 < .001 
R_Rolandic_Operculum 58, 5, 12 394 3.64/3.47 -.40 < .001 
R_Putamen 31, 6, -9 1880 4.81/4.46 -.50 < .001 
R_Insula 27, 18, -16 1880 4.34/4.07 -.46 < .001 
R_Sup_Temporal 47, -16, 3 147 4.66/4.34 -.48 < .001 
R_Mid_Temporal 47, -28, -4 1084 4.51/4.22 -.47 < .001 
R_Postcentral 60, -1, 22 800 4.52/4.23 -.47 < .001 
L_Inf_Frontal_Operculum -54, 12, 31 275 4.43/4.15 -.46 < .001 
R_Mid_Frontal 37, 61, 11 479 4.40/4.13 -.46 < .001 
L_Sup_Orbital_Frontal -14, 9, -20 209 4.40/4.12 -.46 < .001 
R_Medial_Sup_Frontal 12, 69, 11 108 4.15/3.91 -.44 < .001 
R_Mid_Orbital_Frontal 35, 52, -7 269 4.06/3.84 -.43 < .001 
R_Inf_Frontal_Trigone 57, 26, 6 135 4.04/3.82 -.43 < .001 
L_Insula -35, 11, 8 133 4.03/3.81 -.43 < .001 
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L_Inferior_Frontal_Trigone -37, 31, 5 191 3.91/3.71 -.42 < .001 
R_Sup_Temporal_Pole 46, 10, -14 95 3.85/3.66 -.42 < .001 
R_Post_Cingulate 9, -30, 20 107 3.81/3.62 -.41 < .001 
L_Sup_Frontal -12, 72, 37 68 3.78/3.59 -.41 < .001 
R_Ant_Cingulate 8, 55, 6 418 3.76/3.57 -.41 < .001 
L_Putamen -23, 21, -7 80 3.74/3.56 -.40 < .001 
L_Mid_Frontal -46, 31, 41 41 3.73/3.55 -.40 < .001 
L_Thalamus -4, -7, 0 79 3.71/3.53 -.40 < .001 
R_Sup_Frontal 14, 34, 56 72 3.63/3.46 -.40 < .001 
L_Ant_Cingulate -7, 43, 34 66 3.63/3.46 -.40 < .001 
R_Mid_Occipital 36, -54, 33 98 3.62/3.46 -.39 < .001 
R_Sup_Orbital_Frontal 19, 35, -14 68 3.60/3.43 -.39 < .001 
R_Sup_Motor_Area 5, 14, 47 30 3.57/3.41 -.39 < .001 
L_Post_Cingulate -5, -29, 27 38 3.54/3.39 -.39 < .001 
R_Precuneus 8, -56, 36 30 3.52/3.47 -.39 < .001 
8.3.2 Main Effect of Baseline Systolic Blood Pressure on rCBF 12-14 Years Later 
The Main Effect of baseline CHS-CS systolic blood pressure taken in 1989 on rCBF as assessed 
with ASL MRI 12-14 years later is shown in Figure 61. As with the categorical variable of HTN, 
co-morbid MCI and dementia in 2002 were controlled for in the analysis. The figure shows that 
baseline SBP is correlated with lower rCBF measured 12-14 years later in the frontal and 
temporal lobes.  
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 Figure 61: Main Effect of baseline systolic blood pressure on rCBF is observed in frontal, temporal, 
and parietal lobes. 
The section rendered Main Effect of SBP is shown in Figure 62.  This figure shows the 
section rendered Main Effect of baseline SBP on rCBF 12-14 years later. Part a shows that 
higher SBP at CHS-CS baseline evaluation correlated with lower rCBF in the left precuneus 
(crosshairs), even when accounting comorbid MCI and dementia at time of scan. Part b shows a 
similar Main Effect in the right precuneus (crosshairs). Finally, part c shows that higher SBP is 
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correlated with lower rCBF in the right posterior cingulate gyrus (crosshairs). There was no 
corresponding Main Effect on the left posterior cingulate. Correlation effect sizes and cluster 
volumes are provided in Table 28. 
 
Figure 62: This figure that systolic blood pressure in 1989 is correlated with lower rCBF in 2002-
2003 ASL MRI perfusion scans in the following key strategic brain regions: left precuneus (part a, 
crosshairs), right precuneus (part b, crosshairs), and the left posterior cingulate gyrus (part c, crosshairs). 
Table 32 has information on corresponding statistical effect sizes. 
  
Table 32: Peak Maxima of Baseline SBP with rCBF. Key Strategic Brain areas are in bold.  
 Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value Puncorrected 
R_Mid_Temporal 51, -21, 1 416 4.73/4.40 -.49 < .001 
R_Mid_Frontal 35, 64, 6 463 4.59/4.28 -.48 < .001 
R_Postcentral 58, -1, 24 1812 4.56/4.25 -.48 < .001 
R_Precentral 49, -2, 41 1812 4.32/4.05 -.46 < .001 
L_Precuneus -2, -51, 51 266 4.11/3.88 -.44 < .001 
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L_Mid_Frontal -44, 29, 43 33 3.87/3.67 -.42 < .001 
R_Post_Cingulate 9, -30, 25 62 3.74/3.56 -.41 < .001 
R_Precuneus 13, -47, 30 48 3.69/3.52 -.40 < .001 
L_Mid_Cingulate 1, 20, 38 79 3.68/3.51 -.40 < .001 
R_Sup_Temporal 60, -13, 12 49 3.63/3.46 -.40 < .001 
 
8.3.3  Main Effect of Baseline Diastolic Blood Pressure on rCBF 12-14 Years Later 
The Main Effect of baseline DBP on rCBF 12-14 years later is shown in the surface rendered 
image in Figure 63.  Higher DBP is correlated with lower rCBF in largely the right frontal and 
temporal lobes, controlling for co-morbid MCI and dementia.  
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 Figure 63: This figure shows the Main Effect of baseline DBP on rCBF and can be seen largely in the 
right frontal and temporal lobes. 
 
The section rendered Main Effect of DBP on rCBF is shown in Figure 64. This figure 
shows the Main Effect of baseline DBP on rCBF projected onto the Standard Single Subject 
MNI template (puncorrected < .001, FDR < .15, k = 30).  Part a shows the Main Effect in the left 
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precuneus (crosshairs) and the most posterior aspect of the left posterior cingulate (black arrow). 
Part b shows another Main Effect of baseline DBP on the left posterior cingulate (crosshair). 
 
 
Figure 64: Main Effect of baseline DBP on rCBF projected onto the Standard Single Subject MNI 
template (puncorrected < .001, FDR < .15, k = 30).   
 
Table 33 shows that peak local maxima for the baseline DBP Main Effect can be found in 
key strategic brain regions as the posterior cingulate gyrus, precuneus, and orbital frontal cortex. 
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Table 33: Peak Local Maxima for the Main Effect of Baseline DBP on rCBF. 
 Structure Peak MNI 
Coordinates 
(x, y, z) 
Cluster 
Volume 
(mm3) 
t/z scores rp value Puncorrected 
R_Postcentral 57, -4, 27 2009 5.41/4.93 -.54 < .001 
R_Precentral 45, -6, 31 2009 4.30/4.04 -.45 < .001 
R_Mid_Temporal 49, -16, 4 268 4.39/4.11 -.46 < .001 
R_Calcarine 15, -71, 3 84 4.16/3.93 -.44 < .001 
L_Precuneus -6, -57, 31 220 4.10/3.87 -.44 < .001 
L_Post_Cingulate -9, -22, 6 70 4.01/3.80 -.43 < .001 
L_Mid_Temporal -60, -26, 7 71 4.00/3.78 -.43 < .001 
R_Supramarginal 51, -43, 26 196 3.81/3.62 -.41 < .001 
R_Inf_Frontal_Operculum 34, 9, 33 58 3.69/3.52 -.40 < .001 
L_Supramarginal -52, -31, 25 154 3.65/3.48 -.40 < .001 
L_Post_Cingulate -6, -38, 5 33 3.55/3.40 -.39 < .001 
L_Inf_Orbital_Frontal -23, 26, -12 48 3.36/3.23 -.37 .001 
 
 A separate SPM analysis did not show any statistically significant interaction between 
SBP and DBP on rCBF. Additionally, when both variables were entered into the same model in 
SPM, there were no alterations in the Main Effects of either baseline SBP or DBP on rCBF. 
These analyses suggest that systolic and diastolic blood pressures neither mediate nor moderate 
the effect of one another on rCBF.  
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In broader terms, the data in this chapter shows that i) HTN is correlated with lower 
rCBF in the same areas known to be affected by MCI and dementia even controlling for those 
two conditions ii) Baseline SBP and DBP are also correlated with lower rCBF in key strategic 
brain regions. That baseline SBP and DBP showed this relationship but pressures taken during 
the year of the scan did not suggests that the effects of HTN on cerebral perfusion may have to 
be chronic in order for their effects to be detected. Since HTN is also associated with WMHL it 
his likely that HTN results in deleterious reductions in rCBF which may in turn lead to WMHL 
and cerebral atrophy. It important to note that no increased rCBF was detected with any of the 
HTN measures used; that is there was no positive correlation between categorical HTN, baseline 
SBP, and baseline DBP and rCBF. 
The main contributions of this chapter to the overall model are documented in Figure 65 
and this figure represents the completed model asserted by this dissertation. This figure 
summarizes the overall model asserted by this thesis. The specific chapter 8 contributions 
highlight how long standing HTN can lead to reduced cerebral perfusion, as shown by the green 
arrow drawn from hypertension to the reduced cerebral perfusion box. To summarize the entire 
model, age and hypertension pressure are correlated with white matter hyperintense lesions. 
These lesions affect the same areas of gray matter volume loss that are also predicted by aging 
and most importantly moderate the effects of age on gray matter volume loss (red arrow). White 
matter hyperintense lesion atrophy also overlaps with brain areas that are larger in volume in 
correlation with better performance on tests of cognitive function, as represented by the 
cognition box. MCI and dementia also affect many of the same brain regions that are lower in 
volume with higher burden of white matter hyperintense lesions. In groups containing only MCI 
or dementia subjects, white matter hyperintense lesions are themselves predictive of lower gray 
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matter volume and in the case of MCI, there is synergy between that clinical proxy for early 
neurodgeneration and WMHL (blue arrow). Finally, long standing hypertension is correlated 
with lower regional cerebral blood (green arrow) which can conceivably lead to WMHL and 
brain atrophy.  Thus, this dissertation has shown hypertensive vascular disease can underlie the 
structural and function brain changes observed in normal aging, cognition, and 
neurodegeneration and that this convergence occurs in key strategic brain regions. These data 
consequently provide a powerful impetus for the control of HTN as an approach for improving 
brain aging, cognition, and reducing the vulnerability of the brain to neurodegenerative disease. 
 
Figure 65: This figure summarizes the overall model derived from the data presented in Chapters 3-
8. A full description is provided in the text.  
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9.0  CONCLUSIONS AND FUTURE DIRECTIONS 
9.1.1 Conclusions 
The main conclusion of this dissertation is that hypertensive vascular disease overlaps 
and interacts with structural and functional imaging measures of brain aging, cognition, early 
neurodegeneration as reflected by MCI and late neurodegeneration as represented by dementia. 
This dissertation has presented data strongly suggesting that hypertensive vascular disease 
affects many of the same areas of the brain known to be involved in cognitive function and 
neurodegenerative disease. These key strategic brain regions are the orbital frontal cortex, 
anterior cingulate gyrus, the posterior cingulate gyrus, the precuneus, hippocampal formation, 
thalamus, caudate, putamen, globus pallidus, and basal forebrain.  
These effects have been shown with a multiple imaging modalities, namely structural and 
perfusion MRI, in a large population based community cohort with sample sizes ranging from 74 
for the perfusion studies to almost 400 for the structural imaging work. This has maximized the 
probability that all analyses were done with optimal statistical power. The use of VBM has 
ensured unbiased examinations of every portion of GM in the human brain while the use of the 
AAL atlas has ensured that all statistical results obtained can be described in regional terms. 
Additionally, covariates in the majority of statistical analyses have included age, gender, race, 
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head size, education, and MRI identified infarcts. Such a multivariate approach minimizes the 
possibility that the results observed are due to confounding from any one of these variables.  
While many of the models and results of this dissertation have been described in terms of 
statistical language, it is important for the reader to remember that all of my thinking has 
remained grounded in biologically plausible mechanisms. For example, I have shown that 
statistical Main Effects of age, hypertensive vascular disease, and neurodegeneration target 
similar brain areas such as the hippocampus, posterior cingulate gyrus, and precuneus. One 
biologically feasible reason for this is because all three of these phenomena could have a final 
common pathway with respect to affecting the neurovascular unit of the brain. The neurovascular 
unit is a fairly recent term (106) designed to describe all of the major cellular components of the 
brain including neurons, astrocytes, brain endothelium, pericytes, vascular smooth muscle cells 
(VSMC), microglia and perivascular macrophages. The emphasis, however, is on the vascular 
cellular components – that majority of which comprise the neurovascular unit. 
Aging affects the neurovascular unit in ways that are difficult to mechanistically ascribe 
purely to the passage of chronological time. As such, there is overlap between arterial changes 
known to be due to vascular disease, which itself is tightly associated with aging. Consequently, 
age associated changes in the neurovascular unit are commonly described in terms of 
physiological mechanisms that, with the passage of time, result in the histopathological 
alterations that I will ascribe to vascular disease. To understand such physiological changes it is 
necessary to reiterate the unique aspects of cerebrovasculature, particularly the microvasculature.  
Microvasculature in the brain is defined as blood vessels with lumen diameters smaller 
than 300 microns in diameter (22). They are responsible for achieving a compromise between 
providing enough blood for parenchyma metabolic needs while minimizing blood pressures that 
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fragile capillaries are exposed to. Consequences of exposing such capillaries to excessively high 
blood pressures include hyperfiltration, protein leakage, edema formation, and damage to the 
capillaries and tissue (22).  Alterations in myogenic tone of blood vessels are a key determinant 
in achieving this balance. Myogenic tone refers to an intrinsic level of vascular smooth muscle 
cell tension, in the absence of specific vasoactive mediators such as nitric oxide, which is 
enhanced when vascular smooth muscle cells are mechanically stretched. Myogenic contraction 
is influenced in part by tensile strain of integrins attached to the extracellular matrix. It involves 
activation of calcium channels, subsequent changes in cellular calcium concentrations, and 
consequential alterations in the sensitivity of contractile proteins. Thus, myogenic tone plays an 
increasingly important role in modulating resistance to blood flow in progressively smaller 
vessels and controls short-term regulation of local blood flow, particularly in autoregulated 
organs such as the brain and kidneys. These organs have particularly small and intricate networks 
of blood vessels branching off from larger arteries.   
With aging, persistent elevation of myogenic tone is replaced by remodeling of blood 
vessel wall components, which restores wall stress and tone to nominal levels while maintaining 
a new, elevated level of microvascular resistance. Proximal small arteries, which exhibit 
relatively less myogenic tone, undergo a combination of hypertrophy and rearrangement to a 
smaller relaxed lumen diameter.  This process is known as hypertrophic remodeling. The 
microvasculature, which exert comparatively more vigorous myogenic tone, tends to remodel its 
wall components around a smaller lumen with no change in myocyte mass and this is known as 
eutrophic remodeling. Transduction of physical forces through interactions between the 
extracellular matrix, integrins, and the cytoskeleton of vascular smooth muscle cells activates the 
RhoA pathway. This activation, in turn, promotes migration and potentially hypertrophy or 
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hyperplasia of microvascular smooth muscle cells, resulting in a remodeled vascular wall and 
increased tunica media to lumen ratios (16).  Therefore, microvascular remodeling may interfere 
with steady-state and dynamic control of local blood flow and may contribute to or complicate 
the pathogenesis of some forms of hypertension.  
The alterations in the neurovascular unit described with aging are considered pathologic 
when they result in a series of alterations well known to neuropathologists. Macrosopically, the 
distribution of small vessel pathologies in the brain are best reflected by small lacunar infarcts 
found most commonly in the basal ganglia, thalamus, pons, and internal capsule (228-231).  
Microscopically, arteriosclerosis is the most common manifestation of vascular pathology and 
involves concentric thickening of the small arteries and arterioles of approximately 40 – 150 
microns in diameter. The severity of arteriosclerosis is most commonly measured in terms the 
vessel wall thickness to lumen ratio and correlates closely with increasing age and HTN. In 
arteriosclerosis, there is a initial proliferation medial smooth muscles followed by degeneration 
and replacement by collagen. Arteriosclerosis is not collagenous thickening of small 
pervientricular veins, which is more common with WMHL. However, the severity of 
arteriosclerosis can correspond with the severity of WMHL, especially in the frontal and parietal 
lobes (27, 45, 232).  Fibrinoid necrosis can also be seen as an end organ pathological 
consequence of malignant HTN and is distinct from arteriosclerosis. It is also known as 
lypohyalinosis and entails loss of normal vessel wall architecture, asymmetric 
hyaline/collagenous sclerosis, and mural foam cells (233, 234).        
Alzheimer’s pathology affects the cerebral vasculature in several ways. AD specific 
changes in brain blood vessels include atrophy and irregularities of arterioles and capillaries, 
swelling and increased number of pinocytic vesicles in endothelial cells, higher levels of 
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collagen IV, increased heparan sulfate proteoglycans and laminin deposition in the basement 
membrane, disruption of the basement membrane, lower total microvascular density and 
astrocytic end feet swelling (99). There is also considerable degeneration of the endothelium 
itself during disease progression as suggested by reduced staining of endothelial markers CD34 
and CD31 observed in AD brains (235) . Neurovascular unit pathology in AD is also 
characterized by cerebral amyloid angiopathy (CAA) with Aβ deposits in the VSMC layer of 
small cerebral arteries. Aβ plaques also accumulate onto and around cerebral capillaries and 
impaired clearance of Aβ across the blood brain barrier and by cells of the neurovascular unit 
may contribute to CAA and parenchymal Aβ deposits. The prevalence of CAA in AD 
individuals and in the elderly population without AD is >80% and 10–40%, respectively (235).  
Such vascular alterations can also be observed in MCI, though typically to a lesser extent (236).  
Although it is clear that age, vascular disease, and neurodgeneration employ different 
mechanisms, all target cerebral blood vessels as part of a final common pathway. Having 
therefore established that these states share a common pathological target, the findings of this 
dissertation are put into context. In age, vascular disease, and neurodgeneration there were 
repeated findings of the same key strategic brain regions being affected by these processes: the 
orbital frontal cortex, cingulate gyrus, hippocampus, posterior cingulate, and precuneus to name 
a few. Often, the Main Effects of all three phenomena were widespread – often encompassing 
large portions of all major lobes of the brain. This generalized nature of the effects is logical 
when one asserts that since age, vascular disease, and neurodegeneration all affect 
cerebrovasculature, which supplies the entire brain. Thus, if all three entities affect cerebral 
blood vessels it would be expected for their effects to be seen jointly in large areas of the brain 
and particularly in areas that perform cognitive function as these areas generally require 
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considerable energy and nutrients for optimal function (128). This is further supported by the 
fact that the strongest effects of age, vascular disease, and neurodegeneration were seen in such 
areas as the orbital frontal cortex and the hippocampus. Consequently, I posit that a critical 
synergy occurs between these three factors to promote hypoperfusion and brain atrophy in 
regions that have strategic importance with respect to cognitive function and thus risk for 
dementia. This concept extends the established notion that with brain infarcts it is not only the 
volume of brain involved but the location with respect to risk of cognitive impairment.   
Tomlinson and colleagues compared postmortem 50 demented to 28 cognitively normal 
brains and suggested that 100 mL was the amount of brain tissue that had to be destroyed for 
dementia to be clinically expressed. However, this relationship was not direct: two subjects in 
their control group had lesions destroying more 50 mL of brain (91 mL in one case) (237). Thus, 
the authors qualified their results by stating that location of tissue destruction can determine of 
course of whether or not an individual remains cognitively normal or demented.  This concept of 
strategic zones was further articulated by Mesulam (128) and refined by Zekry and colleagues 
(129). These same strategic areas have appeared in this dissertation and from this an emphasis on 
10 key strategic brain areas has been expressed. The key strategic brain areas are orbital frontal 
cortex, anterior cingulate gyrus, the posterior cingulate gyrus, the precuneus, hippocampal 
formation, thalamus, caudate, putamen, globus pallidus, and basal forebrain. What I have shown 
in this dissertation is that all of these areas sustain multiple “hits” in terms of having lower GM 
volumes in association with age, hypertensive vascular disease, and neurodegeneration. These 
associations are independent of each other; that is the hypertension Main Effects held even after 
controlling for age, dementia and other potential confounders. The concept of these brain regions 
sustaining multiple hits from different sources, namely age, HTN, and neurodegeneration, is 
 182 
summarized by Figure 66. This figure shows the strategic areas figure from the Zekry paper and 
Figure 1 and it also shows the volume rendered main effects of age, hypertensive vascular 
disease (i.e. WMHL), and neurodegeneration (as proxy indicated by a clinical classification of 
dementia). This figure shows that all three entities are associated with lower GM volumes in the 
frontal, temporal, and parietal lobes – all locations that are strategic areas of the brain with 
respect to cognitive function. This figure therefore summarizes a fundamental message: that 
there are common brain areas that are jointly affected by age, vascular disease, and 
neurodegeneration.  
 
 
Figure 66: This figure shows the Zekry figure that was utilized in Figure 1 (with strategic areas with 
respect to cognitive function shaded in black) along with the Main Effects of age, hypertensive vascular 
disease, and neurodegeneration. All three of these entities independently effect strategic areas, particularly in 
the frontal, temporal, and parietal lobes.  
Thus, a critical synergy exists between age, vascular disease, and neurodgeneration for 
the promotion of dementia and this is facilitated by the convergence of these phenomena in 
strategic cognitive zones of the human brain.  Of these three, vascular disease is emerging as a 
key component because unlike aging and neurodegeneration, vascular disease such as 
hypertension is currently more effectively treated and can be prevented.  Indeed, this dissertation 
has shown that vascular disease can moderate both age and early neurodegeneration in the gray 
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matter. Consequently, better prevention/treatment of vascular disease may have a beneficial 
effect of attenuating the effects of age and neurodegenerative effects on brain atrophy.  
A growing body of literature provides support of this potentially powerful concept. The 
Rotterdam study followed 6992 cognitively normal individuals aged 55 or older at baseline who 
were participating in the Rotterdam Study and compared the risk for AD in participants with any 
prior use of cholesterol-lowering drugs and those with no prior use, adjusting for differences in 
demographics, vascular risk factors, duration of medication use, and APOE4 (238).  A total of 
582 participants developed AD. Even after accounting for these potential confounders, the use of 
statin cholesterol-lowering drugs (but not nonstatin cholesterol-lowering drugs) was associated 
with a lower AD risk compared with no cholesterol-lowering drug use (HR 0.57; 95% CI 0.37 to 
0.90). Moreover, both lipophilic and hydrophilic statins were associated with reduced risks for 
AD, with no significant difference between the two. This was the largest prospective study to 
date specifically designed to assess cognitive function in elders that addresses the relation 
between statin use and development of AD. It suggests that statins, which lower cholesterol and 
thus reduce risk of cardiovascular disease, could be a viable option for prevention of cognitive 
decline and AD. Another study with results in support of this conclusion was done in 1,674 
persons from the Sacramento Area Latino Study on Aging (SALSA) followed up over 5 years, 
with 27% of the cohort on statins. This study, done only on Mexican-American aged 60 and 
older, found that use of statins conferred a reduction in dementia risk compared to those who did 
not use statins (HR = 0.52; 95% CI 0.34, 0.80) (239). On the other hand the CHS did not find 
any statistically significant benefit of statins either in improving cognitive function 
longitudinally or reducing the risk of dementia (240, 241). Consequently, the investigation of 
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cardiovascular medicines as a pharmacological approach to improving brain vascular health in 
aging and neurodegeneration will continue to remain a research area in need of additional work.  
Non-pharmacological methods for preventing vascular disease have also shown benefit 
with respect to brain health, cognition, and Alzheimer’s pathology. Several studies suggest how 
brain atrophy and dementia risk may be attenuated using caloric restriction and physical exercise. 
Caloric restriction attenuates AD amyloid neuropathology in mouse models (242) and promotes 
brain longevity through several molecular mechanisms. These minimize oxidative damage to 
neurons by upregulation of brain derived neurotrophic growth factor, glial cell-line derived 
neurotrophic growth factor, heat-shock protein 70 and glucose regulated protein 78 (243).  
Physical exercise is another intervention than can improve brain health with aging. Prior 
work comparing structural MRI brain volumes of groups with low and high aerobic fitness 
activity found larger volumes in pre-frontal GM, temporal lobe GM, and anterior WM in the 
higher fitness group (244). Physical exercise promotes increased functional activation on fMRI 
in the anterior cingulate gyrus, which relates to improved cognitive test performance (245). Both 
caloric restriction and physical exercise appear to promote higher brain volumes, better 
metabolic activation, and enhanced cognition. Most importantly, they share a common effect on 
the body by reducing body tissue adiposity. Physical activity was also evaluated in the context of 
a randomized clinical trial in which 170 individuals with subjective memory complaints were 
randomized to either physical activity program (typically aerobic in nature and most commonly 
walking) or a usual care group in which no physical activity intervention was implemented 
(246). Subjects were followed up for a subsequent 18 months and the main outcome was change 
in Alzheimer Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) scores (possible 
range, 0-70). In the physical activity intervention group, participants improved 0.73 points (95% 
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confidence interval, –1.27 to 0.03) on the ADAS-Cog, and those in the usual care group 
improved 0.04 points (95% confidence interval, –0.46 to 0.88), a statistically significant 
difference (p < .05). Finally, a study found that wheel running in rodents increased levels of 
brain derived neurotrophic factor in the brain and improved performance on the Morris Water 
Maze (247). These results of these studies collectively suggest that physical activity can be 
implemented as a viable strategy for improving cognitive function in elderly persons who may be 
at risk for AD.  
In conclusion, this dissertation shows that hypertensive vascular disease, as represented 
by categorical HTH, baseline SBP, baseline DBP, and WMHL, induced functional and structural 
changes in elderly brains that most impressively affect key strategic brain areas that are also 
targeted by aging and neurodegeneration. The main strength of this work is that is utilized large 
numbers of perfusion and structural imaging data from a well characterized clinical cohort. The 
primary disadvantage of this work is that it did not have serial structural and perfusion scans 
from different time points as that would have permitted for meaningful longitudinal analysis. 
Overall, the main message of this dissertation is that vascular disease underlies patterns of brain 
alterations seen in aging and neurodegeneration. This work has potentially broad public health 
implications for the treatment and prevention of vascular disease as a feasible approach for 
attenuating the deleterious effects of brain aging and reducing the risk for dementia.  
9.1.2 Future Directions 
The data presented in this dissertation opens possibilities for additional future studies. Broadly, 
these future studies could be designed in terms of multiple image sequences acquired at different 
time points for the purposes of better evaluating the natural history of vascular disease effects on 
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the human brain. For example, while the work presented in this dissertation suggests that 
perfusion alterations may precede structural brain changes, a longitudinal study would allow for 
a more rigorous examination of this question. Another question that would be very important to 
examine is the extent to which amyloid deposition in the brain is moderated by co-morbid 
vascular disease. This question is possible to answer due to the innovation of Pittsburgh 
Compound B (PiB), a thioflavin-T derivative the selectively binds and labels the amyloid 
plaques seen in Alzheimer’s disease (131). If HTN or other forms of vascular disease to be 
shown to longitudinally modify PiB retention in the brain, it would provide considerable insight 
into the intersection between AD and vascular pathology.  
Thus, one example of a powerful multimodal imaging study I would consider working on 
in the future is scanning elderly subjects longitudinally with 3-D volumetric structural MRI, T2 
scans for WMHL rating, perfusion ASL MRI, PiB scans with PET, and white matter tract 
imaging using diffusion tensor imaging (248). Scanning subjects longitudinally and obtaining 
clinical data on their cardiovascular and cognitive status would not only allow for a truly 
multifaceted picture of how the brain changes with aging, vascular disease, and onset of 
neurodegeneration but it would also allow for interactions and synergy between these factors to 
be investigated. This work would also allow some of the earliest structural changes of AD and 
MCI to be identified, potentially prior to expression of clinical symptoms.  
Such investigations could also involve studies on molecular markers of cellular aging 
itself. Telomere shortening, for example, is a powerful molecular marker for evaluating cellular 
age (249).  Examining the relationship between that marker and image derived measures of 
structure, perfusion, and amyloid could also give additional insights into how vascular disease 
can moderate aging at the cellular level. Another molecular study of that type that could be 
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performed is on BDNF levels in the context of an outcomes study of physical activity 
intervention in the elderly. So, for instance, I could conceivably investigate if BDNF levels are 
higher in elderly persons who engage in physical activity and whether or not these levels are 
correlated with higher GM volumes, higher rCBF, and lower PiB levels.   
While SPM will no doubt remain a key component for analyzing such neuroimaging data, 
other types of image analysis will be applied to compliment this software. There are a variety of 
methods for analyzing brain images. By far the most common methods (as above) utilize t-tests 
(and associated methods) that are useful for determining regional signal (atrophy, hypoperfusion) 
that occurs above a given threshold (functional specialization). However, another group of 
methods has focused on identifying functionally associated regions that may exist within a 
dataset and that can be revealed by analyses that emphasize functional integration. One example 
of such multivariate methods is Partial Least Squares (PLS). PLS, which was originally applied 
to neuroimaging data by McIntosh and colleagues (250, 251), is similar to a Principal 
Components Analysis, except that the solutions are constrained to the part of the covariance 
structure that is attributable to the experimental manipulations. PLS can therefore be used as a 
robust method for extracting distributed differences related to alterations in tissue compartments 
(i.e. GM, WM, CSF) and/or perfusion measures in diseased (ex. HTN, MCI, AD) and non-
diseased states.  Another advantage of PLS is that it allows one to express these differences in 
terms of “Brain scores” which indicate how strongly each subject expresses the observed 
differences. Such scores can be subsequently used to differentiate groups of subjects and 
potentially even single subjects. The main drawback to PLS is the considerable computational 
power required to compute non-parametric statistics, making it difficult to analyze large numbers 
of scans.  
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All of these future directions are investigations that will require new skills, methods of 
analysis and knowledge that will hopefully extend and enrich my life in academic medicine. 
They are efforts that will require participation with an interdisciplinary team of clinicians and 
scientists over multiple departments and institutions. I believe my PhD training and the work 
presented in this dissertation has provided me with a sound foundation with which to pursue 
these endeavors.  
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